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Preface to ”Egg Consumption and Human Health”
Eggs have been a controversial food for many years due to their cholesterol content. In fact, they
have been used as icons for dietary cholesterol. The USDA dietary guidelines of 2015 removed the
upper limit for cholesterol intake thus dietary cholesterol is no longer a nutrient of concern. The
United States was not a pioneer in these recommendations. Many European and Asian countries had
already considered that dietary cholesterol and blood cholesterol were not related and had changed
their dietary guidelines accordingly, years before US.
Eggs, a highly nutritious food has received bad press across history. Recently the formation
of trimethylamine N-oxide (TMAO), a risk factor for heart disease, from dietary sources including
choline has brought eggs yet again to the spotlight as a food of concern. However, although not
shown in this book, research from my laboratory and from other investigators has demonstrated that
eggs increase plasma choline without changing TMAO concentrations.
It is important to understand the historical perspective on how eggs became a food of concern
before the positive attributes of eggs are highlighted. Such history is presented in detail as an
information piece, on how dietary guidelines were created in the past without having enough
evidence derived from rigorous clinical studies or well-analyzed epidemiological data. These
recommendations of no more than 300 mg/day of dietary cholesterol still persist in the minds of the
consumers and of course the main target of these recommendations are eggs.
Eggs in fact are not only a nutritious food characterized for its very high quality protein as well as
being important contributors to the daily recommendations of Vitamin E, selenium and choline but
eggs also have components with properties that go beyond nutrition.
Among the bioactive components of interest that are present in eggs are phospholipids. These
phospholipids may play a role in decreasing heart disease risk twofold by decreasing cholesterol
absorption and by incorporating into HDL and enhancing the uptake of cholesterol into cells and
returning to the liver in the process known as reverse cholesterol transport. The protein in egg
has also been shown to have anti-bacterial properties as well as antioxidant and anti-inflammatory
properties. Lutein and zeaxanthin, two carotenoids present in egg yolk, are also considered bioactive
components of eggs because they protect against oxidative stress and inflammation, as has been
demonstrated in clinical studies. Further, these carotenoids are selectively taken up by the eye and
exert a protective action against age-related macular degeneration, the leading cause of vision loss
in adults over the age of 50. These properties of lutein and zeaxanthin are confirmed by animal
studies, which have consistently shown how these carotenoids protect the liver, reduce systemic
inflammation, and decrease atherosclerosis.
Eggs can also be a highly nutritious food for at-risk populations as has been demonstrated in
studies in children from underdeveloped countries, in individuals who live in poverty and even in
subjects with metabolic syndrome or those with documented diabetes.
The goal of this book is to demonstrate that eggs in addition to being a highly nutritious food,
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Abstract: Eggs are sources of protein, fats and micronutrients that play an important role in basic
nutrition. However, eggs are traditionally associated with adverse factors in human health, mainly
due to their cholesterol content. Nowadays, however, it is known that the response of cholesterol
in human serum levels to dietary cholesterol consumption depends on several factors, such as
ethnicity, genetic makeup, hormonal factors and the nutritional status of the consumer. Additionally,
in recent decades, there has been an increasing demand for functional foods, which is expected to
continue to increase in the future, owing to their capacity to decrease the risks of some diseases and
socio-demographic factors such as the increase in life expectancy. This work offers a brief overview of
the advantages and disadvantages of egg consumption and the potential market of functional eggs,
and it explores the possibilities of the development of functional eggs by technological methods.
Keywords: egg; egg-derived products; functional foods; cholesterol; technological elaboration;
omega-3.
1. Introduction
Nowadays, foods are not intended to only satisfy hunger and to provide necessary nutrients for
humans, but also to prevent nutrition-related diseases and improve physical and mental wellbeing of
consumers [1]. However, human nutrition in developed countries is characterized by an excessive
intake of protein, cholesterol, saturated fatty acids (SFA), n-6 polyunsaturated fatty acids (PUFA),
calories or sodium, whereas consumption is deficient in n-3 PUFA, fiber and antioxidants. These
imbalances are partly responsible for the high incidence of both obesity and the onset of chronic or
degenerative non-transmissible diseases, from which cardiovascular diseases (CVD) are the leading
cause of mortality and morbidity globally [2]. The consumption of a lower fat diet is generally accepted
in all clinical guidelines on CVD prevention, and is based on total fat consumption of 25%–35% of
total calories, of SFA should be no more than 7%–10%, trans fatty acids less than 1%, unsaturated fats,
mainly monounsaturated fats (MUFA) and n-3 PUFA) should represent the rest of the calories from fat
and cholesterol, for a total of less than 300 mg/day [3,4].
In order to improve public health, nutritional experts and related organizations, such as the U.S.
Department of Agriculture and U.S. Department of Health and Human Services [5] of the Spanish
Society of Community Nutrition (SENC) [6], has persistently recommended a reduction in the intake
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of foods that are related to the occurrence of chronic diseases, and am increased consumption of fruits
and vegetables, grains, legumes, low-fat dairy products, lean meats and fish, especially fatty fish
species that are high in n-3 PUFA. Owing to the persistence of these recommendations, there is a
high degree of awareness of this problem in the populations of developed countries, and, fortunately,
nutritional composition is already a major factor in the choice of foods by the consumer. However,
although there is a significant demand for healthier food, consumers are reluctant to change their
dietary habits [7]. This suggests that there is great potential for foods that are consumed regularly
when they are converted to functional foods by changing the composition to include certain ingredients
that are beneficial to health. Another way to obtain functional foods is to modify the quantity of certain
components in the food to make it more suitable to the recommendations of nutrition experts [7].
In this sense, because eggs are a conventional food containing nutrients that play fundamental
roles beyond basic nutrition, their promotion as functional foods should be considered [8]. Eggs are
of particular interest from a functionality point of view, because they offer a moderate calorie source
(about 150 kcal/100 g), a protein of excellent quality, great culinary versatility and low economic
cost [9], which make eggs within reach to most of the population. Eggs are also relatively rich in
fat-soluble compounds and can, therefore, be a nutritious inclusion in the diet for people of all ages
and at different stages of life. In particular, eggs may play a particularly useful role in the diets of those
at risk of low-nutrient intakes such as the elderly, pregnant women and children [10]. Additionally, it
must be mentioned that eggs can be consumed throughout the world, having no use restrictions on
religious grounds [11].
However, eggs are a controversial food for nutritional experts and health agencies, because of the
saturated fat content (about 3 g/100 g) and cholesterol content (about 200–300 mg/100 g) [12]. Owing
to these two characteristics, during the past 40 years, the public had been warned against frequent
egg consumption due to the high cholesterol content in eggs and the potential association with CVD.
This was based on the assumption that high dietary cholesterol consumption is associated with high
blood cholesterol levels and CVD. Afterwards, subsequent research suggests that, in contrast to SFA
and TFA, dietary cholesterol in general and cholesterol in eggs in particular have limited effects on the
blood cholesterol level and on CVD [4].
However, the volume of eggs and egg yolk used by food companies in their formulations is
constantly increasing. Nowadays, egg-yolk products are largely used by the food industry as a result
of three very important properties: manufacture and stabilization of emulsions, foaming stability and
thermal gelation, as it is a fundamental ingredient for the elaboration of several food products [13].
Unfortunately, eggs and egg-derived foods are responsible for a large number of food-borne illnesses
each year, mainly caused by Salmonella [14]. For this reason, as well as for their lower price and ease
of handling and storing compared to shelled eggs, the food service industry and commercial food
manufacturers have shown an increasing interest in the use of liquid pasteurized egg products instead
of fresh whole eggs [15].
Thus, it would be of major interest to develop egg-derived products, appropriate for food
companies, with a modified nutritional composition that helps maintain the health of consumers.
Nowadays, retail markets for functional eggs are available, mainly enriched with n-3 PUFAs or with
low cholesterol content. However, in most cases, these eggs are obtained through modification of
layer-hen’s diet and management, whereas much less attention has been paid to the development of
functional eggs by means of technological methods [16]. In this manuscript, the possible development
of functional pasteurized liquid eggs by technological methods and their advantages in the food
industry and from the point of view of nutritionists are also discussed.
2. Advantages of Egg Consumption for Human Health
Eggs are an inexpensive and highly nutritious food, providing 18 vitamins and minerals, the
composition of which can be affected by several factors such as hen diet, age, strain as well as
environmental factors [16,17]. Nevertheless, although different compositions have been reported by
2
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several authors [10,17], on average, the macronutrient content of eggs include low carbohydrates and
about 12 g per 100 g of protein and lipids, most of which are monounsaturated [8,18,19] and supply the
diet with several essential nutrients (Table 1). Some of these nutrients, such as zinc, selenium, retinol
and tocopherols, are deficient in people consuming a western diet, and given its antioxidant activity,
can protect humans from many degenerative processes, including CVD [10].
There is also scientific evidence that eggs contain other biologically active compounds that
may have a role in the therapy and prevention of chronic and infectious diseases. The presence
of compounds with antimicrobial, immunomodulator, antioxidant, anti-cancer or anti-hypertensive
properties have been reported in eggs [11]. Lysozime, ovomucoid, ovoinhibitor and cystatin are
biologically active proteins in egg albumen, and their activity prolongs the shelf life of table eggs [14].
Some of these protective substances are isolated and produced on an industrial scale as lysozymes
and avidin. Additionally, eggs are an important source of lecithin and are one of the few food sources
that contain high concentrations of choline [8,20]. Lecithin, as a polyunsaturated phosphatidylcholine,
is a functional and structural component of all biological membranes, which acts in the rate-limiting
step of the activation of membrane enzymes such as superoxide dismutase. It has been suggested that
ineffective activation of these antioxidant enzymes would lead to increased damage of membranes by
reactive oxygen species. In addition, lecithin increases the secretion of bile, preventing stagnation in
the bladder and, consequently, decreases the lithogenicity [8].
Table 1. Nutritional composition of hen eggs.
Component (Unit) Amount Component (Unit) Amount
Egg shell (%) 10.5 Calcium (mg) 56.0
Egg yolk (%) 31 Magnesium (mg) 12.0
Egg white (%) 58.5 Iron (mg) 2.1
Water (g) 74.5 Phosphorus (μg) 180.0
Energy (Kcal) 162 Zinc (mg) 1.44
Protein (g) 12.1 Thiamine (mg) 0.09
Carbohydrates (g) 0.68 Riboflavin (mg) 0.3
Lipids (g) 12.1 Niacin (mg) 0.1
Saturated fatty acids (g) 3.3 Folic acid (μg) 65.0
Monounsaturated fatty acids (g) 4.9 Cyanocobalamin (μg) 66.0
Polyunsaturated fatty acids (g) 1.8 Pyridoxine (mg) 0.12
Cholesterol (mg) 410 Retinol equivalents (μg) 227.0
Iodine (μg) 12.7 Potassium (mg) 147
Tocopherols (μg) 1.93 Carotenoids (μg) 10
Selenium (μg) 10 Cholecalciferol (μg) 1.8
Quantities represent an edible portion of about 100 g.
However, as a component of egg lecithin, choline has numerous important physiologic
functions, which include the synthesis of phospholipids, the metabolism of methyl and cholinergic
neurotransmission, and it is a required nutrient that is essential for the normal development of the
brain [21].
Another important nutritional component from eggs is phosvitin, a phosphoglycoprotein present
in egg yolk and represents about 7% of yolk proteins. It has a specific amino-acid composition,
comprised of 50% serine, and 90% of which are phosphorylated. This specific structure makes
phosvitin a strong metal chelator and, by this mechanism, it acts as an important melanogenesis
inhibitor to control excessive melanin synthesis in the melanocytes of animal and human skin [21]. It
was suggested that egg-yolk phosvitin has the potential to be used as a natural bioactive compound as
a hyper-pigmentation inhibitor for human skin [21].
Other interesting egg components from the nutritional point of view are the carotenoids.
Carotenoids are natural pigments in hen egg yolks that confer its yellow color, which can range from
very pale yellow to dark brilliant orange. Egg carotenoids represent less than 1% of yolk lipids, and
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are mainly composed of carotene and xanthophylls (lutein, cryptoxanthin and zeaxanthin) [19,22,23].
The total concentration of lutein and zeaxanthin is 10 times greater than of cryptoxanthin and carotene,
combined [23], and are not endogenously synthesized by the human body and tissue levels therefore
depend on dietary intake. These natural compounds found in the bodies of animals, and in dietary
animal products, are ultimately derived from plant sources in the diet, mainly from dark green
leafy plants [24]. Lutein and zeaxanthin content of eggs depends on different factors, such as the
feed given to laying hens, or the husbandry system. Thus, variable contents of these carotenoids
in non-enriched eggs were recently reported, varying about 167–216 μg/yolk for lutein and about
85–185 μg/yolk for zeaxanthin [22,24]. Additionally, a greater serum response to lutein was reported
following the consumption of eggs compared with the consumption of dietary lutein supplements
or vegetables [22,24]. This could be related with the fact that carotenoids depend on a lipophilic
environment for optimal gastrointestinal uptake [24]. Consequently, eggs are a very important food
source of these carotenoids, especially in the case of people that consume low amounts of vegetables
with a high content of these substances (as occurs in western developed countries).
These carotenoids are, perhaps, best known for their function in the neural retina, where they
are found in high concentration and, along with their isomer mesozaexanthin, are termed macular
pigment [25]. Lutein and zeaxanthin are known to serve light-absorbing and blue-filtering optical
functions, as well as antioxidant and anti-inflammatory functions, and thereby, is considered to play a
role reducing immune-mediated macular degeneration and age-related cataract formation [23–25].
Taking into account the presence of all these components, eggs can be considered a nutritious
inclusion in the diet for people of all ages and at different stages of life, but they may play a particularly
useful role in the diets of those at risk of low-nutrient intakes [10]. Owing to their high nutritional
value, eggs are also an important food that should be included in the planning of diets for patients, and
are especially valuable in feeding people with gout, because it is a source of protein that does not add
purines. Additionally, for people in sports training, egg proteins may have a profound effect on the
training results, because, by its inclusion in the diet, it could be possible to enhance skeletal muscles
synthesis [8]. It is well established that essential amino acids stimulate skeletal muscle protein synthesis
in animal and human models, and the protein in egg has the highest biological value [26]. Fifteen grams
of egg white protein contain about 1300 mg of leucine (the third most common amino acid in egg, after
glutamic and aspartic acids), and is also an abundant source of branched amino acids and aromatic
amino acids. Recent data showed that leucine induces a maximal skeletal muscle protein anabolic
response in young people, which suggests that egg white protein intake might have an important effect
on body mass accretion [27]. Specifically, leucine stimulates skeletal muscle synthesis independently of
all other amino acids in animal models and is a potent stimulator of the cell hypertrophy mammalian
target of rapamycin complex pathway. Additionally, leucine decreases muscle protein breakdown and
breakdown-associated cellular signaling and mRNA expression [26].
3. Undesirable Effects of Egg Consumption
Despite their abovementioned nutritional benefits, egg consumption was traditionally associated
with adverse factors for human health and nutrition. In this sense, egg whites contain anti-nutritional
factors, among which are proteins such as ovomucoid that can inhibit trypsin or avidin, which can
bind biotin. However, these factors are thermo-labile and, therefore, these compounds are usually
destroyed when cooking eggs, after which they do not cause further detrimental effects. Additionally,
eggs have been the subject of numerous recommendations from nutrition experts in order to moderate
egg consumption, owing to its high cholesterol and saturated-fat content. Reducing saturated-fat
intake is the primary dietary strategy recommended for reducing serum cholesterol levels, and this
strategy has often led to a reduction in the consumption of eggs. Nevertheless, substituting eggs
for other animal-protein foods in the diet may result in small changes to low-density lipoprotein
cholesterol (LDL) [10] and, consequently, egg consumption should be considered in a similar way
to other protein-rich foods. Although metabolic studies have shown that dietary cholesterol is a
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major determinant of serum cholesterol concentrations, other studies failed to detect changes in the
serum total-cholesterol concentration when eggs were added to diets that already contained moderate
amounts of cholesterol [28]. In this sense, large research works, and even meta-analyses, have been
conducted to investigate the effects of eggs on serum cholesterol levels and cardiovascular health, with
very different conclusions (Table 2). Several authors state that dietary cholesterol from eggs could be an
important risk factor for cardiometabolic diseases including CVD and diabetes [12,29–31]. Furthermore,
lecithin (approximately 250 mg in a large egg yolk) is converted by intestinal bacteria to trimethylamine,
which is in turn oxidized by the liver to trimethylamine oxide, which is pro-atherosclerotic [32]. In this
sense, a meta-analysis found that an intake increment of four eggs per week could possibly increase
the risk of CVD by 6% and diabetes by 29% [12]. Nevertheless, a recent systematic review found no
clear relation of egg consumption and CVD among diabetic individuals [33].
However, for a large number of researchers, traditional assumptions that dietary cholesterol
consumption translates directly into elevated plasma cholesterol levels and the development of CVD in
all individuals were deemed to be mistaken [10,34,35]. First, a conservative estimate suggests that only
30% of the population would hyper-respond to dietary cholesterol [29], whereas approximately 70% of
humans are hypo-responsive to excess dietary cholesterol consumption [36]. Therefore, clinical studies
have clearly shown that plasma compartment changes, resulting from dietary cholesterol consumption,
are influenced by several factors such as ethnicity, genetic makeup, hormonal factors and body mass
index [36,37]. All of these characteristics determine who would hyper-respond to dietary cholesterol
and those who are hypo-responsive to intake. In addition, those individuals who hyper-respond to
dietary cholesterol intake generally show increased LDL and high-density lipoprotein cholesterol
(HDL) [8], allowing for the maintenance of the LDL/HDL ratio, an important marker for CVD risk.
This suggests that, for healthy individuals, the nutritional benefits clearly outweigh the concern
surrounding the dietary cholesterol provided by one large egg.
Table 2. Recent works regarding effect of eggs consumption on of serum cholesterol and cardio
circulatory human health.
Reference Study Design Number and Type of Subjects Main Conclusion
Djousse, Graziano,
2008a [30] Prospective cohort study
21,275 US male physicians aged
40–85 years
Egg consumption of ≥ 1 per day was
related to an increased risk of heart
failure among male
Djousse, Graziano,
2008b [38] Prospective cohort study
21,327 US male physicians aged
40–85 years
Infrequent egg consumption does not
seem to influence the risk of CVD in
male. In addition, egg consumption
was positively related to mortality,
more strongly so in diabetic subjects
Herron, Fernandez
2004 [8] Expert Opinion -
Current recommendation about limiting
egg consumption are not benefiting the
public as a whole and may have
negative nutritional implications
Hu et al. 1999 [34] Prospective study
37,851 men aged 40 to 75 years
at study outset and 80,082
women aged 34 to 59 years at
study outset, free of
cardiovascular disease, diabetes,
hypercholesterolemia, or cancer
Consumption of up to 1 egg per day is
unlikely to have substantial overall
impact on the risk of CHD or stroke
among healthy men and women
Katz et al. 2005 [39] Randomized crossovercontrolled trial
49 patients healthy adults with a
mean age of 56 years
Short-term egg consumption does not
adversely affect endothelial function in
healthy adults
Li et al. 2013 [12] Meta-analysis 320,778 included in 14 differentstudies
A dose-response association between




For the general population, dietary
cholesterol makes no significant
contribution to atherosclerosis and risk
of cardiovascular disease
5
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Table 2. Cont.




demonstrate that dietary cholesterol
increases both LDL and HDL
cholesterol with little change in the
LDL:HDL ratio
Nakamura et al.
2006 [28] Prospective study
90,735 Japanese men and
women aged 40–69 years
Eating eggs up to almost diary was not
associated with an increase in
CVD-incidence for middle-aged
Japanese men and women
Nakamura et al.
2004 [41] Prospective study
5186 Japanese women and 4077
Japanese men aged 40–69 years
Limiting egg consumption may have
some health benefits, at least in women
in geographic areas where egg
consumption makes a relatively large
contribution to total dietary cholesterol
intake
Mutungui et al.
2008 [42] Clinical trial
31 men aged 40–70 and with a
Body Mass Index of 26–37
Including egg in a
carbohydrate-restricted diet results in
increasing HDL-C while decreasing the
risk factors associated with metabolic
syndrome
Natoli et al. 2007
[10] Review -
Egg consumption results in only a small
increase in serum cholesterol levels in
most people. The inclusion of eggs in
the context of a diet low in saturated fat
and containing cardio-protective foods
is not associated with increased CVD
risk.






Egg consumption was found to be
non-detrimental to endothelial function
and serum lipids in hyperlipidemic
adults, while egg substitute
consumption was beneficial
Quresci et al. 2007
[44] Prospective study
9734 men and women aged 25 to
74 years
Consumption of greater than 6 eggs per
week does not increase the risk of stroke
and ischemic stroke
Rong et al. 2013 [35] Meta-analysis
5847 incident cases for coronary
heart disease, and 7579 incident
cases for stroke
Consumption of up to one egg per day
is not associated with increased risk of
coronary heart disease or stroke
Scrafford et al. 2011
[45] Prospective study
33,994 men and women free of
CVD and completed food
frequency questionnaire
It was not found a significant positive
association between egg consumption
and increased risk of mortality from
CVD or stroke in the US population
Shin et al. 2013 [46] Meta-analysis
A total of 16 studies were
included, including participants
ranging in number from 1600 to
90,735
Egg consumption is not associated with
the risk of CVD and cardiac mortality in
general population
Spence et al. 2012
[31] Prospective study
1262 patients attending vascular
prevention clinics, mean age of
61.5 years
Regular consumption of egg yolk
should be avoided by persons at risk of
cardiovascular disease
Spence et al. 2010
[47] Review -
It does exist evidence about people al
CVD risk must to restrict egg
consumption
Tran et al. 2014 [33] Systematic Review -
Confliting results prevent broad
interpretation to conclude the effects of
egg consumption and cardiovascular
disease among diabetic individuals
Voutilainen et al.
2013 [48] Prospective study 2682 middle-aged men
No evidence was found that people
with cardiovascular risk should restrict
egg consumption
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Table 2. Cont.
Reference Study Design Number and Type of Subjects Main Conclusion
Weggemans et al.
2001 [29] Meta-analysis
17 studies including 556 subjects,
422 men and 134 women
Dietary cholesterol from eggs raises the
ratio of total to HDL cholesterol and,
therefore, adversely affects the
cholesterol profile
Zampelas 2012 [49] Invited Commentary -
Although it becomes increasingly
clearer that, eggs consumption is not
associated with CVD risk in healthy
populations, the evidence cannot be
considered as conclusive in high risk
populations




No association between egg
consumption and the incidence of CVD
was found
In addition to the consumer individual response, there are other important factors of egg
cholesterol that can play an important role in the effect on human health, such as the food matrix in
which it is presented or the total diet consumed. Thus, previous studies have suggested that egg-yolk
consumption raises serum cholesterol to a greater extent than crystalline cholesterol dissolved into a
solution or incorporated into a diet [51]. On the other hand, another important factor in the individual
response to egg cholesterol is the diet consumed. The egg consumption in countries with typical
western diets, such as the United States, accounts for 26%–32% of the total dietary cholesterol intake,
whereas egg consumption accounts for about 48% of total dietary cholesterol intake in Japan [28].
These differences are of major interest from a nutritional point of view, because an increase in serum
cholesterol in response to increased egg consumption is 1.7 times greater when the background diet is
high in saturated fat compared with a low-saturated-fat background diet. The effect may be attenuated
even further in the case of overweight, insulin-resistant people [10].
In addition to nutrition-related risks, egg consumption can also represent a risk for consumers
derived by other factors, such as their microbiological status. Salmonella, and serovars Enteritidis and
Typhimurium are responsible for most food-borne illnesses associated with the consumption of eggs
and egg products. In Europe, S. Enteritidis and S. Typhimurium are the most commonly isolated
serotypes in human cases of salmonellosis, and contaminated eggs still remain the most important
source of infection with S. Enteritidis for humans [14].
In fact, between 1993 and 2002, 9364 food-borne outbreaks were reported in Spain, 4944 (52%)
of which were caused by Salmonella and 3546 (37.8%) of which were associated with egg products,
constituting an obstacle to the well-being of populations and a source of high economic loss [52].
In order to have safe products, European Commission [53] requires the absence of Salmonella in 25
g or 25 mL of eggs and egg-derived foods, and limits the presence of Enterobacteriaceae to a maximum
of 100 cfu/g after the pasteurization treatment. Limits are also given for 3OH-butyric acid (10 mg/kg
dry matter), an index of the presence of incubator reject eggs, and for lactic acid (1000 mg/kg dry
matter), a chemical index of hygienic quality of the raw material, which are to be measured before
treatment [54]. Additionally, to ensure their safety, egg shells must be clean, dry, fully developed, and
with no cracks; although, cracked eggs can be used if they are processed as soon as possible [55]. Eggs
must be broken in a manner that minimizes contamination, from the shells themselves in particular,
and egg contents may not be obtained by centrifuging or crushing the eggs [54].
Despite this strict safety normative, in some countries, the use of fresh eggs to elaborate
egg-derived products in restoration is not allowed. For this purpose, it is mandatory to use pasteurized
egg products. Although food-service industries other than central kitchens, caterers and restaurants
are not bound to use pasteurized egg products, they have shown an increasing interest in their use,
because of its convenience and ease of handling and storing compared to shelled eggs [15].
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Another important human-health risk related to egg consumption is the potential presence of
residues of veterinary drugs, because laying hens treated with pharmaceutical products can produce
contaminated eggs [56]. Certain habits can also compromise health by being a source of exposure
to environmental contaminants. Many of these potentially toxic pollutants are fat soluble, and thus,
any fatty foods (including eggs) may often contain high levels of persistent organic pollutants [57] or
dioxins, that are usually present even in free-range and organic eggs [58].
Additionally, egg allergies represent one of the most common IgE-mediated food allergies
in infants and young children [59]. This allergy can be influenced on several environmental or
demographic factors. Thus, a recent study found that factors as female gender, preterm delivery,
having older siblings, maternal smoking during pregnancy or exposure in the first year to pets
inversely associated with egg allergy. With respect to demographic origin, this work found that
child with a family history of allergy and those parents born in East Asia are at increased risk of egg
allergy [59]. Among infants and young children, egg allergy is the second most common food allergy
after cow’s milk allergy [60]. The overall prevalence of egg allergy in children in the Western Countries
is about 1%–3% [61], with prevalence in European countries about 2.5% [60,62].
The five major allergens identified in hens eggs are ovomucoid (Gal d1), ovalbumin (Gal d2),
ovotransferrin (Gal d3), lysozyme (Gal d4) and albumin (Gal d5). The majority of allergenic proteins
are contained in egg white (Gal d1–4) rather than in egg yolk (Gal d5) [63]. Several other allergens
have been identified in egg yolk, including vitellenin (apovitellenin I) and apoprotein B (apovitellenin
VI), although their role remains jet unclear [64]. However, various studies have demonstrated that
a large number of egg allergic people were able to tolerate heated egg whites [65], an advantage for
thermally processed eggs. Recent publications indicate that up to 70% of children with egg allergy
can tolerate egg baked in a cake or muffin without apparent reaction. Heat treatment destroys the
conformational epitopes that some individuals form IgE against, thus allowing ingestion of the egg
without any adverse reaction. In addition to altering the epitopes, heating the egg protein also acting
to reduce the allergenicity of the protein by affecting the digestibility of the proteins or making the IgE
binding sites less accessible [66].
4. Recommendations and Worldwide Consumption of Eggs
Guidelines from agencies as the U.S. Department of Agriculture and U.S. Department of Health
and Human Services [5] or the SENC [6] advise healthy adults to limit dietary cholesterol intake to
less than 300 mg each day. However, due to the growing body of scientific literature showing a lack
of relationship between egg intake and CVD, recent dietary guidelines indicate healthy people can
consume one egg a day as part of a healthy diet [33]. Other guidelines have yielded different points,
ranging from no restriction to recommending regular intake of eggs [67]. Despite the recommendations
to limit egg consumption, the worldwide production of eggs increased in recent decades and exceeded
64 million tons in 2009, with China as the largest world producer, with 36% of the world’s production.
For consumers, Mexico is the highest consumer per capita, reaching an average consumption of 355
eggs per person and year, followed by China (344) and Japan (325) [68]. The increase in worldwide egg
production and consumption is rational, because egg protein is of excellent quality and low economic
cost, whereas a big demand for protein sources are needed in developing countries, in which a third of
the population are under nourished [69]. Additionally, the fact that eggs are a good food alternative
for the elderly plays an important role in their consumption increase, because it is expected that, by the
year 2020, the number of people worldwide over the age of 60 could reach one billion [8]. Although
elevated total seric cholesterol values have been shown to predict CVD in middle-aged individuals,
this parameter does not seem to be relevant for the elderly demographic. Unfortunately, in the elderly,
the restriction of fat and cholesterol from the diet often results in the subsequent inclusion of foods
that are high in simple sugars. This change in diet composition can be detrimental, causing increases
in seric triglycerides (TG), which are generally accompanied by low HDL levels, which has been
identified as the best lipoprotein indicator of CVD risk in elderly individuals. Furthermore, it has
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been suggested that the consumption of a low-fat diet by elderly individuals may promote insulin
resistance as a consequence of increased levels of LDL and TG and decreased HDL levels in serum [8].
Furthermore, another important factor that could raise egg consumption in the near future is
the fact that typical factors of modern life, such as frequent travel, busy schedules, little time to cook
and eat at home and the inability to eat together as a family, play an important role in the increased
consumption of pre-cooked and processed foods. As eggs are common ingredients employed by the
food industry for their thickening, gelling, emulsifying, foaming, coloring, and flavoring properties, it
is also expected that the worldwide consumption of eggs included in food industry formulations will
increase in next years [13].
However, in the case of pre-cooked and processed foods, the use of pasteurized liquid eggs and
egg powders are more commonly used than fresh eggs [70]. Food industries chiefly make use of
the liquid egg products obtained through the shelling and pasteurization of shelled eggs, and whole
egg products are employed as ingredients for the manufacture of egg pasta, mayonnaise, pastry or
baked foods [13]. The pasteurization process can accelerate reactions between lipids and molecular
oxygen, resulting in losses of nutritional and sensory properties of the egg products. Besides the
possible impact of processing on lipid oxidation, the initial composition of raw materials can impact
the behavior during processing [70].
Thus, there is a large potential market for functional egg products fortified with bioactive
compounds by means of technological methods. Fortification is often the more cost effective and
practical way to provide micronutrients to communities in need, especially if the technology already
exists and if an appropriate and equitable food-distribution system is in place. It is usually possible to
add multiple micronutrients without substantially increasing the total cost of the food product at the
point of manufacture [69], especially when they manufacture large quantities of foods.
5. Potential Markets for Egg-Derived Functional Foods
The increasing demand for functional foods during recent decades can be explained by the
increasing cost of healthcare, the steady increase in life expectancy and the desire for an improved
quality of life in later years. Functional foods may improve the general condition of the body, decrease
the risk of some diseases and may even be used to cure some illnesses. Taking into account the
progressive aging of the population of developed countries, functional foods are a good alternative for
controlling health costs, because medical services for the aging population are rather expensive [1].
Although the term “functional food” has already been defined several times, there is no unitarily
accepted definition for this group of foods. In most countries, there is no legislative definition for the
term and drawing a line between conventional and functional foods is challenging, even for nutritionist
or food experts. The European Commission’s Concerted Action on Functional-Food Science in Europe
(FuFoSE), coordinated by International Life Science Institute (ILSI) Europe stated that “a food product
can only be considered functional if, together with the basic nutritional impact, it has beneficial effects
on one or more functions of the human organism, thus either improving the general and physical
conditions or/and decreasing the risk of the evolution of diseases. The amount of intake and form of
the functional food should be as it is normally expected for dietary purposes. Therefore, it could not
be in the form of a pill or capsule, just as normal food form” [1].
Experts like Sloan [71] has estimated the global functional-food market to be 47.6 billion US$,
with the United States as the largest market segment followed by Europe and Japan. Some estimations
report an even higher global market value (nearly 61 billion US$) [72]. The three dominant markets
(USA, EU and Japan) contribute to over 90% of total sales, from which the European market was
estimated to contribute around 15 billion US$ in 2006 [73]. It should be emphasized, however, that
the European market is heterogeneous, and there are large regional differences in both the use and
acceptance of functional foods. In general, the interest of consumers in functional foods in the Central
and Northern European countries is higher than in Mediterranean countries, where consumers have
appreciated natural, fresh foods and consider them better for health [1]. Additionally, women tend
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to be slightly more health-oriented than men, and middle-aged and elderly consumers tend to be
substantially more health-oriented than younger consumers [74]. It has been suggested that the reason
behind women’s higher awareness of health issues is the heightened responsibility they feel for the
wellbeing of other family members (related to the dominant role of women as the main purchasers of
foods in households). Therefore, middle-aged and elderly consumers are more aware of health issues,
simply because they, or members of their immediate social environment, are much more likely to be
diagnosed with a lifestyle-related disease than younger consumers. However, other recent research
based on surveys did not find clear differences in the acceptance of functional foods between ages,
gender or the country of origin of consumers [75].
It can be assumed that functional foods represent a sustainable category in the food market [76,77],
because it cannot be neglected that functional-food products help to ensure an overall good health
and/or to prevent/manage specific conditions in a convenient way [71,72]. Moreover, it is beyond
doubt that persuading people to make healthier food choices would provide substantial health
effects; therefore, it is in common economic and public interest [77]. This increasing consumer
awareness, in combination with advances in various scientific domains, provides companies with
unique opportunities to develop a large variety of new functional-food concepts [76]. It should also
be considered that functional foods are sold at higher prices, thus containing larger profit margins
than conventional foods, which obviously make the sector attractive for the players in the supply
chain [73]. In general, price premiums of 30%–50% are observed in high-volume functional-food
segments; however, for some products, it can be increased up to 500% [72,73].
Taking into account that eggs and egg-derived products are largely accepted by consumers, owing
to their great culinary versatility and low economic cost, the development of functional eggs and
egg-derived products could be an important way to value the products and to gain profitability for
egg producers and the food industry [8]. Nevertheless, as previously reported [75], functional eggs are
still rarely consumed in Europe. Recent polls revealed that consumers mentioned the consumption of
functional eggs in only two countries. In Sweden, only 3.8% of those asked consumed eggs enriched
with n-3 PUFAs, whereas in Spain, only 6.7% of the respondents consumed eggs enriched with n-3
PUFAs or eggs that were low in cholesterol. Consumers in all other surveyed European countries
reported using no eggs or functional egg products [75].
6. Egg-Derived Products with High Omega-3 Fatty Acid Content
Although the possibility of using other bioactive compounds to obtain functional eggs, such
as lycopene [78], was investigated, the most common bioactive compounds used for this purpose
were n-3 PUFAs [16]. These fatty acids, especially eicosapentaenoic acid (EPA) and docosahesaenoic
acid (DHA), have received great attention from nutritionists and the medical community, because
it is considered that a clear relationship exists between the consumption of EPA and DHA and the
maintenance of normal cardiac function. Thus, n-3 PUFA-fortified products (such as eggs) provide
a means to achieve desired biochemical effects of these nutrients, without the ingestion of dietary
supplements, medications or the need for a major change in dietary habits [19].
Most international agencies and sanitary authorities of western countries recommend a daily
intake of n-3 PUFA between 1000 and 2000 mg daily [19], almost 200 mg/day of which should come
from DHA. Owing to differences in the biological effectiveness, about ten times as much alpha-linolenic
acid (ALA) is required to achieve a similar benefit to EPA and DHA. For this reason, European
Commission [79] states that, in order to advertise and label food as “source of omega-3 fatty acids”, a
food must contain at least 0.3 g of ALA per 100 g and per 100 kcal, or at least 40 mg of EPA + DHA per
100 g and 100 kcal, whereas in order to advertise and label food as “high omega-3 fatty acids’, it must
contain at least 0.6 g of ALA per 100 g and 100 kcal, or at least 80 mg of EPA + DHA per 100 g and
100 kcal.
The content of n-3 fatty acids in eggs and egg-derived products can be increased, either through
feed modifications for hens or through technological methods (in the case of egg-derived products).
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Depending on whether or not we want to produce a product that gets the statement “source of omega-3
fatty acids” or “high in omega-3”, we may choose to supplement the product with a specific raw
material. Thus, if we want to increase the content of ALA, we can use plant oils as a source. Various
plants, such as canola, soybean, walnuts and flaxseed, produce ALA, with the latter being the most
concentrated source [80]. Consequently, flaxseed is the most employed matter for the supplementation
of hens when aiming to obtain n-3 PUFA-enriched eggs by means of increasing the ALA content [16].
However, one of the disadvantages of flaxseed supplementation is that, when the hens feed under such
production parameters, the egg characteristics are very contradictory in terms of feed consumption,
egg production or egg weight [16].
On the contrary, owing to their EPA and DHA content, marine products, such as fish oils, seaweed
or microalgae could be used to obtain egg-derived products with “sources of” or “high in” n-3
PUFA [16]. When using fish oil as source of n-3 PUFA, it is highly recommended to include an
antioxidant substance to prevent sensorial hurdles that are mainly caused by oxidized n-3 PUFA
in eggs [16]. In this sense, recent research has shown that, when seaweed is used as source of n-3
PUFA, it can also act as an antioxidant, as seaweed naturally contains antioxidants such as carotenoids,
polyphenols, and vitamins E and C [81]. Additionally, inclusion of fish oil in the hens’ diets at levels
above 1.5% generates eggs that are generally unacceptable to western consumers, with tastes described
as “fishy”. In this sense, previous works observed that deodorization of fish oil, in order to reduce the
amount of volatiles in the hens’ diet, did not improve the acceptability of the eggs [82]. Similarly, feed
supplementation with microencapsulated fish oil, which is expected to have greater oxidative stability,
still had a negative impact on egg sensory attributes [83]. Oxidative damage in egg yolks fat results
only from direct deposition of oxidized lipids from the feed, as lipids are not further oxidized during
storage [16,80].
With respect to the microalgae supplementation of hens’ diets, autotrophic or heterotrophic
microalgae can be employed. For autotrophic microalgae, despite being an excellent source of n-3
PUFA and other important bioactive compounds such as carotenoids [84], the high price of production
restricts its application in relatively low-value products such as eggs [16]. With respect to heterotrophic
microalgae, recent technology has been developed to produce marine microalgae with an extremely
high DHA content (about 18% of dry mass) through a fermentation process. Oils obtained of two
microalgae, sources of n-3 PUFA, has yet obtained authorization by the European Commission to be
employed as novel food ingredients, (Schizochytrium sp. and Ulkemia sp.) [85,86]. Eggs from hens fed
heterotrophic microalgae typically show similar PUFA profiles to eggs from hens fed fish oil, yielding
eggs with DHA contents up to 200 mg per egg, while maintaining consumer acceptability [16].
Given the relatively limited conversion of ALA into EPA and DHA by the human metabolism,
feed supplementation with long chain n-3 PUFA in the form of fish oil or microalgae is much more
interesting compared to supplementation with their precursor ALA through the addition of flaxseed.
In any case, the obtained enriched eggs by supplementation of hens diet does not affect the cholesterol
content of the eggs [87] and, consequently, consumers could be reluctant to consume eggs as a source
of n-3 PUFA, owing to their high cholesterol content [29,34].
Therefore, one way to diversify the supply and to possibly enlarge the market of egg products
is to produce n-3 PUFA-enriched pasteurized liquid eggs and egg powders. Using technological
methods, it is possible to fortify these by-products with n-3 PUFAs at the same time as reducing
cholesterol content. Moreover, their use as ingredients in a wide range of processed foods could
contribute to increased consumption of n-3 PUFA among the population [70]. Another important
potential advantage of egg-derived products enriched with n-3 PUFA is that the lipid profile is better
preserved at refrigeration temperatures, because storage at room temperature results in a loss of
PUFAs [9]. In some countries, such as those in the EU, it is established that fresh eggs must be stored
and transported at a constant temperature and should, in general, not be refrigerated before sale to the
final consumer (with the exception of French overseas departments) [88]. However, some egg-derived
products, such as pasteurized liquid eggs, are required to be conserved by refrigeration. Thus, in the
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case of bioactive compounds that need refrigeration for better conservation, this could be an advantage
for functional egg-derived products obtained by technological methods with respect to functional
fresh eggs obtained by hens’ diet supplementation.
7. Eggs and Egg-Based Products with Low Cholesterol and Saturated Fats Contents
Eggs represent the major excretory route of the sterol in hens [89], which is almost entirely
contained in the yolk. Different strategies were employed in order to obtain eggs with lower amounts
in cholesterol. Most of these strategies have focused on genetic selection or alteration of the laying hens’
diet, with various nutrients, non-nutritive factors and pharmacological agents [89–91]. Unfortunately,
the vast majority of these experimental approaches only elicited minimal changes (<10%), at best,
or, as in the cases of some strategies such as dietary azasterols and triparanol, they resulted in the
unacceptable replacement of yolk cholesterol by desmosterol [91]. The relatively poor effectiveness of
strategies carried out for reducing yolk cholesterol content was probably due to the relative resistance
of yolk cholesterol content to manipulation by genetic selection. Additionally, there is a lack of available
pharmacological agents that could greatly attenuate hepatic cholesterol biosynthesis and metabolism,
and/or lipoprotein assembly and secretion, without causing a cessation of egg production [89]. In this
sense, copper supplementation to laying hens at pharmacological concentrations (>250 mg/kg) has
been demonstrated to cause a reduction in egg-yolk cholesterol [92], although other researchers did not
find differences in egg-yolk cholesterol after feeding pharmacological levels of dietary cooper [93,94].
On the other hand, the use of atorvastatin in laying hens elicited favorable changes in egg nutrient
composition in addition to the reduction in egg-yolk cholesterol. Thus, eggs obtained from hens
treated with atorvastatin were lower in fat and higher in high-quality proteins that control the eggs [90].
Regarding modification of hens’ diets, feeding hens a diet containing high amounts of fats or oils
generally elevates the yolk cholesterol content [89], whereas feeding hens a diet containing low
amounts of fats or oils slightly reduces the yolk cholesterol content. Other effective approaches to egg
cholesterol reduction include feeding hens garlic paste [95].
In addition to strategies based hen genetic selection or on the modification of the feeding
conditions of laying hens, it is also possible to produce eggs that are low in cholesterol by technological
methods (Table 3). The simplest way is implemented after dehydrating the yolks and whites separately,
developing a new “mix” with more content and less clear yolk, which is where the cholesterol fraction
is found [96]. Another strategy is the removal of cholesterol from egg yolks using organic acids such
as acetone [97]. However, the use of organic acid reduces the emulsifying capacity of the egg yolk,
so detracts technological potential as an ingredient, and could potentially leave residues of these
acids in the egg. Another option is the use of supercritical CO2, an extremely potent solvent for
removing cholesterol from egg yolk [98]. This methodology has obtained very promising results,
but despite its potential, it is not used a lot on the industrial level because of its high price. Other
recent methodology described for this purpose includes the selective degradation of cholesterol in
egg yolks using the enzyme cholesterol oxidase together with ultrasound [99] or using different
species of microorganisms [100–103]. Alternatively, cholesterol can be removed from egg yolks
using microbial degradation or by complexation with β-cyclodextrin, alone or inmobilized in chitosan
beads [104,105], high metoxyl pectins [106], Streamline Phenyl® resin [107] anionic chelating agent [108]
or low-cholesterol liquid food oil [109,110], or by obtaining egg yolk granules [111].
Table 3. Different strategies employed to obtain egg-derived foods with lower amounts in cholesterol
by technological methods.
Reference Method Employed Results Obtained
Aihara et al. 1998 [100]
Degradation of egg yolk
cholesterol by Rodococcus equi No.
23
Degradation of about 60% of egg
yolk cholesterol content
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Table 3. Cont.
Reference Method Employed Results Obtained




Reduction of 92% of cholesterol
content in egg yolk
Christodoulou et al. 1994 [101]
Bioconversion of cholesterol by 3




93% of egg yolk cholesterol
bioconversion
Froning et al. 2008 [98]
Extraction of cholesterol from
dried egg yolk using supercritical
carbon dioxide
Reduction of about 2/3 of total
cholesterol content in egg yolk
Garcia-Rojas et al. 2007 [106]
Extraction of cholesterol in liquid
egg yolk using high methoxyl
pectins
The egg yolk contends of
cholesterol decreased about 14%
Garcia-Rojas et al. 2006 [107]
Removing egg yolk plasma
cholesterol using Streamline
Phenyl® resin
70% of egg cholesterol content
decreased in yolk plasma
Hsieh et al. 1994 [108]
Removing cholesterol and fat from
egg by an anionic chelating agent
(gum arabic)
Obtaining egg yolk essentially free
from cholesterol
Jackeschky 2001 [109]
Dehydrating whole eggs or egg
yolks and there upon treating it
with an extraction based on a
low-cholesterol, liquid food oil
Cholesterol proportion in the egg
yolk being lowered by at least 95%
Kijowski, Lombardo 2000 [110]
Removing cholesterol from egg
yolk by shearing a mixture of
oil:egg yolk:water ratio
Reduction in cholesterol content
about 50%–82% in egg yolk
Laca et al. 2014 [111] Different methods to obtain eggyolk granules
Reduction in cholesterol content
about 80%–90% in egg yolk
granules with respect to egg yolk
Lv et al. 2002 [102]
Bioconversion of yolk powder
cholesterol by extracellular
cholesterol oxidase obtained from
a mutant Brevibacterium sp
More than 85% of the yolk powder
cholesterol was bioconverted
Manohar et al. 1998 [104]
Extraction of cholesterol from egg
materials based on the use of
β-cyclodextrin
Reduction of about 94.5% of total
egg yolk cholesterol and esters
Martucci et al. 1997 [97]
Extraction of cholesterol from
dehydrated hen egg yolk using
acetone as solvent
Reduction about 91% of
cholesterol content in egg
Sotelo, González 2000 [96]
Elaboration o fan egg powder
mixture with a 3:1 proportion of
white and yolk
Reduction about 40% of
cholesterol content in egg
Sun et al. 2011 [99] Ultrasonic-assisted enzymaticdegradation
Cholesterol level in egg yolk was
reduced to 8.32% of its original
concentration without affecting
the quality attributes of the yolk
Valcarce et al. 2002 [103]
Biocenversion of egg cholesterol to
into pro-vitamin D sterols by the
non-pathogenic ciliate Tetrahymena
thermophila
Cholesterol content in egg yolk
was reduced in about 55%
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8. Conclusions
Eggs represent a very important food source, especially for some populations such as the elderly,
pregnant women, children, convalescents and people who are sports training. The volume of both
fresh eggs and eggs used by food companies in their formulations increases constantly. Owing to their
higher security, lower price and easier handing and storing properties, food manufacturers prefer
to use pasteurized egg products rather than fresh eggs. Additionally, the number of functional-food
markets has also increased in recent decades and, owing to some factors such as the progressive aging
of the population of developing countries, are expected to continue to increase in the coming years.
Nevertheless, the presence of functional eggs in the market and knowledge of such products by the
consumers are lower than other groups of foods.
Consequently, the development of functional egg-derived foods through technological methods
could be an interesting way to gain profitability for egg producers and the food industry, in addition
to improving the general conditions of public health. This could be especially interesting for the
addition of bioactive compounds that need to be stored at refrigeration temperatures, because
egg-derived products such as pasteurized liquid eggs must be stored under refrigeration during
the commercialization process. Additionally, these products are safer from the microbiological point of
view, cheaper, easier to hand and store, and because of the heat treatment applied, in some cases are
less allergenic than fresh eggs. Thus, functional egg-derived products obtained through technological
methods are a very interesting option for food manufacturers.
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Abstract: Eggs are a major source of phospholipids (PL) in the Western diet. Dietary PL have emerged
as a potential source of bioactive lipids that may have widespread effects on pathways related to
inflammation, cholesterol metabolism, and high-density lipoprotein (HDL) function. Based on
pre-clinical studies, egg phosphatidylcholine (PC) and sphingomyelin appear to regulate cholesterol
absorption and inflammation. In clinical studies, egg PL intake is associated with beneficial changes
in biomarkers related to HDL reverse cholesterol transport. Recently, egg PC was shown to be a
substrate for the generation of trimethylamine N-oxide (TMAO), a gut microbe-dependent metabolite
associated with increased cardiovascular disease (CVD) risk. More research is warranted to examine
potential serum TMAO responses with chronic egg ingestion and in different populations, such as
diabetics. In this review, the recent basic science, clinical, and epidemiological findings examining
egg PL intake and risk of CVD are summarized.
Keywords: atherosclerosis; cardiovascular disease; egg; HDL; phosphatidylcholine; phospholipids;
sphingomyelin; TMAO
1. Introduction
Cardiovascular disease (CVD) claims upwards of 17 million lives worldwide each year [1]. In
the United States, more than one third of adults suffer from some form of CVD which accounts
for approximately one out of three deaths [2]. Atherosclerosis is a key contributor to CVD and is
characterized by the hardening and thickening of the artery wall caused by accumulation of fatty
plaque. Atherosclerosis is an insidious and progressive chronic inflammatory disease that takes
decades to develop in humans [3]. Atherosclerosis is not only an inflammatory disease characterized
by infiltration of immune cells, but also a lipid disorder; subendothelial accumulation of lipids derived
from plasma lipoproteins is a key initiator of plaque development [4]. Lipoprotein metabolism is
therefore critical to the development of atherosclerosis [5]. Lipoproteins have evolved to facilitate
the extracellular transport of water-insoluble lipids in multicellular organisms [6]. Apolipoprotein
B-containing lipoproteins that originate from the liver, such as very-low-density lipoprotein (VLDL)
and low-density lipoprotein (LDL), contribute to the CVD process. In contrast, high-density lipoprotein
(HDL) improves CVD through its ability to remove excess lipid from the artery and transport it back to
the liver for excretion from the body, a pathway termed “reverse cholesterol transport” (RCT) [7]. The
atheroprotective effect of HDL is mainly attributed to its role in RCT, with plasma HDL-cholesterol
(HDL-C) considered to be a surrogate metric for this pathway [8]. The relationship between blood
cholesterol and CVD is well-established, with the lowering of LDL-cholesterol (LDL-C) levels being
the primary target of preventive therapy [9]. There has also been considerable interest in studying
the relationship between dietary cholesterol intake and CVD risk [10]. Eggs are one of the richest
sources of cholesterol in the diet. However, numerous large-scale epidemiological studies have failed
to find any association between the intake of eggs and CVD risk [11–13]. This lack of association may
be related to the other factors found in eggs that may influence CVD risk, such as the antioxidant
carotenoids lutein and zeaxanthin [14]. Besides being an important contributor of dietary cholesterol
in the Western diet, eggs are also a rich source of phospholipids (PL) [15]. Dietary PL have emerged
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as a potential source of bioactive lipids that may have widespread effects on pathways related to
inflammation, cholesterol metabolism, and HDL function. The aim of this review is to summarize the
recent basic science, clinical, and epidemiological research examining egg PL intake and CVD risk.
2. Phospholipid Content and Composition of the Chicken Egg
PL are key components of all biological membranes and are abundantly found in the diet,
primarily as glycerophospholipid and sphingolipid classes. Dietary glycerophospholipids are made up
of two fatty acids (FA), a glycerol backbone, a phosphate group, and a polar organic molecule (choline,
serine, inositol, or ethanolamine) (Figure 1A). Dietary glycerophospholipids are primarily absorbed
in the gastrointestinal (GI) tract as lysophospholipids and free FA after pancreatic phospholipase
A2 (PLA2) hydrolyzes the fatty acyl bond at the sn-2 position [16]. Glycerophospholipids are
absorbed into the GI tract with high efficiency, for example, >90% of phosphatidylcholine (PC) is
absorbed [17]. Dietary sphingolipids are primarily in the form of sphingomyelin (SM) [18], which
consists of a ceramide (a FA linked to a long-chain sphingoid base through an amide linkage) with a
phosphorylcholine head group (Figure 1B). Digestion of SM in the intestine is slow and incomplete,
with initial hydrolysis of SM to ceramide by alkaline sphingomyelinase and subsequent hydrolysis
to sphingosine by neutral ceramidase [19]. Both ceramide and sphingosine can be absorbed into
intestinal mucosal cells [19]. Chicken eggs contain approximately 28% of total lipids by weight as
PL, with the remaining 66% as triglycerides (TG) and 5% as cholesterol [20]. The average large egg
contains approximately 1.3 g of PL [15,21], which are almost exclusively found in the yolk. A typical
Western diet contains about 2–8 g of dietary PL per day [22]. Estimates of average egg intake in the
U.S. [23] indicate that egg-derived PL contributes 10%–40% (or 0.8 g) of daily consumed PL. The major
PL species found in egg include PC, phosphatidylethanolamine (PE), SM, and phosphatidylinositol
(PI) [24]. The typical PL composition of egg is shown in Table 1, which reveals PC as the predominant
species making up almost three quarters of the total PL. The typical FA compositions of egg PL
species vary [25,26] and are shown in Table 1. These FA compositions can be influenced somewhat by
modifying the dietary FA intake of the hen [25,27,28]. Egg PC typically consists primarily of palmitic
acid (16:0) and oleic acid (18:1) at the sn-1 and sn-2 positions, respectively. The major PC molecular
species include PC (16:0/18:1), PC (22:6/16:0), and PC (22:6/16:1) [28,29]. Egg PE consists primarily of
saturated FA such as stearic acid (18:0) at the sn-1 position, with a balanced mixture of unsaturated
FA at the sn-2 position. The major PE molecular species include PE (16:0/18:1), PE (18:0/18:1), PE
(18:0/18:2), and PE 18:0/20:4 [28–30]. Egg SM contains primarily saturated FA with palmitic acid (16:0)
and stearic acid (18:0) making up ~80% of SM FA.
Figure 1. Structures of major phospholipids in egg yolk. Major molecular species of egg glycerophospholipids
(A) and sphingomyelin (B). Lipid structures were drawn using Lipid MAPS tools [31].
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3. Egg Phospholipids and Lipid Absorption
Inhibition of luminal cholesterol absorption is an attractive target to lower blood cholesterol
and reduce CVD risk. Cholesterol absorption is widely recognized to influence serum lipids [32].
Pharmacological agents, such as ezetimibe, have been developed to reduce intestinal cholesterol
absorption as a means of lowering serum cholesterol and CVD risk [33]. Large intakes of dietary
lecithin have long been known to influence serum cholesterol levels in humans [34]. Meta-analysis
of soy lecithin trials has suggested that the unsaturated FA component was primarily responsible for
the hypocholesterolemic effects observed in early studies [35]. However, recent studies with more
saturated sources of PL, such as egg, show that intact PL strongly influence lipid absorption through
molecular interactions. Dietary phospholipids are known to inhibit cholesterol absorption when added
in significant amounts to the diet (as reviewed by Cohn et al. [22]). Animal studies have shown that
egg PL, such as PC and SM, reduce cholesterol and FA absorption by possibly interfering with lipid
mobilization from mixed micelles [36–39].
Table 1. Typical Composition of Egg Phospholipids.
Egg PL Composition [24]
Egg Yolk PC PE LysoPC SM LysoPE PI
Concentration (mg/100 g yolk) 5840 1500 270 190 90 330
Percentage of total PL (%) 71.1 18.3 3.3 2.3 1.1 4.0
Egg PC FA Composition [25]
Position 16:0 16:1 18:0 18:1 18:2 20:4 22:6
sn-1 62.8 1.4 27.2 6.5 0.8 Trace -
sn-2 6 1 2 56 24.5 5.6 2.9
Total 31 1.2 14.1 33.4 13.4 3.3 1.9
Egg PE FA Composition [25]
Position 16:0 18:0 18:1 18:2 20:4 22:6
sn-1 34.2 51.2 10.5 0.3 Trace -
sn-2 7 4.3 32.1 17.5 23.9 11
Total 16.4 28.3 21.5 10.2 14 6.8
Egg SM FA Composition Adapted from [26]
16:0 18:0 18:1 20:0 22:0 22:1 23:0 23:1 24:0 24:1
68 10 1 4 6 1 2 - 3 6
Abbreviations: FA, fatty acid; LysoPC, lysophosphatidylcholine; LysoPE, lysophosphatidylethanolamine;
PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PL, phospholipid;
SM, sphingomyelin.
Although biliary PC is a critical emulsifier of dietary lipids and aids in their digestion and
absorption in the GI tract, excess luminal PC appears to inhibit lipid absorption. Young and
Hui [40] showed that hydrolysis of surface PC by pancreatic PLA2 is required for proper pancreatic
lipase/colipase digestion of TG and absorption of cholesterol and FA from lipid emulsions. With high
PL concentrations in lipid emulsions (>0.3 PL/TG molar ratio), pancreatic lipase/colipase hydrolysis
of TG was impaired and cholesterol absorption into rat IEC-6 intestinal cells was diminished [40].
Furthermore, micellar PC was shown to inhibit dietary cholesterol absorption into Caco-2 cells, which
was reversed by conversion to lysophosphatidylcholine by pancreatic PLA2 [41]. PC-enriched micelles
appear to impede diffusion across the unstirred water layer of the intestine [42,43]. Thus, digestion
of surface PC appears to be necessary for proper absorption of lipids from both lipid emulsions
and micelles. Jiang et al. [36] showed that duodenal infusion of a lipid emulsion containing egg PC
significantly reduced cholesterol absorption by ~20% in lymph duct cannulated rats. The influence
of PC on cholesterol absorption appears to be dependent on FA saturation, as egg PC inhibited the
absorption of cholesterol into lymphatics greater than the more unsaturated soy PC in the same study.
Soy PC infusion actually increased cholesterol and FA absorption compared to no PC control lipid
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emulsion. Furthermore, hydrogenated egg PC had a greater effect on cholesterol and TG absorption
than egg PC. PC that is saturated at the sn-1 position is known to be a poor substrate for pancreatic
PLA2 hydrolysis [44]. Thus, it appears that the saturation of egg PC makes it more effective at inhibiting
cholesterol absorption than more unsaturated PC, such as soy PC.
SM and other sphingolipids have been shown to dose-dependently reduce the absorption of
cholesterol, TG, and FA in rodents [37–39]. SM interacts with cholesterol with high affinity and appears
to alter its micellar solubilization. The amide portion of SM can interact with the hydroxyl group of
cholesterol through hydrogen bonding [45]. Furthermore, the strength of association appears to be
influenced by SM FA chain length and saturation [38]. Ceramide and sphingosine, which are products
of SM digestion, also appear to reduce lipid absorption into intestinal cells through hydrogen bonding
with the hydroxyl group of cholesterol [46] and possibly through interactions with the carboxylic
acid group of FA [39]. Sphingosine can form complexes with cholesterol and limit uptake via the
cholesterol transporter Niemann-Pick C1 like 1 (NPC1L1) [46]. Duivenvoorden et al. [39] supplemented
the diets of APOE*3Leiden mice with different types of sphingolipids (including SM, ceramide, and
sphingosine) and examined their effects on plasma lipids. Dietary sphingolipids dose-dependently
lowered plasma cholesterol and TG in Western-type diet-fed mice through an inhibition of luminal FA
and cholesterol absorption. While egg SM makes up only about 2% of total PL in egg yolk [24], this
amount may still influence cholesterol absorption. Feeding of 0.2% and 0.4% egg SM to Western-type
diet-fed APOE*3Leiden mice resulted in plasma cholesterol reductions of >20% [39]. Dried egg powder
contains about 0.25% SM by weight, so this could potentially have an impact on inhibiting blood
cholesterol changes that would normally occur from ingesting the amount of cholesterol found in the
yolk. Milk SM has been shown to be a more potent inhibitor of cholesterol and FA absorption when
compared to egg SM [38]. The greater inhibitory effect of milk SM on lipid absorption appears to be
associated with its greater saturation and longer chain-length of its fatty acyl group, which may allow
for stronger hydrophobic interactions [38]. Milk SM primarily consists of very long-chain FA (22:0,
23:0, 24:0), whereas egg SM consists primarily of the long-chain FA palmitic acid (16:0) [38].
Feeding of dietary PE has been shown to lower serum cholesterol in rats [47,48]. Mono-
and di-unsaturated PE may influence cholesterol absorption like SM, as it has been shown
to display a similar affinity to cholesterol as SM [49,50]. Both 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphoethanolamine (POPE) [49] and 1-stearoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine
(SLPE) [50], major PE molecular species in egg yolk [30], have been shown to interact with cholesterol
in monolayers to a similar degree as SM; this suggests an important role for PE in lipid raft formation
at the inner membrane leaflet of cells where it is most abundant. Due to the high affinity for cholesterol
observed with certain PE species, dietary PE from egg may influence the absorption of luminal
cholesterol similar to dietary SM.
4. Egg Phospholipids and Hepatic Lipid Metabolism
In animal models, egg PL appear to influence hepatic lipid metabolism through effects on
cholesterol and bile acid synthesis, FA oxidation, and lipoprotein secretion [51–53]. Hepatic lipid levels
are often shown to be reduced by dietary PL in animals, and this may be due to indirect effects via
inhibition of intestinal lipid absorption and direct effects on hepatic nuclear receptors that regulate
lipid metabolism. Feeding rats an egg yolk-enriched diet (~5% egg PL by weight) for 12 weeks
lowered serum and hepatic lipids, and increased fecal sterol excretion compared to a cholesterol and
fat-matched control group [51]. These changes were related to lower hepatic expression of cholesterol
biosynthesis genes and increased expression of bile acid synthesis genes.
Peroxisome proliferator-activated receptor-α (PPARα) is a nuclear receptor abundantly expressed
in the liver, where it functions as a key regulator of hepatic FA metabolism through transcriptional
control of beta oxidation-related genes [52]. In vitro and rodent studies suggest that PC, specifically the
16:0 and 18:1-containing species PC (16:0/18:1), is a natural agonist of hepatic PPARα. Chakravarthy
et al. [52] showed that portal vein infusion of PC (16:0/18:1) reduced hepatic steatosis in C57BL/6
mice and induced PPARα-dependent gene expression; although, this effect was not observed with
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intraperitoneal administration. Furthermore, incubation of PC (16:0/18:1) with the Hepa 1–6 mouse
hepatoma cell line induced PPARα-target genes involved in FA oxidation. PC (16:0/18:1) was found to
be a minor PL species in the liver which suggests it acts as a signaling molecule in this organ. Thus,
this data suggests that providing PC (16:0/18:1) in the diet may affect hepatic PPARα activation if
sufficient amounts reach the liver, as this is only a minor PL species in this organ [52]. Interestingly,
PC (16:0/18:1) is the major PC species in eggs [29]. However, Cohn and colleagues [54] showed that
feeding C57BL/6 mice a high fat diet supplemented with egg PC (1.25% by weight) for 3 weeks did
not alter hepatic lipids and expression of a PPARα target gene (acyl-CoA oxidase) compared to control
high fat diet. In contrast, feeding mice a hydrogenated form of egg PC, which contained only saturated
FA, significantly lowered hepatic lipid levels [54]. Hydrogenated egg PC is associated with a greater
inhibition of lipid absorption in rodents compared to natural egg PC [36]. Thus, it appears that at least
in mice, the effects of short-term feeding of PC on hepatic lipids may related to its interference with
lipid absorption, rather than modulation of PPARα.
Rye and colleagues [53] studied the effects of egg SM on hepatic lipid metabolism in Western-type
diet-fed C57BL/6 mice. Egg SM feeding (0.6% of diet by weight) for 18 days was shown to reduce
hepatic lipid levels and increase fecal cholesterol output compared to control mice. Although egg SM
feeding substantially reduced hepatic lipids and led to a ~30% reduction in cholesterol absorption, it
did not affect plasma cholesterol or TG levels. Sphingoid bases have been shown to activate PPARα
transcriptional activity in vitro [55]. However, egg SM feeding of Western-type diet-fed mice reduced
the hepatic expression of PPARα-target genes involved in FA oxidation [53]. The reduced hepatic lipid
levels in egg SM-fed mice coincided with significantly lower hepatic expression of genes involved in
cholesterol and FA metabolism [53].
The choline moiety of PL also appears to influence hepatic lipid metabolism and lipoprotein
production. PC and SM are both sources of choline in the Western diet. Choline is an essential nutrient
and is not synthesized in adequate amounts to meet the needs of humans [56]. Dietary choline is
considered especially important for maintaining a healthy liver [57]. Methionine- and choline-deficient
diets (MCD) are well-known inducers of liver injury in mice and are used as a model of nonalcoholic
steatohepatitis [58]. This combined nutrient deficiency causes hepatic lipid accumulation by enhancing
lipid uptake and reducing VLDL secretion [58]. In humans, a single-nucleotide polymorphism in the
PC-synthesizing enzyme, phosphatidylethanolamine N-methyltransferase (PEMT), is associated with
greater risk for non-alcoholic fatty liver disease (NAFLD) [59]. Dietary choline may also influence more
advanced stages of liver disease, as low intake of choline was shown to be associated with increased
hepatic fibrosis in postmenopausal women with NAFLD [60].
While there has been no reports specifically examining the effects of dietary egg PE on hepatic
lipid metabolism, feeding soy PE to rats has been shown to lower hepatic cholesterol levels [47]. Soy
PE consists of primarily PE (16:0/18:2), PE (18:2/18:2), and PE (16:0/18:1) molecular species [30].
5. Egg Phospholipids and HDL Metabolism
Therapies aimed at increasing plasma HDL-C may be beneficial for preventing CVD. Plasma
HDL-C has been shown to be inversely related to the extent of atherosclerosis [61]. According to data
from large prospective cohort studies, it can be estimated that for every 1 mg/dL (0.0259 mmol/L)
increase in HDL-C, there is an approximate 2–3% reduction in CVD risk [62]. Strong experimental
evidence confirms that atherosclerosis is directly alleviated by HDL [63–65]. HDL is thought to
improve CVD outcomes largely by its ability to remove cholesterol from the artery via RCT. Regular
egg yolk consumption has been shown to increase plasma HDL-C and increase the mean size of HDL
particles in healthy [66], overweight [67], and metabolic syndrome (MetS) populations [68]. These
increases in HDL-C and HDL size may be due to the high intake of egg PL.
PL feeding has been associated with increases in HDL-C in animal and human studies [69,70]. PL
content of HDL has been shown to be a major factor in its ability to accept cholesterol from cells during
the initial stages of RCT [71,72]. Dietary PC has been observed to preferentially incorporate into HDL
particles after ingestion. Zierenberg and Grundy [17] examined the metabolic fate of 3H/14C-labeled
24
Nutrients 2015, 7, 2731–2747
polyunsaturated PC in men. Soybean PC was labeled in its FA (14C) and choline moiety (3H), given
orally at a dose of 1 g, and then blood was collected from 6–24 h post-ingestion. The 4C and 3H
radiolabels preferentially incorporated into plasma lipoproteins compared to red blood cells, with
higher specific activity appearing in plasma HDL than in apoB-containing lipoproteins. This increased
appearance of radiolabeled PC in plasma HDL may be explained by the exchange of chylomicron-PC
to HDL in circulation or direct secretion of PC into nascent intestinally-derived HDL. Tall et al. [73]
examined the incorporation of oral 3H/14C-labeled polyunsaturated PC into HDL subclasses. Major
peaks in radiolabel specific activity appeared after 5–8 h in the PL fraction of several HDL subclasses,
in the order of HDL2a (1.11–1.12 g/mL) > HDL3 (1.19 g/mL) > HDL2b (1.07–1.09 g/mL). Thus, the
results suggest that the HDL2a subclass is the major HDL acceptor of oral PL, but all HDL subclasses
appear to incorporate dietary PL to some extent. Plasma HDL-PL content has been shown to increase
postprandially after egg yolk feeding [74]. Thus, dietary egg PL appears in serum HDL after meals
and may impact HDL function.
Clinical studies where subjects were fed egg yolks demonstrated improvements in other markers
of RCT besides HDL-C, such as plasma lecithin-cholesterol acyltransferase (LCAT) activity [68,75,76]
and serum cholesterol efflux capacity [77]. Recently, HDL cholesterol efflux capacity has emerged as
a significant predictor of heart disease status, even after adjusting for plasma HDL-C and its major
protein, apolipoprotein (apo) A-I [78]. PL-enrichment of HDL with either PC or SM improves its ability
to mobilize cholesterol from cells [71,72]. The first component of RCT, involving cellular cholesterol
mobilization, relies on apo A-I and HDL particle interactions to promote cholesterol efflux by a variety
of passive and active mechanisms [79]. Important factors in HDL cellular cholesterol efflux include
cholesterol mobilization via ABC transporters (ATP-binding cassette transporters A1 and G1) and
scavenger receptor B1 (SR-B1), desorption of free cholesterol via aqueous diffusion, and esterification
of cholesterol by LCAT [79]. Preferred acceptors for ABCG1 and SR-B1 are larger HDL particles
containing PL [71,72]. Egg yolk feeding was shown to increase HDL-PE and decrease HDL-TG [77].
Interestingly, egg ingestion shifted HDL-SM towards molecular species that more closely resembled
egg SM, suggesting that egg SM may be incorporated into HDL [77]. Thus, increasing dietary intake of
egg PL may change HDL-PL content and this could explain the increases in serum cholesterol efflux
capacity and enlargement in HDL particle size observed with egg yolk intake in humans [68,77]. The
increases in HDL-C associated with egg PL intake may reflect a greater capacity for RCT.
6. Egg Phospholipids and Inflammation
In addition to effects on lipid metabolism, dietary intake of egg PL may also reduce inflammation.
Consuming three eggs per day for 12 weeks resulted in a reduction in plasma C-reactive protein
(CRP) and an increase in adiponectin in overweight men; changes which were not observed with
yolk-free egg substitute [80]. Egg consumption has also led to improvements in circulating plasma
inflammatory markers in adults with MetS [81]. In combination with moderate carbohydrate restriction,
the addition of three eggs per day led to decreases in plasma TNFα and serum amyloid A in men
and women with MetS, whereas no changes were observed in subjects consuming a yolk-free egg
substitute [81]. Egg yolk contains a significant amount of choline as PC. Dietary choline intake has been
shown to be inversely associated with serum inflammation markers in healthy adults [82]. Choline
administration to mice has been shown to significantly reduce plasma TNFα and enhance survival in
response to an endotoxin challenge [83]. Choline seems to act through nicotinic acetylcholine receptor
subunit α7 (α7nAChR) activation, which has a tonic inhibitory effect on immune cell inflammatory
responses [83,84]. Some studies have suggested that dietary PC may reduce inflammation in the GI
tract [85,86]. Therapeutic usage of oral PC (>1 g daily) in ulcerative colitis is well-documented and
improves inflammation [85,86]. This GI anti-inflammatory effect of PC may be of significance to MetS,
as there is evidence linking GI inflammation to the development of obesity and insulin resistance in
animal models [87]. Furthermore, intestinal inflammation is associated with impaired formation of
intestinally-derived nascent HDL in Crohn’s disease [88,89].
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7. Egg Phospholipids and Trimethylamine N-Oxide (TMAO) Formation
Recently, Hazen and colleagues [90] used unbiased metabolomics to identify three metabolites
of dietary PC (choline, TMAO, and betaine) which were predictors of CVD in a large clinical cohort.
The presumed atherogenic factor, TMAO, is a known metabolite of dietary choline. Dietary choline
can undergo catabolism in the GI tract by gut microflora to form the gas trimethylamine (TMA),
which is absorbed and rapidly oxidized to TMAO in the liver by the hepatic enzyme flavin containing
monooxygenase 3 (FMO3) [91,92]. Hazen and colleagues [90] showed that feeding apoE−/− mice
diets rich in either choline (0.5% or 1% wt/wt) or TMAO (0.12% wt/wt) for 20 weeks resulted in
increased aortic root lesion size despite no changes in traditional CVD risk biomarkers. Highlighting
the role of gut microflora in this process, TMAO formation from dietary PC and the atherogenic
effect of choline feeding were abolished when the mice were germ-free or co-administered broad
spectrum antibiotics to deplete gut bacteria. Additionally, the plasma levels of TMAO in mice and
humans were associated with the expression of hepatic FMO3. Thus, formation of blood TMAO
subsequent to dietary PC intake requires intact gut microflora and may be influenced by hepatic FMO3
expression. Interestingly, TMAO levels do not appear to be strongly influenced by genetic factors in
humans [93], suggesting that diet and gut microflora primarily determine differences in plasma TMAO
levels between individuals. TMAO formation was also shown to be formed from the consumption
of another dietary trimethylamine compound, carnitine [94]. Subsequently, the relationship between
TMAO and CVD was confirmed in a larger prospective cohort [95]. The investigators suggested that
the atherogenic effect of TMAO is due to inhibition of RCT and increased macrophage scavenger
receptor expression, resulting in enhanced foam cell formation [96]. Increases in plasma TMAO that
occurred after carnitine and choline feeding of mice were associated with impaired RCT at the stage of
bile acid production [94]. TMAO was also shown to induce the scavenger receptors CD36 and SR-A in
macrophages [90,94].
Notably, it was shown that healthy participants who consumed a dietary PC challenge
(hard-boiled eggs and deuterium (d9)-labeled PC) had acute increases in plasma TMAO in a gut
microflora-dependent manner [95]. Furthermore, Zeisel and colleagues [97] performed a small,
double-blind, randomized dose-response study where healthy subjects (n = 6) consumed a breakfast
with 0, 1, 2, 4 or 6 egg yolks and levels of plasma TMAO were measured at pre- and post-breakfast
time intervals (up to 24 h). Egg intake dose-dependently increased mean plasma TMAO area under
the curve (AUC) values, with TMAO response peaks occurring 6–8 h after ingestion. Interestingly,
there were >4-fold differences in plasma TMAO levels between subjects at similar dosages, potentially
due to differences in gut microflora or hepatic FMO3 activity. Regardless of the large interindividual
variation in plasma TMAO, each subject displayed an increase in plasma TMAO when increasing
the number of egg yolks consumed. Collectively, these two studies demonstrate that acute intake of
PC from egg may influence postprandial plasma TMAO levels in humans. The effect of chronic egg
intake on TMAO levels has not been examined yet. Findings from chronic egg intake studies would
be more meaningful than acute egg feedings in regards to atherosclerosis risk, since it is a disease
that takes decades to develop. Chronic egg intake could influence gut microflora composition and
this would presumably impact TMAO formation from choline, such as that observed with chronic
exposure to carnitine [94]. It remains to be seen whether there is an “optimal” egg dose, where the
RCT-promoting aspects or other HDL-promoting effects outweigh any possible TMAO effects on
RCT and CVD risk. It will also be important to determine whether chronic or acute egg intake in
humans affects the expression of scavenger receptors in peripheral blood mononuclear cells (PBMCs).
Although egg ingestion may increase plasma TMAO to some extent, it potentially may not reach the
threshold level needed to affect scavenger receptor expression.
The majority of luminal PC available for absorption comes from the endogenously-derived PL
found in bile (10–20 g/day) [98]. Biliary PC, however, does not seem to be a major contributor to
TMAO levels, as plasma TMAO is low in the absence of large amounts of dietary choline [90]. It is
unclear why the large amounts of biliary PC normally found in the intestine do not result in very high
levels of plasma TMAO regardless of dietary PC intake. High amounts of dietary PC, particularly
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saturated PC [44], may overwhelm pancreatic PLA2 activity since it is known to be less efficient than
other lipases [16]. Intact PC digestion in PLA2−/− mice demonstrates additional enzymes in the
intestine are capable of phospholipase activity [99]. Ileal phospholipase B acts in the distal intestinal
mucosa to hydrolyze PC [100]. Thus, a large dietary PL load may result in greater amounts of intact
PC reaching the distal parts of the intestine, where more bacteria reside and can contribute to the
PC-TMA-TMAO pathway.
Daily egg intake has not been shown to be associated with CVD risk in healthy populations [11–13].
In contrast, several large cohort studies have found a positive association between egg intake and CVD
in diabetics [11,12,101,102]. Consequently, patients with diabetes may be discouraged from eating
eggs. These relationships are suggested to be caused by components found in the egg yolk, such
as cholesterol and saturated fat [101]. It is also possible that the PC-TMA-TMAO pathway is more
important or altered in diabetes. Serum TMAO levels have been shown to be elevated in those with
type 2 diabetes [103]. This may be related to the kidney dysfunction that is often seen with diabetes, as
TMAO levels can build up in the blood if they are not cleared by the kidneys. Regardless of kidney
function, however, TMAO is a strong predictor of all-cause mortality risk [104,105]. If the plasma
TMAO response to egg intake is increased in diabetics relative to non-diabetics, that may explain
the consistent link between egg intake and CVD in diabetics. Further research is warranted to see if
plasma TMAO response to egg intake is altered in insulin-resistant or diabetic humans.
8. Conclusions
Egg PL are important contributors to the overall dietary PL intake in the Western diet. Based
on pre-clinical studies, egg PC and SM appear to regulate lipid absorption, hepatic lipid metabolism,
and inflammation. In clinical studies, egg PL intake is associated with beneficial changes in serum
biomarkers related to HDL function. However, the recent evidence linking acute ingestion of eggs
with postprandial increases in plasma TMAO warrants concern. More research needs to be done to
examine TMAO responses to chronic egg intake and in different populations, such as diabetics. It will
be critical determine if the perceived benefits of egg PL intake on CVD risk markers outweigh the risk
of potential TMAO formation (Figure 2).
Figure 2. Potential pathways egg phospholipids could influence atherosclerosis. Egg phospholipids
may lessen risk for cardiovascular disease (CVD) via reducing lipid absorption (PC, SM), reducing
hepatic lipids (PC, SM), increasing HDL cholesterol efflux (PC, SM), and reducing inflammation
(PC). Egg PC may also influence CVD risk via gut microflora-dependent catabolism to TMA and
liver conversion to TMAO. TMAO may increase CVD risk via increasing macrophage scavenger
receptors and decreasing RCT via reduced bile acid synthesis. Abbreviations: ABCG1, ATP-binding
cassette transporter G1; CD36, Cluster of Differentiation 36; FMO3, flavin containing monooxygenase
3; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PC, phosphatidylcholine; PE,
phosphatidylethanolamine; SM, sphingomyelin; SR-A, scavenger receptor A; SR-B1, scavenger receptor
B1; TMA, trimethylamine; TMAO, trimethylamine N-oxide.
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Abstract: There is concern that egg intake may increase blood glucose in patients with type 2
diabetes mellitus (T2DM). However, we have previously shown that eggs reduce inflammation in
patients at risk for T2DM, including obese subjects and those with metabolic syndrome. Thus, we
hypothesized that egg intake would not alter plasma glucose in T2DM patients when compared
to oatmeal intake. Our primary endpoints for this clinical intervention were plasma glucose and
the inflammatory markers tumor necrosis factor (TNF)-α and interleukin 6 (IL-6). As secondary
endpoints, we evaluated additional parameters of glucose metabolism, dyslipidemias, oxidative
stress and inflammation. Twenty-nine subjects, 35–65 years with glycosylated hemoglobin (HbA1c)
values <9% were recruited and randomly allocated to consume isocaloric breakfasts containing either
one egg/day or 40 g of oatmeal with 472 mL of lactose-free milk/day for five weeks. Following a
three-week washout period, subjects were assigned to the alternate breakfast. At the end of each
period, we measured all primary and secondary endpoints. Subjects completed four-day dietary
recalls and one exercise questionnaire for each breakfast period. There were no significant differences
in plasma glucose, our primary endpoint, plasma lipids, lipoprotein size or subfraction concentrations,
insulin, HbA1c, apolipoprotein B, oxidized LDL or C-reactive protein. However, after adjusting for
gender, age and body mass index, aspartate amino-transferase (AST) (p < 0.05) and tumor necrosis
factor (TNF)-α (p < 0.01), one of our primary endpoints were significantly reduced during the egg
period. These results suggest that compared to an oatmeal-based breakfast, eggs do not have any
detrimental effects on lipoprotein or glucose metabolism in T2DM. In contrast, eggs reduce AST and
TNF-α in this population characterized by chronic low-grade inflammation.
Keywords: diabetes; eggs; lipoproteins; TNF-α; IL-6; glucose; inflammation
1. Introduction
Epidemiological studies report controversies on the effects of dietary cholesterol and egg intake
on the risk for heart disease in patients with diabetes [1,2]. There is also uncertainty regarding
the associations between dietary cholesterol and the development of diabetes [3,4]. While some
epidemiological studies report a correlation between dietary cholesterol and diabetes risk [5,6], others
fail to find this relationship [3,7]. Thus, there is a need for randomized clinical trials to fully understand
the effects of egg intake on plasma glucose and markers of heart disease risk in patients diagnosed
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with type 2 diabetes mellitus (T2DM). Individuals with T2DM are characterized by having impaired
glucose metabolism, atherogenic dyslipidemia [8], and chronic low-grade inflammation [9], therefore,
recommended foods for diabetic patients should either improve, or have no detrimental effect on
biomarkers associated with these conditions.
Oatmeal is recognized as a heart-healthy breakfast due to the effects of β-glucan on reducing
plasma LDL cholesterol (LDL-C) [10]. Oatmeal has also been shown to decrease blood glucose in 14
patients with uncontrolled T2DM [11]. In contrast, eggs are identified as a food that might raise plasma
LDL-C [12], or that could potentially alter glucose metabolism and lead to diabetes [13].
It has been documented that the Latino population has a genetic predisposition for developing
T2DM [14]. In Mexico, 35.7 and 37.2% of adults ≥20 years old are overweight and obese,
respectively—a dramatic increase from 2006 (26 and 29%) [15]. This obesity epidemic, combined
with the genetic predisposition of Latinos for developing T2DM, contributes to one of the highest
incidences of diabetes worldwide [16], with the northern state of Sonora having one of the greatest
rates of diabetes in the country [17].
We aimed to compare two breakfasts with perceived differences in effects on heart disease risk,
eggs and oatmeal, by conducting a randomized, crossover clinical trial in subjects with T2DM. We
evaluated the effects of consuming one egg per day for a relatively extended period (five weeks) versus
1/2 cup (40 g) of oatmeal per day on plasma glucose and inflammatory markers, our primary endpoints.
Our secondary endpoints included plasma lipids, markers of oxidative stress, and parameters of
glucose metabolism, such as glycosylated hemoglobin (HbA1c). We hypothesized that eating one egg
per day would not adversely affect primary or secondary endpoints when compared to an oatmeal
breakfast. We further hypothesized that eggs would reduce inflammatory markers in this population,
likely due to the presence of highly bioavailable carotenoids [18]. Due to the high rate of diabetes,
in combination with the fact that Mexico is one of the countries that consumes most eggs per capita
(approx. one egg/person/day) [19], we chose our intervention population from the city of Hermosillo,
Sonora to conduct this clinical trial.
2. Experimental Section
2.1. Experimental Design
We recruited 33 subjects (aged 35–65 years) diagnosed with T2DM to participate in this
randomized crossover design study in the city of Hermosillo, Mexico. Based on the standard deviation
from our previous studies where we observed changes in inflammatory markers and using a Z value of
1.96 (95% confidence interval), we estimated that 25 subjects would be sufficient to observe differences
between groups [20,21]. We aimed to recruit 35 subjects to allow for attrition. The study took place
between June–December 2013, from the first subject who was enrolled to study completion by the
last enrolled participant. The exclusion criteria were uncontrolled diabetes, retinopathy, heart disease,
cancer, or renal problems. In addition, participants had to have HbA1c <9% (74.9 mmol/mol). On an
alternating basis, participants were randomly allocated by one of the researchers to consume either
one egg/day or 40 g of oatmeal with 2 cups (472 mL) of lactose-free milk/day for 5 weeks. At the end
of the first period, subjects had a 3-week washout followed by allocation to the alternate breakfast
for an additional 5 weeks. Eggs, oatmeal and lactose-free milk were provided to the subjects every 2
weeks and they returned the uneaten portions, which were recorded by the researchers. Compliance
for both breakfasts was 98 ± 2%. Eggs were purchased from Bachoco, Inc. (Hermosillo, Mexico).
Eggs weighed an average of 65 g and contained 8 g protein, 6.8 g fat and 0.3 g carbohydrate. The
content of cholesterol was 250 mg and lutein was 180 μg as previously determined [22]. Oatmeal
(Quaker oatmeal) was purchased from the local super-market. The average consumption was 1/2
measured cup (40 g) consisting of 5.5 g protein, 3.6 g fat, 23.6 g of total carbohydrate; total fiber was
3.2 g and soluble fiber 0.85 g. Subjects were provided with measuring cups for the oatmeal and they
were told not to consume oatmeal or eggs during the whole intervention except those provided by
the researchers. Subjects were closely monitored by random phone calls to ensure compliance. All
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analysis for the study, including experimental analysis of primary and secondary endpoints, were
conducted by researchers who were blinded to breakfast allocation.
Twenty-nine subjects finished both dietary interventions. Three subjects dropped out of the study
due to personal reasons and 1 subject was removed due to non-compliance with the dietary treatments.
In order to maintain control of T2DM, all subjects were taking glucose-lowering medications, as
prescribed by their physician, including metmorfin (n = 26) and insulin (n = 6). In addition, 18 subjects
were taking blood pressure medication and 9 were on reductase inhibitors. The intervention protocol
was approved by the University of Connecticut Institutional Review Board, the Ethical Committee
from Centro de Investigacion en Alimentacion y Desarrollo (CIAD), and the Review Board from
Hospital Chávez. All subjects gave written informed consent prior to initiating the study. This study is
registered at Clinicaltrials.gov (trial # NCT02181244)
2.2. Diet and Exercise Assessment
Diet was assessed by using four 24-h dietary recalls at the end of each breakfast period, which
included 2 weekdays and 2 weekend days. Subjects were visited by trained dietitians, who interviewed
the subjects to complete all dietary recalls. Nutrient analysis was conducted utilizing ESHA Food
Processor II, version 2007, to which typical diets associated with this region in Mexico have been
added. Subjects received specific instructions to include all foods and ingredients in their dietary recall,
in addition to their respective breakfast foods during the intervention. Participants were instructed
to abstain from consuming oatmeal or eggs during the whole 13-week of the intervention, with the
exception of treatment foods provided by the researchers. A typical breakfast consisted of either
one egg, usually scrambled, accompanied by vegetables and 2 slices of bread or 2 tortillas, or 40 g
of oatmeal with 2 cups (472 mL) of lactose-free milk. We provided lactose-free milk to control for
potential lactose intolerance, which is very common in adults from Hispanic origin. The average
amount of calories consumed for breakfast was 313 kcal/day for the egg period and 335 kcal/day
for the oatmeal period. An exercise diary was also provided to subjects to ensure that there were no
changes in their activity level during the interventions. Subjects provided 3 exercise dairies at the
end of each breakfast period. All participants were very closely monitored by their physician (HV)
throughout the whole study to ensure that they did not change their medications. They were also
monitored by the researchers to ensure compliance with egg and oatmeal intake, and to ascertain
that they did not change the rest of their dietary habits or their level of physical activity during the
13-week intervention.
2.3. Anthropometrics, Body Fat and Blood Pressure
Weight was measured to the nearest 0.1 kg, height was measured to the nearest centimeter, and
body mass index (BMI) was calculated as kg/m2. Body fat was measured by electric bioimpedance
using an Impedimed IMP5™ (Impedimed Pty Ltd, Carlsbad, CA, USA). Blood pressure was measured
with an automated blood pressure monitor (Desk Model Sphingomanometer, Model 100, Bannockburn,
IL, USA) after a 5 min rest. The average of 3 separate recordings is reported.
2.4. Plasma Lipids, Oxidized-LDL and Apolipoprotein B
Subjects fasted 12 h prior to blood draws. Plasma was separated from red blood cells by
centrifugation at 2400× g to measure plasma total cholesterol (TC), LDL (LDL-C), HDL (HDL-C)
and triglycerides by using the Cobas c-111 Clinical Analyzer (Roche Diagnostics, Indianapolis, IN,
USA). Oxidized-LDL was measured by using an ELISA kit from Mercodia (Uppsala, Sweden) and
Apolipoprotein B by utilizing an ELISA kit from Abcam (Cambridge, MA, USA).
2.5. Glucose, Insulin and Homeostatic Mode Assessment (HOMA)
Fasting glucose concentrations, one of our primary endpoints, was analyzed by an enzymatic
colorimetric method (Roche Diagnostics, Indianapolis, IN, USA). Plasma insulin was determined
with an ELISA method (ALPCO Diagnostics, Salem, NH, USA). The homeostasis model assessment
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(HOMA) was used to calculate insulin resistance [23]. HbA1c was measured by utilizing an
immunoturbidimetric method standardized by the National Glycohemoglobin standardization
program (Roche Diagnostics, Indianapolis, IN, USA).
2.6. Determination of Size and Concentrations of VLDL, LDL and HDL Subfractions
Lipoprotein subclass profiles and diameters were measured by proton NMR spectroscopy as
previously reported [24]. This method uses characteristic signals broadcast by lipoprotein subclasses
of different size.
2.7. Inflammatory Markers, Liver Enzymes and Adiponectin
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and C-reactive protein
(CRP) were measured using the Cobas c-111 Clinical Analyzer. Interleukin-6 (IL-6) and tumor
necrosis factor-α (TNF-α), the other two primary endpoints, were measured utilizing ELISA kits
(BD Biosciences, San Jose, CA, USA). Adiponectin was measured by using a Quantikine ELISA by RD
Systems Inc. (Minneapolis, MN, USA).
2.8. Statistical Analysis
SPSS version 13.2 was used for Statistics. A paired t-test was used to evaluate differences in all
measured parameters between the oatmeal and the egg periods. Values are reported as mean ± SD. A
p-value < 0.05 was considered to be significant. Those parameters that were significantly different by
paired t-test were further analyzed by using gender, age and initial BMI as covariates.
3. Results
3.1. Flow Chart of the Study
As indicated in Figure 1, we consented 37 patients for this study. Four of them were excluded
because they did not meet the inclusion/exclusion criteria. From these four, three had HbA1c levels
>9%, and one did not have diabetes as determined by blood glucose levels and glucose tolerance
tests. The 33 patients who met the inclusion criteria were randomly allocated to consume eggs (n = 16)
or oatmeal (n = 17). Before the crossover, three patients decided not to continue the study and one
was removed by the investigators due to non-compliance. Twenty-nine patients finished the whole
intervention. All measured variables presented are for these 33 patients.
Figure 1. Flow chart of the study.
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3.2. Baseline Characteristics
The baseline characteristics of subjects are presented in Table 1. The average age of this population
was 53.5 years and the gender distribution was 19 females and 10 males. The mean value for HbA1c
was 6.75% (50 mmol/mol) indicating good average glycemic control in this population. Seven subjects
were taking statins and 18 subjects were taking hypotensive medications. The majority of subjects (n =
27) had plasma TC < 2.5 mmol/L, LDL-C < 1.2 mmol/L, and blood pressure < 130/85 mmHg. Plasma
triglycerides were high with a mean 2.2 ± 1.2 mmo/L, typical of a diabetic population.
Table 1. Baseline Characteristics of Subjects *.
Parameter (n = 29) Values
Age (years) 53.5 ± 8.3
Gender (n = F/M) 19/10
Total Cholesterol (mmol/L) 4.1 ± 0.7
LDL Cholesterol (mmol/L) 2.3 ± 0.6
Triglycerides (mmol/L) 2.2 ± 1.0
HDL Cholesterol (mmol/L) 1.0 ± 0.2
LDL-C/HDL-C 2.4 ± 1.1
Glucose (mmol/L) 9.0 ± 3.1
Glycosylated Hemoglobin (%) (mmol/L) 6.75 ± 0.89
(50 ± 9.7)
* Values are presented as mean ± SD; n = 29.
3.3. Primary end Points
Results for the primary endpoints are presented in Figure 2. There were no differences in plasma
glucose concentrations between the egg and oatmeal periods (Figure 2A). Similarly, there was a
significant reduction in TNF-α, the other primary endpoints after the egg breakfast period, while IL-6
was, was borderline significant (p = 0.051). (Figure 2B).
Figure 2. Plasma concentrations of glucose (A) and plasma concentrations of interleukin 6 (IL-6) and
tumor necrosis factor-α (TNF-α) (B) after the egg (dark bar) and the oatmeal (white bar). Mean values
for plasma glucose were 9.0 ± 3.0 mmol/L and 8.8 ± 2.3 mmol/L after the oatmeal periods. IL-6 were
3.8 ± 2.7 pg/mL following the egg breakfast (p = 0.051) and 5.2 ± 4.8 pg/mL after the oatmeal and for
TNF-α were 6.7 ± 2.8 pg/mL after the egg breakfast (p = 0.007) and 7.9 ± 2.7 pg/mL after the oatmeal.
*Indicates significantly different p < 0.05 and ** p < 0.01. NS = non-significant.
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3.4. Diet
Dietary intake in egg and oatmeal periods is presented in Table 2. Total energy and percent
energy from protein were not different between periods. In contrast, percent energy from carbohydrate
was higher in the oatmeal period (p < 0.01), while percent of energy from total fat, and saturated,
monounsaturated and polyunsaturated fatty acids (g) were higher during the egg period (p < 0.001).
Total and soluble fiber intake was higher during the oatmeal period (p < 0.01), while dietary cholesterol
was higher during the egg period (p < 0.01) (Table 2). Interestingly, intakes of lutein and zeaxanthin,
the carotenoids present in eggs, were not different between dietary periods (Table 2).
Table 2. Dietary intake during Egg and Oatmeal Periods *.
Parameter Egg Oatmeal p Value
Energy (Kcal) 1629 ± 410 1686 ± 362 0.278
Protein (%) 18.9 ± 3.5 20.0 ± 3.5 0.134
Carbohydrate (%) 50.3 ± 6.5 55.1 ± 7.3 0.010
Total Fat (%) 31.6 ± 5.6 24.7 ± 6.8 <0.0001
SFA (g/day) 21.0 ± 8.9 17.3 ± 9.4 0.043
MUFA (g/day) 17.0 ± 5.3 12.8 ± 6.6 0.006
PUFA (g/day) 8.1 ± 2.4 6.3 ± 2.8 0.009
Total Fiber (g/day) 26.0 ± 10.1 27.5 ± 9.2 0.345
Soluble Fiber (g/day) 5.2 ± 3.3 6.7 ± 3.1 0.008
Insoluble Fiber (g/day) 13.3 ± 5.6 15.2 ± 5.7 0.073
Cholesterol (mg/day) 435.0 ± 119.8 149.4 ± 77 <0.0001
Lutein + Zeaxanthin (μg/day) 1213 ± 1731 1003 ± 1742 0.185
Glycemic Index 49.2 ± 8.7 48.5 ± 7.7 0.752
Glycemic Load 17.3 ± 9.4 17.1 ± 21.3 0.828
* Values are presented as mean ± SD; n = 29 subjects.
3.5. Anthropometrics, Blood Pressure, Plasma Lipids, HbA1c and Insulin
There were no significant differences in body weight, body fat, BMI or blood pressure between
the egg and oatmeal periods (Table 3). Similarly, body weight was not different from baseline or the
washout period (data not shown). While only nine subjects were taking blood pressure medications, all
subjects had systolic and diastolic blood pressure < 130/85 mmHg. Similarly, there were no significant
differences in TC, LDL-C, HDL-C, triglycerides, LDL-C/HDL-C ratio, apolipoprotein B, Ox-LDL,
HbA1c, insulin and insulin resistance measured by HOMA when comparing the egg versus oatmeal
periods (Table 3). Values for anthropometrics, plasma lipids, glucose and HbA1c were not different
between baseline and washout periods (p > 0.05) (data not shown).
3.6. Lipoprotein Number and Subclasses
There were no differences in total lipoprotein number or concentrations of lipoprotein subclasses
between the egg and the oatmeal periods including the atherogenic lipoproteins large VLDL, IDL and
small LDL (Table 4).
3.7. CRP and Liver Enzymes
CRP (6.96 ± 10.15 vs. 6.87 ± 8.98 mg/L), adiponectin (6.2 ± 3.2 vs. 5.6 ± 2.2 μg/mL), and ALT
24.3 ± 11.7 vs. 26.3 ± 13.0 IU/L) were not different when compared at the end of egg and oatmeal
periods, respectively. However, AST was significantly reduced following the egg period (p < 0.05).
Data for liver enzymes is presented in Figure 3.
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Table 3. Anthropometrics, Blood Pressure (BP), Plasma Lipids, Oxidized LDL, Apolipoprotein B,
Glucose, Glycosylated Hemoglobin, Insulin and HOMA after the Egg and Oatmeal Breakfasts *.
Parameter (n = 29) Egg Oatmeal
Weight (kg) 82.1 ±17.0 82.1 ± 17.1
BMI (kg/m2) 30.8 ± 6.4 30.8 ± 6.5
Body Fat (%) 45 ± 9 44 ± 8
Systolic BP (mmHg) 123.5 ± 11.1 123.8 ± 11.3
Diastolic BP (mmHg) 76.1 ± 7.4 76.1 ± 8.0
Total cholesterol (mmol/L) 4.1 ± 1.5 4.0 ± 0.8
LDL cholesterol (mmol/L) 2.5 ± 0.6 2.4 ± 0.6
Triglycerides (mmol/L) 1.48 ± 0.47 1.53 ± 0.55
HDL cholesterol (mmol/L) 1.17 ± 0.23 1.14 ± 0.21
LDL-C/HDL-C 1.99 ± 0.72 1.95 ± 0.68
Apolipoprotein B (mg/L) 90.8 ± 33.9 95 ± 38
Oxidized LDL (U/L) 76.9 ± 25.3 80.6 ± 32.7
Glycosylated Hemoglobin (%) 6.55 ± 0.93 6.60 ± 1.04
Insulin (pmol/L) 101.4 ± 63.2 86.8 ± 50.7
HOMA 3.7 ± 0.7 3.1 ± 0.6
* Values are presented as mean ± SD. There were no significant differences between groups in any of these
parameters as measured by paired t-test.
Table 4. Concentrations of VLDL, IDL, LDL, and HDL subclasses after the egg and oatmeal breakfasts *.
Parameter (n = 29) Egg Oatmeal
Total VLDL Particles (mmo/L) 53.8 ± 27.7 53.1 ± 26.4
Large VLDL (mmol/L) 7.0 ± 4.5 7.6 ± 5.1
Medium VLDL (mmol/L) 21.9 ± 12.3 21.6 ± 13.5
Small VLDL(mmol/L) 24.9 ±17.6 23.8 ± 13.1
Total LDL (mmol/L) 1117 ± 290 1064 ± 253
Large LDL(mmol/L) 189 ± 147 215 ± 141
Small LDL(mmol/L) 775 ± 251 715 ± 230
IDL(mmol/L) 152 ± 89 134 ± 103
Total HDL Particles (μmol/L) 32.7 ± 5.8 33.2 ± 6.3
Large HDL(μmol/L) 3.74 ± 1.88 3.64 ± 1.98
Medium HDL(μmol/L) 8.21 ± 5.33 8.34 ± 5.41
Small HDL(μmol/L) 20.71 ± 3.71 21.17 ± 3.94
* Values are presented as mean ± SD. There were no significant differences between groups in any of these
parameters as measured by paired t-test.
Figure 3. Concentrations of liver enzymes after the egg (dark bar) and the oatmeal (white bar) periods.
ALT did not differ between treatments; However, AST was significantly reduced (p < 0.05) after the egg
period (21.9 ± 5.8 vs. 23.7 ± 6.4 IU/L)
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4. Discussion
In this very well-controlled randomized, crossover clinical trial, we have demonstrated that
consuming 1 egg per day for breakfast during 5 weeks did not alter plasma glucose one of the primary
end points. This is a key finding in regards to the current controversies of egg intake affecting plasma
glucose levels in individuals with diabetes [3,4]. Further, our results have shown that consuming
1 egg per day could be considered potentially beneficial for this population as documented by the
observed reductions in the inflammatory marker, TNF-α, the other primary end point, when compared
to consumption of oatmeal.
We have also demonstrated that consuming 1 egg per day for breakfast during 5 weeks did not
alter plasma lipids, atherogenic lipoproteins, other parameters of glucose metabolism and CRP when
compared to an oatmeal-based breakfast in individuals diagnosed with T2DM. We have previously
shown that 4 weeks is sufficient time to see lipid changes following dietary egg challenges [25,26].
For this study, we followed subjects for an additional week, yet still observed no modifications in
plasma lipids.
This is one of the first clinical trials in which egg effects on cholesterol and glucose metabolism
were determined in a compromised population characterized by having dyslipidemias, insulin
resistance and elevated concentrations of plasma inflammatory markers. The results suggest that egg
intake (one per day) can be easily incorporated into the diets of patients with T2DM, with no apparent
concerns for causing dysregulation of glucose metabolism or formation of atherogenic particles. The
beneficial effects on inflammatory markers confirm what we have observed in past studies regarding
the effects of eggs in decreasing inflammation in other populations at high risk for heart disease and
diabetes, including obesity [20] and metabolic syndrome [21]. In a recent clinical trial, high and low
cholesterol diets were compared in 65 individuals with T2DM [27]. Similar to our design, authors
used eggs as a source of dietary cholesterol and they reported that the egg diet was more effective in
improving glycemic control and the lipid profile by raising HDL-C [27].
Oatmeal has been shown to decrease LDL-C in healthy and hypercholesterolemic individuals [28]
in clinical trials, possibly due to the presence of β-glucan, a component present in oats that has been
shown to lower cholesterol by disrupting micelle formation and decreasing absorption of dietary
cholesterol and bile acids [29]. Thus, it is well recognized that oatmeal is a “heart healthy” food that is
recommended for all populations, including diabetic subjects [30]. In contrast, due to the high content
of dietary cholesterol, eggs have been identified as a food that should be avoided not only in diseased
patients, but also in healthy populations [31]. We have previously demonstrated that consumption
of two to three eggs per day for periods between 4 to 12 weeks does not increase the risk profile for
heart disease in healthy populations [25,26,32]. Most of our subjects (about 2/3 of the population) do
not experience fluctuations in plasma cholesterol following a dietary cholesterol challenge. For those
who have increases in plasma total cholesterol, both LDL-C and HDL-C raise with maintenance of the
LDL-C/HDL-C ratio [25,26,32]. Further, during weight loss interventions, plasma LDL-C does not
change even after consuming three eggs per day during 12 weeks, while HDL-C increases with an
improvement of the LDL-C/HDL-C ratio [20,21].
Contrary to the findings of Pearce et al. [27], who were using a high protein, energy-restricted
diet, our current study found that neither LDL-C nor HDL-C were altered by the egg breakfast when
compared to the oatmeal breakfast, an interesting finding due to the documented effect of oatmeal in
lowering LDL-C [27]. Although we have previously shown that egg intake increases the formation of
large HDL, which has been postulated to promote reverse cholesterol transport [33], and the formation
of large LDL, a particle that has been suggested to be less atherogenic [34], we failed to observe any
changes in LDL or HDL size between dietary periods in these diabetic patients.
These results indicating a lack of effect of egg and oatmeal consumption on plasma lipids
and lipoproteins may be attributable to several factors. In our previous studies, we challenged
our subjects with two to three eggs per day [25,26,32], whereas this current study evaluated the
effect of consuming only one egg per day; thus, the higher concentrations of both cholesterol and
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egg phospholipids provided in our previous studies may be related to the formation of the larger
lipoprotein particles [34,35]. Another interpretation is that diabetes substantially alters lipoprotein
metabolism [36], and consumption of one egg per day was not sufficient to reverse these metabolic
abnormalities. Although the number of large and small LDL particles found in this study are
similar to those observed in overweight/obese [35] and metabolic syndrome [21,37] populations,
the concentrations of intermediate-density lipoprotein (IDL) and large VLDL are higher in this study
compared to previous observations in other high-risk populations [21,35,37]. The higher levels of IDL
could be associated with the hypertriglyceridemia that is common in diabetes [36], which can lead to
the formation of more IDL and large atherogenic VLDL particles.
In addition to maintaining fasting plasma glucose levels, our main finding in this study is that
TNF-α and AST were reduced following the 5-week, one-egg-per-day breakfast. Chronic low-grade
inflammation is a hallmark of diabetes and diabetic patients are characterized by having elevated
concentrations of inflammatory markers [9]; thus, the observed reductions in plasma concentrations
of AST and TNF-α following egg intake deserve further consideration, and may be explained by the
presence of lutein and zeaxanthin in egg yolk. Although intake of these dietary carotenoids was not
different between dietary periods, we have previously shown that plasma concentrations of lutein
and zeaxanthin are significantly higher when eggs are the dietary source [38]. This is likely due to the
higher bioavailability of egg-derived carotenoids [22]. In addition, lutein and zeaxanthin have been
shown to have anti-oxidative and anti-inflammatory properties in cell studies [39], animal models [40]
and humans [20,21]. The results from the current study highlight the importance of certain dietary
carotenoids that could exert a protective effect against inflammation in those populations characterized
by having chronic low-grade inflammation, as is the case of patients with diabetes.
The main strength of this study is that it was a controlled clinical intervention. We performed
thorough dietary recalls and ensured that subjects did not change their activity level during the
intervention period. We also provided the intervention foods and monitored consumption. In addition,
the recruited subjects had good diabetic control as monitored by their HbA1c plasma concentrations, as
well as the absence of extreme diabetes complications, which was a key element for subject compliance.
Further, we ensured that subjects did not change their medication dose/type during the 13-week
intervention. The weaknesses of this study include the short duration of the trial, which might not
have been sufficient to determine changes in some of the measured parameters, and the fact that
the data cannot be extrapolated for those diabetic patients with uncontrolled diabetes or additional
complications associated with T2DM. Another perceived weakness is the lack of blinding of the
subjects and that no intention to treat analysis was performed.
5. Conclusions
In this study, we have shown that eggs should not be a concern for those individuals with T2DM
when HbA1c levels are well controlled. When compared to an oatmeal breakfast, one egg per day
did not result in changes in plasma glucose, our primary end point, LDL-C, triglycerides or in the
concentration of atherogenic particles including large VLDL, IDL or small LDL. Further, there were
no changes in plasma insulin, HOMA or HbA1c, indicating that eggs can be consumed without any
detrimental changes in lipoprotein or glucose metabolism in this population. The most interesting
finding, however, was that eggs—possibly due to their content of highly bioavailable lutein and
zeaxanthin—reduced inflammation in diabetic subjects when compared to oatmeal intake.
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Abstract: Protein is a main nutrient involved in overall iron metabolism in vivo. In order to assess the
prevention of iron deficiency anemia (IDA) by diet, it is necessary to confirm the influence of dietary
protein, which coexists with iron, on iron bioavailability. We investigated the usefulness of the egg
structural protein in recovery from IDA. Thirty-one female Sprague-Dawley rats were divided into a
control group (n = 6) fed a casein diet (4.0 mg Fe/100 g) for 42 days and an IDA model group (n = 25)
created by feeding a low-iron casein diet (LI, 0.4 mg Fe/100 g) for 21 days and these IDA rats were
fed normal iron diet with different proteins from eggs for another 21 days. The IDA rats were further
divided into four subgroups depending on the proteins fed during the last 21 days, which were those
with an egg white diet (LI-W, 4.0 mg Fe/100 g, n = 6), those with an ovalbumin diet (LI-A, 4.0 mg
Fe/100 g, n = 7), those with an egg yolk-supplemented diet (LI-Y, 4.0 mg Fe/100 g, n = 6), and the
rest with a casein diet (LI-C, 4.0 mg Fe/100 g, n = 6). In the LI-Y group, recovery of the hematocrit,
hemoglobin, transferrin saturation level and the hepatic iron content were delayed compared to the
other groups (p < 0.01, 0.01, 0.01, and 0.05, respectively), resulting in no recovery from IDA at the
end of the experimental period. There were no significant differences in blood parameters in the
LI-W and LI-A groups compared to the control group. The hepatic iron content of the LI-W and
LI-A groups was higher than that of the LI-C group (p < 0.05). We found that egg white protein was
useful for recovery from IDA and one of the efficacious components was ovalbumin, while egg yolk
protein delayed recovery of IDA. This study demonstrates, therefore, that bioavailability of dietary
iron varies depending on the source of dietary protein.
Keywords: dietary protein; iron deficiency anemia; egg-yolk protein; ovalbumin
1. Introduction
Protein is one of the main nutrients involved in all aspects of in vivo iron metabolism including
iron absorption, transport, hematopoiesis and storage [1,2]. Thus, adequate intake of not only iron, but
also protein, is important in the maintenance of normal iron metabolism. Dietary protein differs in the
composition of amino acids and the amino acid score by the food origin. Moreover, peptides, which
are the digestive form of proteins, are thought to modulate biological functions, and have recently
been shown to have various physiological functions. In assessing prevention of iron deficiency anemia
(IDA) by diet, it is therefore necessary to confirm the influence and biological use of dietary protein,
which coexists with iron, on iron absorption.
Of the three major nutrients (carbohydrate, protein, and lipid), protein has been reported to
have the greatest influence on iron absorption [3–6]. For example, Cook et al. reported that soybean
protein inhibited iron absorption more than egg white protein by a factor of about 5 [7]. Although the
whole egg is a food that contains a large amount of iron [8], it is often cited as a food that inhibits iron
absorption [9–11]. The majority of iron in eggs is found in the yolk. Although it has been reported
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that the absorptivity of iron from egg origin is low [12,13], iron absorption was shown to increase and
contribute to a delay in the decrease in hemoglobin concentration in an iron-deficient state where iron
demands were high [14]. The mineral absorption promoting effect of casein phosphopeptide (CPP)
of milk origin is well known from the past researches [15–17]. Although a number of studies have
examined the influence of dietary protein on iron absorption, there are few reports on the contribution
of dietary protein in the iron deficient state that is accompanied by abnormal iron metabolism [3–17].
We previously examined the effects of various dietary protein sources consumed simultaneously
with dietary iron on recovery from IDA. Our previous research showed the possibility that egg white
contributes to prompt recovery from IDA compared to soybeans. Furthermore, we showed that the
protein form resulted in an increase in serum iron and maturation of red blood cells compared to the
peptide form, because the protein form maintained its iron-reducing characteristics in the digestive
tract, compared to the peptide form [18]. In the present study, therefore, we investigated the usefulness
of the egg structural protein for recovery from IDA.
2. Experimental Section
2.1. Animal Experimental Protocol
This experimental study was approved by the ethics committee of Kyoto Prefectural University,
and performed in accordance with the Guidelines for Animal Experimentation at Kyoto Prefectural
University. Thirty-one 4-week-old female Sprague-Dawley rats were used in this study (Japan SLC,
Inc., Hamamatsu, Japan). The rats were individually housed in stainless steel cages at a controlled
temperature of 22–24 ◦C, a relative humidity of 40%–60%, and a light cycle of 12 h with free access to
distilled water (the iron content of the distilled water was previously measured). Body weight and
food intake were recorded at the same time everyday.
The 31 rats were divided into two groups on the basis of body weight. The first group (C group, n
= 6, weighing 106–112 g) was fed a control diet for 42 days. The second group (base LI group, n = 25,
weighing 94–121 g) was fed a low-iron diet for 21 days to induce IDA. IDA rats were then divided into
four subgroups based on weight and hemoglobin concentration such that the mean values of these
parameters for each subgroup were the same. Each subgroup was fed either an egg white diet (LI-W
group, n = 6, weighing 155–195 g), an ovalbumin diet (LI-A group, n = 7, weighing 153–177 g), an
egg-yolk supplemented diet (LI-Y group, n = 6, weighing 158–184 g), or the control diet (LI-C group, n
= 6, weighing 163–182 g) for another 21 days. The compositions of the diets used in the experiments are
shown in Table 1. All diets were prepared according to the AIN-76 formulation with one modification
(the addition of choline chloride). The low-iron diet contained 0.4 mg Fe/100 g without any ferrous
citrate in the mineral mixture. The amount of protein and lipids within all experimental diets was
adjusted to be equal to that of the control diet. During the pair- feeding period, the LI-W, LI-A and
LI-Y groups were provided with the same amount of diet that was freely provided to the LI-C group,
on the following day.
Table 1. Composition of experimental diet.
Control Diet Low Iron Diet Egg White Diet Ovalbumin Diet Egg York Diet
(g/kg)
Casein a 200 200 - - 171
Egg White powder b - - 214 - -
Ovalbumin c - - - 211 -
Egg York powder d - - - - 81
α-starch 457 457 447 448 455
Sucrose 228 228 224 225 228
Mixed oil e 50 50 50 50
47
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Table 1. Cont.
Control Diet Low Iron Diet Egg White Diet Ovalbumin Diet Egg York Diet
(g/kg)
Vitamin mixture f 10
Mineral mixture g 35
Cellose 20
(mg/kg)
Iron (III) Citrate 204 - 205 196 163
Iron content 39.6 4.4 40.0 39.9 40.0
a 13.73 gN/100 g. b 12.97 gN/100 g. c 13.10 gN/100 g. d 4.91 gN/100 g. e Rapeseed oil/soybean oil ratio = 7/3. f
AIN-76 vitamin mixture (per g mixture): vitamin A, 400 IU; vitamin D3, 100 IU; vitamin E, 5 mg; vitamin K3, 0.005
mg; vitamin B1, 0.6 mg; vitamin B2, 0.6 mg; vitamin B6, 0.7 mg; vitamin B12, 0.001 mg; D-biotin, 0.02 mg; folic acid,
0.2 mg; calcium pantothenate, 1.6 mg; nicotinic acid, 3 mg; choline chloride, 200 mg; sucrose, 0.968 g. g AIN-76
mineral mixture (g/kg mixture): calcium phosphate dibasic, 500.0; sodium chloride, 74.0; potassium citrate, 220.0;
potassium sulfate, 52.0; magnesium oxide, 24.0; manganese carbonate, 3.5; zinc carbonate, 1.6; cupric carbonate, 0.3;
potassium iodate, 0.01; sodium selenite, 0.0066; chromium potassium sulfate, 0.55; sucrose, 124.03.
Blood was drawn from the tail vein of all of the animals every 4 days during the experimental
period. At the end of each study period, the rats were euthanized under ether anesthesia during the
early phase of the light cycle in a non-fasted state, and blood samples drawn from the inferior vena
cava were collected in tubes with heparin. Samples from the liver and small intestinal mucosa (upper
side, 1/4th) were also collected.
2.2. Blood Constituent Analysis
The blood hemoglobin concentration was measured using Hemoglobin B test Wako (Wako Pure
Chemical Industries, Osaka, Japan). The hematocrit level was measured after centrifugation of the
blood at 12,000 rpm for 5 min at 4 ◦C. Red blood cell (RBC) counts were determined using a Thoma
hemacytometer following a 1:200 dilution with Hayem’s solution in a pipette. Mean cell volume
(MCV), mean corpuscular hemoglobin (MCH) and mean cell hemoglobin concentration (MCHC) were
calculated as follows:
MCV (pg) = Hb (g/dL)/RBC (×106/μL) × 10 (1)
MCH (fL) = Ht (%)/RBC (×106/μL) × 10 (2)
MCHC (%) = Hb (g/dL)/Ht (%) × 100 (3)
Serum iron and unsaturated iron binding capacity (UIBC) were measured using Detaminer Fe
and UIBC (Kyowa Medix Co., Ltd., Tokyo, Japan) with an automatic biochemical analyzer (CL-8000;
Shimadzu Corp., Kyoto, Japan). Total iron binding capacity and serum transferrin saturation were
calculated as follows:
Total iron binding capacity = serum iron + UIBC (4)
Serum transferrin saturation = serum iron/Total iron binding capacity × 100 (5)
2.3. Estimation of Gene Expression
Total RNA was isolated from the homogenized mucosa and liver samples using the Total
RNA Isolation mini kit (Agilent Technologies, Inc., Santa Clara, CA, USA), and converted to cDNA
using a reverse transcriptase enzyme ReverTra Ace (Toyobo Co., Ltd., Osaka, Japan) according to
the manufacturer’s instructions. Each target DNA fragment was amplified using the respective
TaqMan gene expression assay kits and a real-time polymerase chain reaction (PCR) system using
cDNA as a template. Real-time PCR for gene expression analysis was performed using DNA
Engine Opticon and Opticon Monitor software (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
TaqMan primer pairs/probes for gene analysis were obtained using a TaqMan Gene Expression Assay
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(Applied Biosystems, Inc., Carlsbad, CA, USA). Assay IDs were Rn00565927_m1, Rn00591187_m1 and
Rn00667869_m1 for DMT1, Ferroportin and β-actin, respectively. Reactions were performed with 10
μL of Premix EX Taq (Takara Bio, Inc., Ohtsu, Japan), 1 μL of the primer pairs/probes sets and 3 μL
of cDNA in a final volume of 20 μL. After heating the test sample at 96 ◦C for 10 s, 50 PCR cycles
were performed as follows: 95 ◦C for 7 s, 60 ◦C for 30 s, and 72 ◦C for 20 s. The cycle thresholds of the
genes of interest were compared with the housekeeping gene β-actin to determine relative changes
in expression.
2.4. Iron Content of Hepatic Tissue
Liver samples were perfused with saline, and treated by the wet ash method using a microwave
extraction system (Ethos; Milestone Srl., Sorisole, Italy). The ash was suspended in dilute hydrochloric
acid solution after evaporation, and left to dry. Iron concentrations were measured by polarizing
Zeeman-effect atomic absorption spectrometry (Z-6100; Hitachi, Ltd., Tokyo, Japan) after suitable
dilution. We determined that the coefficient of variation was 0.04. Iron concentrations were expressed
on a wet-weight basis.
2.5. Statistical Analysis
Data were presented as means ± standard error (SEM). Before assessing the different variables,
we carried out a Bartlett test to check the normal distribution of the variables. Data that fit the normal
distribution were compared by 1–way analysis of variance (ANOVA) followed by the Tukey-Kramer
test (Table 2, Figures 1 and 2), or Student’s t test (Table 2). The level of significance was set at p < 0.05.
Table 2. Body weight gain, food intake and blood parameters on the day 21 and day 42 after the start
of study.
A. day 21
Base LI C Student’s t-testp value
Body weight gain (g/day) 3.0 ± 0.1 3.4 ± 0.2 0.138
Food intake (g/day) 11.7 ± 0.1 a 12.7 ± 0.4 b 0.034
Hematocrit level (%) 33.0 ± 0.7 a 47.1 ± 1.2 b <0.001
Hemogrobin concentration (g/dL) 9.7 ± 0.3 a 15.4 ±0.7 b <0.001
B. day 42
LI-W LI-A LI-Y LI-C C ANOVAp value
Body weight gain (g/day) 1.4 ± 0.3 1.5 ± 0.1 1.3 ± 0.1 1.5 ± 0.2 1.7 ± 0.1 0.196
Food intake (g/day) 10.9 ± 0.0 a 10.9 ± 0.0 a 10.9 ± 0.0 a 10.9 ± 0.0 a 11.9 ± 0.5 b 0.006
Hematocrit level (%) 49.9 ± 1.5 a 49.3 ± 1.0 a 44.4 ± 3.2 b 48.5 ± 2.8 a 50.7 ± 1.0 a 0.002
Hemogrobin concentration (g/dL) 18.0 ± 0.6 a 17.8 ± 0.6 a 15.0 ± 0.6 b 17.4 ± 1.0 a 18.2 ± 0.5 a <0.001
Red blood cell counts (×106/μL) 14.8 ± 1.1 13.0 ± 1.5 13.5 ± 1.3 14.1 ± 1.8 15.8 ± 2.2 0.072
Mean cell volume * (fL) 12.0 ± 0.4 ab 13.8 ± 1.8 a 11.2 ± 1.1 b 12.4 ± 0.7 ab 11.7 ± 2.0 ab 0.013
Mean corpuscular hemoglobin ** (pg) 33.2 ± 1.0 a 38.4 ± 4.0 b 33.3 ± 4.5 a 34.4 ± 2.0 a 31.6 ± 4.7 a 0.043
Mean cell hemogrobin concentration *** (%) 36.0 ± 1.6 ab 39.0 ± 1.1 ab 33.7 ± 1.4 a 31.4 ± 0.3 ab 36.0 ± 0.6 b 0.022
Normal rats fed low iron diet (base LI, n = 25) for 21 days or control diet (C, n = 6) for 42 days. Base LI group
divided four subgroups, were fed either an egg white diet (LI-W, n = 6), an ovalbumin diet (LI-A, n = 7), an egg
york-supplemented diet (LI-Y, n = 6) or control diet (LI-C, n = 6) for another 21 days. Values are mean ± SEM.
Values with an unlike letter were significant: p < 0.05. * Mean cell volume (pg) = Hb (g/dL)/RBC (×106/μL) × 10,
** Mean corpuscular hemoglobin (fL) = Ht (%)/RBC (×106/μL) × 10, *** Mean cell hemogrobin concentration (%) =
Hb (g/dL)/Ht (%) × 100.
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Figure 1. Total iron binding capacity (A); serum iron (B); transferrin saturation (C) on day 21, 26, 31, 36
and 42 after start of experimental period. Iron deficiency anemia rats, fed low iron diet for 21 days,
divided four subgroups, was fed either an egg white diet (LI-W, n = 6), an ovalbumin diet (LI-A, n = 7),
an egg york diet (LI-Y, n = 6) or a control diet (LI-C, n = 6) and normal rats fed the control diet (C, n = 6)
for 42 days. Values were represented as mean. Values with an unlike letter were significant: p < 0.05.
Figure 2. Iron content (A) and hepcidin mRNA expression (B) in the liver, and iron transporter DMT1
(C) and Ferroportin (D) mRNA expression in small intestines on day 42 after start of study. Iron
deficiency anemia rats, fed low iron diet for 21 days, divided four subgroups, was fed either an egg
white diet (LI-W, n = 6), an ovalbumin diet (LI-A, n = 7), an egg york diet (LI-Y, n = 6) or a control diet
(LI-C, n = 6) and normal rats fed the control diet (C, n = 6) for 42 days. The cycle thresholds of the
genes of interest were compared with the housekeeping gene β-actin to determine relative changes in
expression. Values were represented as means ± SEM. Values with unlike letter were significant: p <
0.05.
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3. Results
3.1. Body Weight Gain, Food Intake and Blood Parameters
Body weight gain, food intake and blood parameters on day 21 and day 42 after the start of the
study are shown in Table 2. There was no significant difference in body weight gain or food intake
between the two base groups on day 21. The hematocrit level and hemoglobin concentration of the
base LI group (LI-W, LI-A, LI-Y and LI-C group) were lower than those of the C group on day 21
(hematocrit: 33.0 ± 0.7 vs. 47.1 ± 1.2%; p < 0.001, hemoglobin: 9.7 ± 0.3 vs. 15.4 ± 0.7 g/dL; p < 0.001),
confirming that the base LI group had developed IDA. On day 42 after the start of the study, the
hematocrit level and hemoglobin concentration of the LI-Y group were significantly lower than that
of the other four groups (Table 2, hematocrit: LI-Y 44.4 ± 3.2 vs. C 50.7 ± 1.0 and LI-C 48.5 ± 2.8%;
p < 0.05, LI-Y vs. LI-A 49.3 ± 1.0 and LI-W 49.9 ± 1.5%; p < 0.01, hemoglobin: LI-Y 15.0 ± 0.6 vs.
LI-W 18.0 ± 0.6, LI-A 17.8 ± 0.6, LI-C 17.4 ± 1.0 and C 18.2 ± 0.5 g/dL; p < 0.01 for all); however,
no statistical difference was found among the LI-W, LI-A, LI-C, and C groups. The MCV of the LI-Y
group was significantly lower than that of the LI-A group (p < 0.05) and the MCH of the LI-A group
was higher than that of the other four groups (p < 0.05). There were no significant differences in body
weight gain, food intake, RBC and MCHC among four groups of base LI.
3.2. The Changes in the Total Iron Binding Capacity, Serum Iron and Transferrin Saturation Level of the
Groups
Figure 1 shows the changes in the total iron binding capacity, serum iron and transferrin saturation
level of the groups on days 21, 26, 31, 36 and 42 after the study. On day 21, the base LI group (LI-W,
LI-A, LI-Y and LI-C group) exhibited lower serum iron and transferrin saturation and higher total iron
binding capacity compared to the C group (p < 0.01 for all). The total iron binding capacity, serum
iron and transferrin saturation level of the base LI group fed the diets containing iron were gradually
restored. The total iron binding capacity of the LI-Y group was statistically higher than that of the C
group from day 21 to day 42 (p < 0.01 for all). From day 21 to day 31, the total iron binding capacity of
the LI-C group was higher than that of the C group (p < 0.01 for all); however, there were no significant
differences between the LI-W, LI-A and C groups on day 31. There were also no statistical differences
among the LI-W, LI-A and LI-C groups after day 21, until day 42 (Figure 1A). The serum iron level
of the LI-Y group was statistically lower than that of the C group from day 21 to day 36 (p < 0.01
for all). There were no significant differences among the LI-W, LI-A, LI-C and C groups on day 36
and no significant differences between LI-W, LI-A and LI-C after day 21 to the end of the experiment
(Figure 1B). The transferring saturation level of LI-Y group was statistically lower than that of the C
group from day 21 to day 42 (p < 0.01 for all). There were no significant differences among the LI-W,
LI-A, LI-C and C groups on day 36 (Figure 1C).
3.3. The Hepatic Iron Content and the mRNA Expression Level of Liver and Mucos
The hepatic iron content of the base LI group (LI-W: 55.2 ± 9.0, LI-A: 62.3 ± 10.8, LI-Y: 23.2 ± 2.2
and LI-C: 42.2 ± 4.9 μg/g liver) was much lower than that of the C group (73.7 ± 20.3 μg/g liver) on
day 42. The iron content of hepatic tissue of the LI-W and LI-A groups was dramatically increased
compared with that of the LI-Y group (p < 0.05), and higher than that of the LI-C group but no
significant differences were observed among the three groups (Figure 2A). A correlation between the
mRNA expression level of hepatic hepcidin and hepatic iron content was observed in both groups
(Figure 2B–D). The hepcidin mRNA expression level of the LI-Y group was lower compared with
the other groups, but no significant difference was shown among five groups (Figure 2B). The DMT1
mRNA expression levels of the LI-W, LI-A and LI-C groups were lower than those of the C group. In
contrast, the mRNA expression level of the LI-Y group was increased compared with the C group, but
there were no statistical differences between the C and the other groups (Figure 2C). The pattern of
expression levels of ferroportin mRNA was similar to the DMT1 mRNA expression levels (Figure 2D).
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4. Discussion
In the present study, we examined the usefulness of egg constitutive proteins on recovery of IDA.
Our results provided new finding that egg yolk protein delayed recovery of IDA while ovalbumin
was useful in recovery of IDA, and that the bioavailability of dietary iron varies depending on dietary
protein source.
Although the iron content of all diets was equivalent, the transitions of total iron binding capacity,
transferring saturation level, and serum iron in the LI-Y group of IDA rats, which were fed the diet
containing egg yolk, showed delayed recovery compared with the other groups, and resulted in no
recovery at the end of the experimental period. Moreover, the blood properties and hepatic iron
content of the LI-Y group were lower than those of the other groups on day 42. These data suggest
that egg yolk resulted in delayed recovery from IDA. On the other hand, the mRNA expression of
hepatic hepcidin, which regulates iron absorption in the gut [19,20], was decreased in the LI-Y group
compared to the other diet groups, and it correlated with hepatic iron content. The mRNA expression
of ferroportin and DMT1, which are transporters of iron absorption in the small intestine [21,22],
were up-regulated in the LI-Y group compared to the C group, suggesting that in this group, iron
storage was insufficient and iron absorption was promoted by homeostasis. Nevertheless, expression
of the iron transporters was up-regulated. One reason for the lack of recovery from IDA in the Li-Y
group may be that the absolute quantity of dietary iron transported in the small intestines was low.
A previous study reported that intake of egg yolk protein decreased the apparent absorption of iron,
calcium and magnesium compared with casein and soy protein in normal rats [23]. Most of the iron in
egg yolk is combined with phosvitin of phosphate protein. Phosvitin is known to have a very high
binding capacity for divalent metals, especially iron [24]. It was observed that the amount of insoluble
iron in the small intestines of rats fed the diet containing phosvitin was higher than that in rats fed
diets without phosvitin [25]. In the present study, feeding the diet containing egg yolk may have
delayed recovery from IDA because the iron in the egg yolk iron and/or other dietary iron may have
strongly combined with phosvitin, and formed an insoluble iron complex in the small intestine. Since
phosvitin is a resistant protein [26], it is possible that the insoluble iron complex was excreted from the
body without being used in vivo. These findings suggest, therefore, that iron from eggs is not readily
used in vivo, and ingredients from egg yolk reduce the bioavailability of dietary iron. In cases of IDA,
the choice of egg yolk as the source of protein and iron should be avoided.
Conversely, at the end of the experimental period, the blood parameters of the LI-W group, which
was fed egg white, the LI-A group, which was fed ovalbumin, and the LI-C group, which was fed
casein, were not significantly different from those of the control group, suggesting that IDA improved
in these groups. The hepatic iron content of the LI-W, LI-A, and LI-C groups was significantly lower
than the C group, however, and iron storage was not recovered in these groups despite receiving the
standard amount of dietary iron given to IDA rats for 3 weeks. The total iron binding capacity of the
LI-W and LI-A group was lower than that of the LI-C, but was not significantly different from the C
group. In addition, the hepatic iron content of the LI-W and LI-A groups was higher than that of the
LI-C group, but there were no significant differences among the three groups. These findings show
that IDA of the LI-W and LI-A groups, which were fed egg white protein, was promptly recovered
due to inhibition of transferrin production at an early stage compared with the LI-C group, which was
fed casein protein. We conclude, therefore, that the egg white protein contributed to an improvement
in the iron deficient state compared to casein protein. These results are in agreement with our previous
reports [18]. If iron absorption in the LI-C group, which was fed casein protein, was promoted by
CPP, this raises the possibility that egg white protein has the absorption promoting effect on iron
that exceeds CPP. On the other hand, a previous study reported that the specific amino acid that
accelerated iron absorption exists in animal protein, such as red meat [27]. These results suggest that
the mechanism for promotion of recovery from IDA by egg white protein differs from the rise in iron
absorption caused by red meat, since the existence of this amino acid in egg has not been reported even
though eggs are from animal sources. Moreover, we assume that the component of egg white protein
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active in recovery of IDA was ovalbumin, because there were no significant differences in changes in
blood parameters and in hepatic iron content between the LI-W and LI-A groups. Albumin possesses
a large number of negative carboxylate sites (−CO2−) on the surface of the molecule, many clustered
in groups of three or more [28]. These sites are suitable for binding iron (III) [29]. Indeed, albumin has
been demonstrated to be a sufficiently powerful ligand for binding iron (III) even when transferrin
is not fully saturated [30]. Therefore, the combination of dietary iron and albumin in the lumen may
form a soluble complex that is advantageous for iron absorption.
Despite the fact that the amount of stored iron in the LI-W, LI-A, and LI-C groups was not restored,
the ferroportin and DMT1 mRNA levels in the small intestine significantly decreased in these groups
compared with the C group. Accordingly, iron absorption by the transporters was suppressed in the
LI-W, LI-A, and LI-C groups, even though they were in an iron-deficient state. It is known that the
expression of the iron transporter ferroportin is down-regulated by secretion of hepcidin [31]; however,
there was no correlation between hepatic iron content and the level of hepatic hepcidin and ferroportin
mRNA expression in this study. Thus, these findings raise the possibility of the presence of another
mechanism for regulation of ferroportin expression in the absence of secretion of hepcidin.
One of the limitations of the present study is that we did not directly measure the rate of iron
absorption as the trend of dietary iron in the intestine is one of clues to comprehend the usefulness of
the dietary iron for the recovery of IDA. In order to elucidate the effects of egg protein on the promotion
of iron absorption, further studies should be conducted to investigate iron balance. Moreover, our
findings suggest that phosvitin, contained within egg yolk protein, likely reduces the bioavailability of
dietary iron. Further research is required to investigate the role of egg yolk phosvitin in the recovery
of IDA and its possible usefulness in iron removal therapy. Although the results obtained in this study
have some implications for public health, it is necessary to keep in mind that the iron bioavailability
varies with different cooking processes, especially of egg yolk.
5. Conclusions
We demonstrated that the origin of dietary protein influenced iron absorption and maturation of
red blood cells without affecting iron transport and hematogenesis in recovery from IDA. In particular,
we showed that egg white protein was useful for recovery from IDA, and one of the efficacious
components was ovalbumin and egg yolk protein delayed recovery of IDA. This study demonstrates,
therefore, that bioavailability of dietary iron varies depending on the source of dietary protein. Further
analysis of the mechanism for IDA recovery by ovalbumin may lead to the development of a new
diet therapy for IDA such as thalassaemias, that does not include iron loading. Conversely, egg yolk
protein may be useful in iron removal therapy without the need for medicine and may potentially be
used in the treatment of diseases such as haemochromatosis, which require control of iron absorption.
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Abstract: The guidelines for dietary cholesterol and/or egg intake for both the general population
and those at higher risk of cardiovascular disease (for example, people with type 2 diabetes mellitus
(T2DM)) differ between countries, and even for different specialist societies in a country. The disparity
between these guidelines is at least in part related to the conflicting evidence as to the effects of
eggs in the general population and in those with T2DM. This review addresses the effect of eggs on
cardiovascular disease (CVD) risk from both epidemiological research and controlled prospective
studies, in people with and without cardio-metabolic disease. It also examines the nutritional qualities
of eggs and whether they may offer protection against chronic disease. The evidence suggests that a
diet including more eggs than is recommended (at least in some countries) may be used safely as part
of a healthy diet in both the general population and for those at high risk of cardiovascular disease,
those with established coronary heart disease, and those with T2DM. In conclusion, an approach
focused on a person’s entire dietary intake as opposed to specific foods or nutrients should be the
heart of population nutrition guidelines.
Keywords: dietary cholesterol; eggs; type 2 diabetes mellitus; cardiovascular disease
1. Introduction
Despite our increased understanding of the pathophysiology of cardiovascular disease, there
remains uncertainty regarding the role of dietary cholesterol and eggs in its pathophysiology. The
guidelines for dietary cholesterol and/or egg intake for both the general population and those at
higher risk of cardiovascular disease (for example, people with type 2 diabetes mellitus (T2DM)) differ
between countries, and even for different specialist societies in a country. For example, the National
Heart Foundation guidelines recommend that all Australians, including those with T2DM or metabolic
syndrome, restrict their egg intake to six eggs or fewer per week [1]; the British Heart Foundation and
Diabetes United Kingdom do not have a limit for dietary cholesterol or egg consumption [2]; and the
American Diabetes Association (ADA) until very recently had a limit on total cholesterol consumption
for both the general population and those with T2DM of 300 mg per day [3], with one egg containing
approximately 200 mg cholesterol. This guideline has since been changed and there is no longer a
limit on dietary cholesterol intake [4]. The American Heart Foundation and the American College of
Cardiology have also abolished their dietary cholesterol restrictions, but another group in the United
States, the National Lipid Association (NLA), has since revised their guidelines and is recommending
<200 mg per day of dietary cholesterol for those with dyslipidaemia [5–7]. The disparity between these
guidelines is at least in part related to the conflicting evidence as to the effects of eggs in the general
population and in those with T2DM. This review addresses the effect of eggs on cardiovascular disease
(CVD) risk from both epidemiological research and controlled prospective studies, in people with and
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without cardio-metabolic disease. Cardio-metabolic risk refers to risk factors associated with increased
risk of cardiovascular disease and metabolic disease, and these two conditions are in turn related.
Metabolic disease or disorders include T2DM, insulin resistance, hypertension and dyslipidaemia. The
review also examines the nutritional qualities of eggs and whether they may offer protection against
chronic disease.
2. Epidemiological Evidence Suggesting That a High-Egg Diet Is Safe for the General Population
But Has Adverse Cardio-Metabolic Effects, Particularly in Those with Diabetes Mellitus
Epidemiological studies to date have indicated very little association between a high egg intake
and cardiovascular disease or mortality in the general population; however, evidence suggests an
adverse effect in sub-groups of the population, notably in those with diabetes mellitus. A summary of
each of the epidemiological studies is provided in Table 1. Some of these studies of longer-term follow
up or larger sample size will be reviewed below in greater detail.
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Earlier evidence as to the effect of egg intake on cardio-metabolic outcomes comes from
the Framingham study (follow up of 24 years), which aimed to determine factors related to the
development of cardiovascular disease. In doing so it addressed the effect of dietary intake (including
egg consumption) on circulating cholesterol levels and on the incidence of coronary heart disease
in a free living population in Framingham, MA, USA [8]. Egg intake in this population ranged
from 0 to 24 eggs per week in males and from 0 to 19 per week in females, with an average egg
consumption of 5.9 per week for males and 3.8 per week for females. Results showed no significant
association between the number of eggs consumed with all-cause mortality, total coronary heart disease,
myocardial infarction, or angina pectoris. Furthermore, a low versus high egg consumption had no
effect on blood cholesterol level. This finding supported the data from intervention studies conducted
at the same time (late 1970s) showing no effect of egg feeding in the general population [40–42].
Importantly, the Framingham study also suggested that focus should be placed on a person’s entire
dietary intake rather than egg or cholesterol intake alone, because circulating cholesterol distribution
curves of the subjects according to tertiles of egg or cholesterol intake were more or less identical. This
study has been supported by several other large epidemiological studies conducted later. Hu and
colleagues reported on egg consumption and risk of cardiovascular disease in two large prospective
cohort studies examining both males from the Health Professionals Follow-up Study (n = 37,851)
and females from the Nurses’ Health Study (n = 80,082) [43]. Both studies found a decline in the
average egg consumption from 2.3 per week in 1986 to 1.6 eggs per week in 1990 for males, and a
decline from 2.8 eggs per week in 1980 to 1.4 eggs per week in 1990 for females. This coincided with
the increased emphasis in the USA during that same period [44,45], to restrict dietary cholesterol
intake to less than 300 mg per day and limit egg consumption due to the high dietary cholesterol
content of eggs. Egg consumption (one egg per day) had no significant association with nonfatal
myocardial infarction or mortality from coronary heart disease, or risk of total stroke or its subtypes,
whether or not subjects with diabetes or hypercholesterolemia were included in the analyses [43].
However, when examining subgroups of the population, a positive association between a higher egg
intake and relative risk of coronary heart disease was found for those with diabetes [43]. Results
were similar in the Physicians Health Study (n = 21,327), in that egg consumption (<7/week) was
not associated with myocardial infarction, stroke or total mortality in male physicians [21]. However,
consumption of greater than or equal to seven eggs per week was associated with a greater risk of
mortality for this entire cohort of male physicians. This positive correlation to mortality with a higher
intake of eggs (≥7 eggs/week) was evident more so in those with diabetes [21]. At the time when the
Physicians Health Study was conducted (as well as the majority of the other epidemiological studies),
a public health campaign (which was emphasised in the early 1980s) was advising people to limit their
cholesterol intake (including their consumption of eggs) [44,45]. Individuals (particularly physicians)
consuming a high number of eggs during that time may have been less likely to have been following
healthy dietary and lifestyle advice in general. Indeed, in this study [21], male physicians consuming a
higher intake of eggs were also following other unhealthy behaviours including reduced frequency of
exercise and increased smoking, and had a higher prevalence of diabetes and hypertension [21].
Epidemiological data from studies conducted in Japan [15–17], Italy [10] and Finland [11] and
systematic and meta-analytic reviews [37,38] also support the above-mentioned data from the United
States (Framingham Study [8], Health Professionals Follow-up Study, Nurses’ Health Study [43]) as
well as data from other United States studies listed in Table 1 [13,19,28], in that egg consumption
showed no significant association with the risk of coronary heart disease or cardiovascular heart
disease in the general population. However, again, as seen with some studies conducted in the United
States [21,27,43], this result was not consistent when analysing sub-groups of the population, such as
in those with self-reported diabetes [17,18]. With respect to egg consumption and incidence of diabetes,
again there are inconsistencies. Despite most studies suggesting an increased association of diabetes
incidence and egg consumption [20,29,31,32,36,38], some studies show no association between egg
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consumption and risk of developing T2DM [26,33], with one study even showing a higher egg intake
being associated with a 38% lower risk of developing T2DM [35].
While the above-mentioned studies show no overall effect of eggs on CVD (at least up to an
intake of six eggs per week), and an increased incidence of T2DM with increased egg consumption,
when considering stroke, some of these epidemiological studies have shown a significant inverse
relationship between a high egg consumption and reduced risk of total and haemorrhagic stroke, and
stroke mortality [19,28,46]. This data provides circumstantial and weak evidence that eggs may have
protective effects against certain pathologies.
In summary, there are inconsistencies in the findings between these prospective cohort
studies in terms of the risk of CVD and mortality, and incidence of diabetes mellitus.
Most studies show no association between egg consumption and CVD risk in a healthy
population [8,10,11,13,17,19,28,30,34,47], while others suggest an increased risk of CVD with higher
egg consumption (≥7 eggs per week) [12,16,21,24]. With respect to the incidence of diabetes with
egg consumption, most studies suggest an increased association of diabetes incidence and egg
consumption [20,29,31,32,36,38], some studies show no association between egg consumption and
risk of developing T2DM [26,33], and one study shows a protective effect of higher egg intake
and incidence of T2DM [35]. Conversely, the risk of stroke appears to be lower with higher egg
consumption [19,28,46]. Similar discrepant findings are seen in subgroups of the population and
specifically in people with diabetes mellitus, with some studies showing no increased risk in CVD
with egg consumption [8,17,28,35], but the majority suggesting that a higher egg intake (usually ≥7
eggs per week) may increase the risk of CVD in this group [18,19,21,27,43]. An important limitation of
these epidemiologic studies in general is the presence of confounding factors that have a known effect
on coronary artery disease and cardiovascular heart disease that may not have been accounted for.
Despite adjusting for some confounding factors in statistical models in the Physicians Health Study,
detailed dietary data (total energy intake and saturated fat) and other important variables (markers
of insulin resistance and lipids) that predict the onset of cardiovascular disease were not taken into
account [21]. Intake of energy, total fat, fruit or wholegrains, as well as body mass index and family
history, were only controlled for in a minority of the above-mentioned epidemiological studies [28,43].
These limitations highlight the need for controlled, prospective studies to determine the impact of
eggs per se on cardio-metabolic health. Importantly, it is now known that dietary cholesterol is not the
principal factor affecting circulating cholesterol levels, with the main determining dietary factors being
saturated and trans-fat intake [48,49], for which only one [28] of these epidemiological studies adjusted.
In this study that adjusted for saturated fat intake [28], there was no increased risk of coronary heart
disease mortality or stroke in those eating greater than six eggs per week compared to those eating one
to six eggs per week.
3. Controlled Prospective Studies of the Effects of a High Egg Diet on Dietary Cholesterol Intake
and Circulating Cholesterol Levels
3.1. The Relationship between Dietary and Circulating Cholesterol
The effect of dietary cholesterol intake on circulating cholesterol level is small. A meta-analysis of
cholesterol feeding studies including both healthy populations and populations with cardio-metabolic
disease, using a variety of sources of dietary cholesterol (including eggs) showed that for every
100 mg per day increase in dietary cholesterol intake, circulating total cholesterol increased by 0.06
mmol/L, high-density lipoprotein (HDL) increased by 0.008 mmol/L, and the ratio of total to HDL
cholesterol increased by 0.020 [50]. One large egg contains approximately 200 mg of dietary cholesterol,
so consuming an egg a day would be expected to increase total circulating cholesterol levels by
approximately 0.12 mmol/L [50]. While mean changes in lipoproteins in response to dietary cholesterol
are small, considerable heterogeneity has been observed in circulating cholesterol responses to dietary
cholesterol [51]. For example, there appears to be less efficient absorption of dietary cholesterol in those
who have obesity and insulin resistance, when compared to those who are lean and insulin sensitive [52,
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53]. However, meta-analyses comparing the effects of dietary cholesterol and fat on circulating lipid
and lipoprotein levels reveal that dietary saturated and trans-fat elicit much stronger effects, and taking
into consideration their higher percentage energy contribution in the diet relative to dietary cholesterol,
saturated and trans-fat are the major contributors to circulating total and low-density lipoprotein
(LDL) cholesterol levels [48,49,54]. For every 2.8-gram per day reduction in saturated fat intake, total
cholesterol reduces by approximately 0.08 mmol/L. Therefore, while increasing egg intake by one egg
per day would be expected to increase total cholesterol by approximately 0.12 mmol/L, a concomitant
reduction in saturated fat intake by 6 g per day (the amount of saturated fat in a tablespoon of butter,
for example) would be expected to reduce circulating cholesterol levels by a similar amount.
3.2. Studies Conducted in the General Population
Prospective controlled studies conducted in the general population (that is, in those that are
relatively healthy without cardio-metabolic disorders) have shown differing effects of egg consumption
on CVD risk. There have been numerous cholesterol feeding studies conducted in a free-living general
population over the last 50 years and some of these studies are referenced in the following section.
However, a summary of only those controlled prospective studies conducted in the general population
since the meta-analytic review performed by Weggemans and colleagues [50] is provided in Table 2.
In some studies in which additional cholesterol (in the form of eggs) has been added to peoples’
diet under strict control, there have been increases in circulating total and LDL cholesterol noted [55–57],
whilst in other such studies there have been no changes [40–42,58–60]. In some studies, circulating
HDL cholesterol levels significantly increased with the addition of eggs to the diet [61–63], which
was also found in the meta-analytic review of dietary cholesterol feeding in 556 subjects from 17
heterogeneous studies using both eggs and high cholesterol products [50]. However, in that review
the authors reported the adverse coronary risk finding of an increase in the ratio of total to HDL
cholesterol by 0.02 units [50]. The majority of these studies (15 of 17 of them) involved subjects
from an otherwise healthy population without metabolic disorders, but one study included those
with type 1 diabetes mellitus (T1DM) and another included subjects with hypercholesterolemia and
hyperlipidaemia. While there was a small but statistically significant adverse change in the total to
HDL cholesterol ratio overall, five of the 17 studies showed no adverse effects of cholesterol feeding
on the lipid profile, six studies showed equivocal effects, and only six studies showed adverse effects.
More importantly, this change in lipid profile appeared to be dependent on the quality of the diet
prescribed, or background diet of the population group [50,64,65]. This meta-analytic review [50]
found that in subjects who were fed a high cholesterol diet and who had a background diet that was
low in saturated fats (a polyunsaturated to saturated fat ratio > 0.7), the increase in LDL cholesterol
was less apparent than in those studies in subjects in whom the background diet was high in saturated
fats (a polyunsaturated to saturated fat ratio ≤ 0.7) [50]. Thus, these observations suggest that a person
consuming a higher dietary cholesterol diet in the context of a diet lower in saturated fat is unlikely to
experience any adverse effect on circulating lipids.
Table 2. Effect of egg consumption on cholesterol levels in the general population.
Reference Study Details Cholesterol/Egg Intake
Effect on Lipids from High
Cholesterol or Egg Intake
Greene et al. 2005 [66]
42 healthy
postmenopausal women
and men > 60 years
3 eggs/day for 1 month
(compared to egg
substitute)
LDL and HDL cholesterol levels
increased; LDL:HDL and TC:HDL
ratios did not change
Katz et al. 2005 [67] 49 healthy adults
2 eggs/day for 6 weeks
(compared to oats
breakfast)
No effect on total cholesterol or
endothelial function
Goodrow et al. 2006 [68] 33 adults > 60 years
1 egg/day for 5 weeks
(compared to egg
substitute)
No increase in total cholesterol,
LDL cholesterol or HDL cholesterol
levels
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Table 2. Cont.
Reference Study Details Cholesterol/Egg Intake
Effect on Lipids from High
Cholesterol or Egg Intake
Harman et al. 2008 [69] 45 overweight or obeseadults (18–55 years)
2 eggs/day as part of an
energy restricted weight
loss diet (compared to no
eggs/day)
Decreased total and LDL
cholesterol
Mutungi et al. 2008 [61] 28 overweight or obesemen (40–70 years)
3 eggs/week as part of a
CHO restricted weight
loss diet (compared to
egg substitute)
Increased HDL cholesterol; no
change in LDL cholesterol levels
Rueda et al. 2013 [70] 73 university students
Breakfast with eggs 5







No significant differences in total,
LDL cholesterol or HDL cholesterol
between the two groups
Clayton et al. 2015 [71] 25 healthy young adults(18–35 years)
2 eggs per day
(compared to a bagel
breakfast) for 12 weeks
No impact on total cholesterol,
HDL cholesterol or LDL cholesterol
levels
The egg breakfast led to
improvements in triglyceride levels
Abbreviations: CHO, carbohydrate; HDL, high density lipoprotein; LDL, low density lipoprotein; TC,
total cholesterol.
Of the more recent studies completed (Table 2), five of the seven studies have shown no adverse
effects on the lipid profile following a high egg intake [66–68,70,71] and two have shown improvements
in circulating lipids with an increased egg consumption [61,69].
3.3. Studies Conducted in people with High Risk of Cardiovascular Disease, Established Coronary Heart
Disease, or with Diabetes Mellitus
In contrast to the variable effects of cholesterol feeding on circulating lipid profiles in the general
population (that is, in those that are otherwise healthy and without cardio-metabolic disorders), with
some studies showing an increase in the ratio of total to HDL cholesterol and LDL cholesterol, but
others showing no adverse effects, in people with a high risk of cardio-metabolic disease the effects of
a high egg diet appear generally positive. As there has been only a small number of well-designed
studies conducted in such a population (that is, in people with high risk of cardiovascular disease
or T2DM, established coronary heart disease, or with diabetes mellitus), these will be reviewed in
greater detail. Six of these studies have been conducted in individuals at high risk of cardiovascular
disease or T2DM [52,53,72–78], one in those with established coronary heart disease [79], and three in
those with T2DM [80–82]. Of these, three studies have shown beneficial effects of a high egg diet on
cardio-metabolic risk factors with respect to the comparator or control group [72–75,81,82], five have
shown no adverse effect [53,76,78–80], and two have shown a detrimental effect, but only in sub-groups
of the population being investigated [52,77]. A summary of each of the controlled prospective studies
conducted in people with cardio-metabolic disease is provided in Table 3.
Table 3. Effect of egg consumption on cholesterol levels in those with cardio-metabolic disease,
including type 2 diabetes mellitus.
Reference Study Details Cholesterol/Egg Intake
Effect on Lipids from Increased
Cholesterol or Egg Intake
Edington et al. 1987 [76] 168 adults withhyperlipidaemia
2 eggs/week or 7 eggs/week
as part of a low fat, high
fibre diet for 8 weeks
No change to total, LDL or HDL
cholesterol
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Table 3. Effect of egg consumption on cholesterol levels in those with cardio-metabolic disease,
including type 2 diabetes mellitus.
Reference Study Details Cholesterol/Egg Intake
Effect on Lipids from Increased
Cholesterol or Egg Intake




2 eggs/day as part of an
American Heart Association
diet for 6 weeks
Increased LDL and HDL
cholesterol levels;
Adults with only high cholesterol
had only non-significant
increases in LDL cholesterol
Knopp et al. 2003 [52] 197 adults with insulinresistance 4 eggs/day for 4 weeks
Increased LDL cholesterol;
This increase in LDL cholesterol
was less in insulin resistant
individuals compared to insulin
sensitive individuals
Tannock et al. 2005 [53]
201 lean insulin-sensitive
adults and lean or obese
insulin resistant adults
4 eggs/day as part of a low
fat diet for 4 weeks
HDL cholesterol increased in all
subjects; non HDL cholesterol
levels increased in lean
insulin-sensitive subjects but not
insulin-resistant subjects
Njike et al. 2010 [78] 40 adults withhyperlipidemia
3 and then 2 eggs/day (acute





No change to total, LDL or HDL
cholesterol. No detrimental
effects on flow mediated
dilatation
Pearce et al. 2011 [81]
65 adults with type 2
diabetes or impaired
glucose tolerance
2 eggs/day as part of an
energy restricted, high
protein diet for 12 weeks
(compared to animal protein
substitute)
Increased HDL cholesterol levels
Blesso et al. 2013 [73–75]
and Andersen et al. 2013
[72]
37 adults with metabolic
syndrome
3 eggs/day as part of
carbohydrate restricted diet
for 12 weeks (compared to
egg substitute)




Fuller et al. 2015 [80]
140 overweight or obese
adults with impaired
glucose tolerance or type
2 diabetes
2 eggs/day for 6 days/week
as part of a 3 month weight
maintenance diet (compared
to <2 eggs/week)
No difference in change in HDL
cholesterol, total cholesterol or
LDL cholesterol levels between
the two groups
Katz et al. 2015 [79] 32 adults with CAD 2 eggs/day for 6 weeks
Daily consumption of eggs
showed no adverse effects on
total cholesterol levels compared
to a high-carbohydrate breakfast
Abbreviations: CAD, coronary artery disease; HDL, high density lipoprotein; LDL, low density lipoprotein.
In a study investigating the effect of high egg intake (three eggs per day) versus egg substitute
(which is comprised of 99% egg white and contains no cholesterol or fat) in those with metabolic
syndrome, improvements in dyslipidemia were noted for both groups when accompanied by a
three-month weight reduction program. However, reductions in circulating concentrations of the
inflammatory markers tumour necrosis factor alpha (TNF-α) and serum amyloid A (a protein secreted
in response to inflammatory stimuli) only occurred in the egg group [74]. Thus the high egg diet had a
beneficial effect in reducing inflammation in this population with metabolic syndrome.
One study has been conducted in people with established coronary heart disease, and in contrast
to the majority of studies, the primary outcome was endothelial function, assessed by flow-mediated
dilatation. The authors found no difference in flow-mediated dilatation or circulating lipid levels
between subjects that were following a high egg diet of two eggs per day compared to those following
a high carbohydrate breakfast or a breakfast containing egg substitute [79]. One other study in which
subjects with hyperlipidaemia were prescribed three eggs during the acute phase and two hard-boiled
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eggs during the sustained phase for breakfast along with their habitual diet, found no detrimental
effects on flow mediated dilatation or lipid profile when compared to baseline levels [78].
In an earlier study in those with either hypercholesterolemia or hyperlipidaemia, subjects followed
the National Cholesterol Education Program (NCEP) Step I Diet for six weeks before being randomised
to 2 eggs or egg substitute daily [77]. There was no difference between the hypercholesterolemia or
hyperlipidaemia egg fed groups for change in LDL cholesterol, when compared to a control group
not fed eggs. However, the authors also reported on within group changes and found that there were
significant increases in LDL cholesterol relative to baseline in the hyperlipidaemic egg fed group, and
significant increases in HDL cholesterol in both the hypercholesterolemia and hyperlipidaemic egg fed
groups from baseline to 12 weeks [77]. However, an important limitation of this study is that the group
on the high egg diet also had a significantly higher intake of saturated fat compared to the control
group not fed eggs [77].
There have been only three controlled, prospective studies investigating the effects of a high egg
diet specifically in people with T2DM, and only one study in people with T1DM [83]. This short-term
study over three weeks examined cholesterol feeding in both subjects with and without T1DM. There
was an increase in the ratio of LDL to HDL cholesterol over a three-week period for those with T1DM
only when 800 mg of cholesterol was added to their diet daily (as a liquid supplement containing egg
yolk) [83]. One of the studies conducted in subjects with T2DM was accompanied by a weight loss
prescription, which may have counteracted any potential detrimental effects of eggs on cardiovascular
markers. In that study, there was no difference in LDL cholesterol between the high (two eggs per day)
and no egg diet groups, and those on a high egg diet had a significant increase in HDL cholesterol
compared to the no egg diet [81]. The other two studies were conducted under weight maintenance
conditions. Over the course of a three-month weight maintenance study examining the effects of a
high (12 eggs per week) versus low-egg (<2 eggs per week) diet [80] in those with impaired glucose
tolerance or T2DM, the findings were similar to those reported by Pearce et al. in their weight loss
study [81]. During this study subjects were required to maintain their weight and activity level, with
an emphasis placed on replacing saturated fat with poly- and mono-unsaturated fatty acids in the
diet. No adverse changes in circulating lipid profiles were evident when compared to those following
a low egg diet [80]. Lastly, in a study comparing the consumption of one egg per day for breakfast
versus an oatmeal-based breakfast in those with T2DM, there was no difference in fasting plasma
glucose between groups after a five-week period. Similarly to the study in subjects with metabolic
syndrome [74], there was a significant reduction in the inflammatory marker TNF-α in the one egg per
day group [82].
Thus, apart from one small study of short duration (three weeks) which showed an increase in
the ratio of LDL to HDL cholesterol with the addition of 800 mg dietary cholesterol daily in people
with T1DM, all other studies conducted to date in subjects with cardio-metabolic disease or T2DM,
have shown either a positive or no adverse effect on cardiovascular risk factors from a high egg diet.
4. Positive and Negative Nutritional Qualities of Eggs
Eggs are very high in dietary cholesterol, and despite an increase in circulating LDL cholesterol
levels seen in some but not all dietary cholesterol feeding studies, eggs do possess nutritional benefits
that may have benefits on health outcomes and CVD risk.
Eggs contain carotenoids (lutein and zeaxanthin) recognised for their role in protecting against
age-related macular degeneration and cataracts, as well as for their antioxidant and anti-inflammatory
properties [75,84]. They provide arginine (a precursor to nitric oxide), which in turn causes blood
vessels to dilate, thereby playing a key role in endothelial function [85], and folate, which may
reduce the risk of T2DM and cardiovascular disease [86,87], and risk of neural tube defects during
pregnancy [88].
Omega-3 fortified eggs may also serve a role in the diet, particularly for people with
hypertriglyceridemia and those who avoid fish. Two studies have shown consumption of omega-3
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supplemented eggs to be associated with a significant decrease in circulating triglycerides [89,90],
consistent with the improvements in triglyceride levels seen with fish or fish oil consumption [91,92].
Eggs are a substantial source of choline, which is a known neurotransmitter involved in cognitive
function [93], but dietary phosphatidylcholine is associated with the production of a proatherosclerotic
metabolite, trimethylamine-N-oxide (TMAO) in a gut-flora dependent manner, and this has been
associated with an increased risk of cardiovascular events [94]
However, to date the effect of long term egg intake on TMAO levels has not been assessed. Thus
despite the potential for an adverse effect of the cholesterol in eggs on LDL cholesterol, it is conceivable
that specific components of eggs could also contribute to favourable health outcomes and reduced
CVD risk in people who consume a high egg diet. When eggs are included in the context of a healthy
diet, these nutritional benefits could conceivably outweigh any adverse effects of eggs, albeit further
well-controlled studies are required to test this.
5. Conclusions
Despite conflicting guidelines between countries regarding dietary cholesterol and specifically egg
intake, the evidence suggests that a diet including more eggs than is recommended (at least in some
countries) may be used safely as part a healthy diet in both the general population and for those at
high risk of cardiovascular disease, those with established coronary heart disease, and those with type
2 diabetes mellitus. The background or intervention diet appears to be a key nutritional component. A
high egg diet in the context of a background diet that is low in saturated fats (a polyunsaturated to
saturated fat ratio > 0.7), or a diet that replaces saturated fats with poly- and mono-unsaturated fats,
is likely to result in positive or no adverse changes in LDL cholesterol, and could be safely advised.
Hence, an approach focused on a person’s entire dietary intake as opposed to specific foods or nutrients
should be the heart of population nutrition guidelines.
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Abstract: Inflammation is a normal acute response of the immune system to pathogens and tissue
injury. However, chronic inflammation is known to play a significant role in the pathophysiology
of numerous chronic diseases, such as cardiovascular disease, type 2 diabetes mellitus, and cancer.
Thus, the impact of dietary factors on inflammation may provide key insight into mitigating chronic
disease risk. Eggs are recognized as a functional food that contain a variety of bioactive compounds
that can influence pro- and anti-inflammatory pathways. Interestingly, the effects of egg consumption
on inflammation varies across different populations, including those that are classified as healthy,
overweight, metabolic syndrome, and type 2 diabetic. The following review will discuss the pro- and
anti-inflammatory properties of egg components, with a focus on egg phospholipids, cholesterol,
the carotenoids lutein and zeaxanthin, and bioactive proteins. The effects of egg consumption of
inflammation across human populations will additionally be presented. Together, these findings have
implications for population-specific dietary recommendations and chronic disease risk.
Keywords: eggs; inflammation; phospholipids; cholesterol; lutein; bioactive proteins; healthy adults;
metabolic syndrome; type 2 diabetes mellitus
1. Introduction
Inflammation is a normal, adaptive physiological response to pathogenic insult, including
microbial infection and tissue injury; however the incidence of chronic low-grade, systemic
inflammation underlying multiple highly prevalent chronic metabolic diseases has warranted the
evaluation of inflammatory processes in disease pathogenesis [1,2]. Acute inflammatory responses
mediated by immune system cells are considered beneficial if executed in a local, controlled manner,
as they function to rapidly and effectively eliminate pathogenic stimuli and return the affected tissue
to a normal, homeostatic state through coordinated activation and resolution of pro-inflammatory
leukocyte activity [1]. However, failure of the body to appropriately execute and resolve acute
inflammatory responses can lead to a detrimental chronic inflammatory tissue state, characterized
by pathological tissue remodeling, fibrosis, and impaired functioning due to persistent inflammatory
cell infiltration, activation, and leukocyte-mediated tissue damage [3,4]. These detrimental effects
are observed in cases of inappropriate activation of the immune system, such as autoimmune
conditions and allergic responses [5–7]. It has additionally been well established that similar adverse
physiological adaptations occur in obesity-related disorders, where prolonged metabolic stress and
tissue malfunction play a role in the development of chronic diseases, such as metabolic syndrome,
cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and cancer—all of which coincide
with a chronic state of systemic, low-grade inflammation [8–11].
Given its significant role in the pathophysiology of many chronic diseases, inflammation has
become a primary target for nutritional intervention. Various dietary patterns, functional foods,
nutrients, and bioactive components have been shown to modulate inflammatory processes within
the context of disease risk and progression [12–15]. Within this category, eggs are one of the most
complex and controversial foods [16]. Eggs contain a variety of essential nutrients and bioactive
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components, but are most often recognized as a relatively rich source of high-quality protein and dietary
cholesterol [17–19]. This had led to discrepancy in dietary recommendations across populations, where
egg consumption has traditionally been considered more advisable to young, healthy populations
and/or athletes (e.g., those with greater protein needs that can withstand a dietary cholesterol
“challenge”), whereas egg intake by individuals at risk for CVD has been discouraged [20,21].
These recommendations have held, despite numerous epidemiological studies finding no association
between egg intake and risk of coronary heart disease (CHD) mortality or stroke in the general U.S.
population [22–25]. However, some studies have found eggs to be associated with an increased risk
for T2DM [26,27], although these findings are not consistent across studies [28,29]. While the majority
of egg nutrition studies have focused on parameters of lipid metabolism and markers of CVD risk,
research has additionally revealed differential inflammatory responses across human populations.
These findings indicate that healthy individuals often have greater pro-inflammatory responses to
egg intake [30,31], whereas egg consumption by individuals who are overweight [32], classified with
metabolic syndrome [33–37], or type 2 diabetic [38] is associated with a reduction in inflammatory
markers. In this review, egg components known to modulate inflammatory pathways will be discussed,
with a focus on their composition, bioavailability, and known mechanisms of action in cell, animal,
and human models. The effects of egg consumption of inflammation across human populations will
additionally be presented. Together, these findings have important implications for the role of eggs in
modulating inflammation within the context of chronic diseases and immune defense.
2. Composition and Bioavailability of Egg Components
Eggs contain a wide variety of essential nutrients and bioactive compounds that can impact
human health [17,39]. At only 72 kilocalories/large egg, eggs are a good source of high quality
protein, fat-soluble and B vitamins, minerals, and choline, while providing relatively less saturated
fat per gram compared to other animal protein sources [17,40]. This review will focus on primary
components of eggs that are relatively abundant, bioavailable, and have pro- and anti-inflammatory
properties: phospholipids, cholesterol, the carotenoids lutein and zeaxanthin, and egg white- and
yolk-derived proteins.
2.1. Phospholipids
Eggs—particularly the yolk fractions—are one of the richest dietary sources of phospholipids [41,
42]. On average, one large egg contains approximately 1.3 g of phospholipids [43,44], which
represent approximately 28%–30% of total lipids by weight [45]. The predominate phospholipid
class found in eggs is the glycerophospholipid phosphatidylcholine, representing approximately
~72% of phospholipids. Additional phospholipid classes include phosphatidylethanolamine (~20%),
lysophosphatidylcholine (3%), phosphatidylinositol (2%), and the sphingolipid sphingomyelin
(3%) [46]. While the fatty acid composition of egg phospholipids varies across classes, the majority
of phospholipids contain long-chain saturated and monounsaturated fatty acids—the distribution of
which can be somewhat reflective of the hen’s diet, age, and environmental conditions [44,47,48].
The majority of egg-derived phospholipids are highly bioavailable, with glycerophospholipid
classes such as phosphatidylcholine being absorbed at >90% efficiency [49,50]. Tracer studies
have demonstrated that dietary phospholipids are preferentially incorporated into plasma
high-density lipoprotein (HDL) fractions over apoB-containing lipoproteins, red blood cells, or
total blood fractions [50]. Similar findings were observed in subjects classified with metabolic
syndrome, where consumption of 3 eggs per day for 12 weeks resulted in greater enrichment of
HDL-phosphatidylethanolamine when compared to subjects consuming a yolk-free egg substitute.
Further, subjects consuming whole eggs exhibited greater enrichment of egg-derived sphingomyelin
species, indicative of the high bioavailability egg phospholipids and incorporation into HDL
particles [46]. In general, phospholipids are known to influence plasma lipids and preferentially
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raise HDL-cholesterol [51,52], making them the likely egg component attributable to increases in
HDL-cholesterol observed from egg intake [34,53].
2.2. Cholesterol
Eggs are one of the richest sources of dietary cholesterol, with an average large egg providing
approximately 186 mg cholesterol [17]. Similar to the majority of phospholipids, cholesterol is
localized to the yolk fraction; however, cholesterol only contributes ~5% of total yolk lipids by
weight [45,54]. Although dietary recommendations for egg intake are often based on their cholesterol
content, absorption efficiency of dietary cholesterol has been shown to be highly variable between
individuals, ranging from 15% to 85% [55]. Efficiency of cholesterol absorption additionally seems to
vary across human populations, with individuals who are insulin-resistant absorbing less cholesterol
then insulin-sensitive counterparts [56,57], regardless of body weight status [58]. However, obese and
insulin resistant subjects exhibit increased rates of endogenous cholesterol synthesis, contributing
to hypercholesterolemia commonly observed in these populations [56–58]. Obesity is additionally
associated with elevated secretion of biliary cholesterol, which may compete with dietary cholesterol
for micellarization and absorption [59–61].
In addition to body weight and health status, cholesterol absorption efficiency is
affected by food matrix composition [43,58,62,63]. The absorption of egg-derived cholesterol
can be altered by interactions with phospholipids, potentially altering the mobilization of
cholesterol from micelles in the intestine [41,43,63]. In Sprague-Dawley rats, egg-derived
phosphatidylcholine and sphingomyelin lowered the intestinal absorption of cholesterol [43,63],
whereas, the addition of lysophosphatidylcholine increased cholesterol absorption [64]. Given
that phosphatidylcholine represents that vast majority of egg phospholipid species [46], intestinal
cholesterol-phosphatidylcholine interactions likely limit egg-derived cholesterol absorption [43,64].
Cholesterol that is absorbed is packaged into chylomicrons and HDL by the enterocyte for ultimate
release into the circulation and delivery to the liver and peripheral tissues [65,66]. Interestingly, in
healthy young men (age 17–22 years), consumption of 3 whole eggs + labeled tracer led to a 52%
slower fractional clearance rate of 14C-cholesteryl ester in plasma, indicating an increased retention
time in chylomicron remnants following egg consumption [67], potentially through downregulation of
receptors involved in systemic cholesterol clearance [67,68]. Overall, while cholesterol intake is known
to impact plasma lipid levels, it is difficult to attribute changes in plasma lipids solely to cholesterol
provided in eggs, due to the similarity of effect on plasma lipids from providing whole eggs or isolated
phospholipid [51–53].
2.3. Lutein and Zeaxanthin
In addition to phospholipids and cholesterol, egg yolks contain various antioxidant
carotenoids [69]. Carotenoids are plant-derived pigments that confer yellow, orange, and red color to
fruits and vegetables [70]. As such, the carotenoid composition of egg yolk is reflective of the hen’s
diet, with greater intake of carotenoid-rich grains resulting in greater yolk enrichment [71]. Lutein and
zeaxanthin are the predominant carotenoid species found in egg yolk, although β-carotene, α-carotene,
and β-cryptoxanthin are also present at lower levels [69].
Lutein and zeaxanthin are dipolar xanthophylls comprised of hydrophilic ionone ring structures
with hydroxyl groups on each end, connected by a lipophilic central chain consisting of conjugated C =
C bonds. Lutein and zeaxanthin structures are near identical, apart from a difference in the positioning
of a double bond the ring structure [72,73]. The predominant isomers of carotenoids found in raw
chicken eggs include all-E-lutein, all-E-zeaxanthin, 13′-Z-lutein, 13-Z-zeaxanthin [74,75].
Compared to plant sources, eggs contain a relatively low amount of lutein and zeaxanthin;
however, egg-derived carotenoids have been shown to be significantly more bioavailable [76]. Factors
affecting the bioavailability of egg-derived lutein and zeaxanthin include method of cooking and the
food matrix [74,75,77]. Using an in vitro gastrointestinal model, Nimalaratne et al. [75] found that
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the primary egg carotenoids, all-E-lutein and all-E-zeaxanthin, were highly stable during digestion,
yet the method of cooking impacted carotenoid bioaccessibility—the release of the carotenoids from
the whole food matrix to allow for micellarization into an absorbable form [75,77]. Boiled eggs
promoted the greatest bioaccessibility, whereas scrambling had the most deleterious effect [75].
Cooking methods have additionally been shown to differentially promote the formation of Z-isomers
from all-E-lutein [74], which may impact downstream micellarization and absorption [78]. Carotenoid
absorption can further be influenced by phospholipid interactions in the intestine [79–81].
Dietary consumption of egg-derived lutein and zeaxanthin often correlates with concentrations in
plasma, where carotenoids are carried by lipoproteins [69]. In a crossover study conducted in healthy
men, serum lutein concentrations were increased to the greatest extent following consumption of a
lutein-enriched egg, as opposed to a lutein supplement, lutein ester supplement, or spinach [76].
Plasma lutein and zeaxanthin levels have also been shown to be increased in healthy adults
following consumption of one lutein- or zeaxanthin-enriched egg per day for 90 days [82], as well
as hypercholesterolemic adults who consumed 1.3 egg yolks per day for 4.5 weeks [83]. Increases
in plasma lutein, zeaxanthin, and β-carotene were observed in subjects with metabolic syndrome
who consumed 3 eggs per day for 3 weeks. These changes corresponded to enrichment of HDL
(+20%, +57%) and low-density lipoproteins (LDL) (+9%, +46%) fractions with lutein and zeaxanthin,
respectively [69].
Once in circulation, lutein is preferentially localized to the retina of the eye, which has been shown
to increase macular pigment density and protect against age-related macular degeneration [72,84].
In older adults (60 years +), consumption or 2 or 4 eggs per day for 5 weeks increased serum lutein
and zeaxanthin, in addition to increasing macular pigment optical density [85]. Serum zeaxanthin
and macular pigment density was additionally increased in adult women (age 24–59) who consumed
6 eggs/week for 12 weeks [86]. In addition to accumulating in the eye, lutein supplementation
increases lutein concentrations various other tissues, including skin [87], liver [84], and adipose [88,
89]. Interestingly, obesity is associated with increased carotenoid deposition in adipose and lower
circulating levels of carotenoids, potentially making them less available for other tissues [90].
2.4. Egg Proteins
Eggs are a good source of high-quality protein that promote protein synthesis and maintenance of
skeletal muscle mass [91–93]. On average, one large egg provides ~6.3 g protein that is rich in essential
amino acids [17,94]. Eggs also contain a variety of bioactive proteins that possess antimicrobial and
immunoprotective properties—that majority of which can be found in the egg white fraction [54,95–97].
The predominant egg white proteins that can impact inflammation include ovalbumin (54% of
egg white protein by weight), ovotransferrin (12%), ovomucin (3.5%), lysozyme (3.4%), and avidin
(0.5%) [54]. Egg white additionally contains ovoinhibitor, a serine proteinase inhibitor that can reduce
enzymatic digestion by trypsin and chymotrypsin, and it has been demonstrated that certain egg
proteins can be absorbed intact [98–100]. Lysozyme is absorbed intact via endocytic and paracellular
transport in proximal intestine of rats [99], whereas ovalbumin is preferentially absorbed in the
distal intestine via paracellular and receptor- and clatharin-mediated endocytic transport [100]. The
absorption of intact egg proteins has been implicated in mediating allergic responses to egg proteins,
whereas heating and digestion of egg proteins can lower allergenicity [99–101]. Methods of cooking
and preparation of eggs may further impact overall egg protein bioavailability. Using tracer studies,
cooked egg proteins have been found to be highly digestible (~91%) as compared to raw egg protein
(~51%) [102].
3. Pro- and Anti-Inflammatory Properties of Egg Components: Mechanisms of Action
The components of eggs highlighted above each possess unique pro- and/or anti-inflammatory
properties that likely contribute to the effects that egg intake has on inflammation in human
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populations [30–32,36,54,72,103]. The following section summarizes known mechanisms of action for
each egg component as it relates to inflammation and human health.
3.1. Phospholipids
Egg-derived phospholipids have pro- and anti-inflammatory properties via both direct and
indirect mechanisms. The majority of research investigating inflammatory properties of phospholipids
has focused on phosphatidylcholine. In Caco-2 cells, phosphatidylcholine (200 μmol) has
been shown to inhibit TNFα-induced alterations of plasma membrane architecture required for
receptor-mediated signaling, activation of the pro-inflammatory mitogen-activated protein kinases
(MAPKs), extracellular-signal-regulated kinase (ERK) and p38, nuclear factor κB (NF-κB) subunit
translocation to the nucleus, and up-regulation of pro-inflammatory cytokines, such as tumor
necrosis factor α (TNFα), interleukin (IL)-8, intercellular adhesion molecule (ICAM)-1, monocyte
chemoattractant protein (MCP)-1, interferon γ-induced protein (IP)-10, and matrix metalloproteinase
(MMP)-1 [104,105]. Individuals with ulcerative colitis have lower levels of phosphatidylcholine in
the gastrointestinal mucus layer, and supplementation of phosphatidylcholine has positive clinical
outcomes [106–108]. Phosphatidylcholine supplementation through diet enrichment has additionally
been shown to reduce adverse leukocyte-endothelial interactions and inflammatory joint damage
in a chronic murine model of rheumatoid arthritis [109]. In a rat model of neuroinflammation, oral
administration of phosphatidylcholine reduced lipopolysaccharide (LPS)-induced plasma TNFα and
mitigated disturbances in hippocampal neurogenesis [110].
Despite the evidence to suggest that phosphatidylcholine is anti-inflammatory, egg phospholipids
have recently been implicated in the promotion of inflammation and atherosclerosis due formation
of trimethylamine-N-oxide (TMAO) [31,111]. Production of TMAO is dependent upon intestinal
microbiota-induced conversion of phosphatidylcholine to trimethylamine (TMA), followed by
oxidation of TMA by hepatic flavin-containing monooxygenase 3 (FMO3). TMAO has been shown to
promote atherosclerosis in animal models, whereas high levels of plasma TMAO has been associated
with increased risk for major adverse cardiovascular events in a cohort of 4007 patients [31,112].
TMAO has additionally been shown to increase adipose tissue inflammation and impair glucose
tolerance in mice [111]. Egg intake has also been shown to dose-dependently increase post-prandial
TMAO concentrations in plasma, although large interindividual variability was observed [113].
Variation between individuals may be attributable to differences in FMO3 expression and/or intestinal
microbiota composition [114]. However, intake of more than one egg per day has been associated with
lower atherosclerotic burden, as determined by coronary angiography [115]. Given that numerous
epidemiological studies have failed to find an association between egg intake and atherosclerosis,
additional long-term studies are needed to determine whether egg-induced TMAO production has
detrimental effects on inflammation and disease risk.
3.2. Cholesterol
Dietary cholesterol is known to be pro-atherogenic and pro-inflammatory in animal studies [116,
117]; however, these studies are often not representative of egg consumption, as cholesterol is provided
in high doses as an isolated form, thus failing to take into account the phospholipid matrix, realistic
dose provided by eggs, and the variability in cholesterol absorption across populations [17,43,55,57].
Nevertheless, cholesterol is known to possess pro-inflammatory properties by inducing cytotoxicity in
its free, unesterified form, in addition to promoting the formation of lipid rafts in plasma membranes
of leukocytes, resulting in greater hypersensitivity to activation by pro-inflammatory signaling
pathways [118,119]. Increased lipid raft formation has been associated with increased pro-inflammatory
responses in macrophages and T lymphocytes [119–122]. In mouse models, dietary cholesterol
provided by standard atherogenic diets has additionally been shown to promote aortic inflammation
and the formation of macrophage foam cells—the hallmark of atherosclerosis [123,124]. In guinea pigs
fed a low-carbohydrate diet, the addition of high cholesterol (0.25/100 g) increased concentrations
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of total and free cholesterol in the aorta and adipose tissue, while also increasing pro-inflammatory
cytokine levels in adipose [125]. In line with its atheroprotective properties, HDL and its related
lipid transporter, ATP-binding cassette transport A 1 (ABCA1), have been shown to exert direct and
indirect anti-inflammatory activity by reducing cellular cholesterol levels, lipid raft formation, and
mitigating leukocyte inflammation [120,121,126–128]. This may have significant implications for egg
consumption, which is known to favorably modulate HDL metabolism, as discussed in greater detail
below [33,34,36,46].
3.3. Lutein and Zeaxanthin
Despite the relatively high bioavailability of both lutein and zeaxanthin from egg yolk [69,76],
lutein has gained considerably more attention due to its protective effects against age-related macular
degeneration [72,129]. Supplementation with lutein alone or in combination with zeaxanthin has been
shown to have anti-inflammatory effects in a variety of experimental models. The anti-inflammatory
properties of lutein are thought to be related to its antioxidant activity, conferred by its conjugated C = C
double bonds that can readily quench singlet oxygen species, triplet states of photoreactive molecules,
and scavenge free radicals [130,131]. Lutein has been shown to protect against cisplatin-induced DNA
damage, chromosome instability, and oxidative stress in mice and HepG2 human liver cells [132–134].
In guinea pigs fed a hypercholesterolemic diet, lutein supplementation (0.01 g/100 g) has been shown to
exert anti-inflammatory effects in the liver, aorta, and eye [84,131]. Following a 12-week period, lutein
treatment lowered aortic pro-inflammatory cytokines, in addition to oxidized LDL (oxLDL) in plasma
and aorta. Aortic morphology further indicated protective effects of lutein against atherosclerosis [131].
Similar anti-inflammatory effects were observed in the liver, as lutein supplementation lowered the
NF-κB p65 DNA binding activity compared to control animals, in addition to lowering liver TNFα
protein and hepatic free cholesterol by 43% [84]. Reductions in eye TNFα and IL-1β were additionally
observed in the lutein-supplemented group [84]. In apoE−/− mice, combined supplementation of
lutein and egg yolk reduced detrimental ultrastructural alterations of the retina, whereas egg yolk
additionally reduced the degree of systemic lipid peroxidation [135].
Studies have further shown lutein to protect mice from LPS-induced lethality, while also
inhibiting NF-κB-mediated pro-inflammatory gene expression induced by hydrogen peroxide [136].
Following LPS injection, dietary lutein supplementation (50 mg/kg of feed) dose-dependently reduced
TNFα mRNA expression in the spleen of F-line turkeys, while increasing mRNA expression of
anti-inflammatory IL-10 [137]. Interestingly, Meriwether et al. [138] found that the lutein status of laying
hens impacted the inflammatory immune response in chick offspring, where depletion/deficiency of
lutein during embryonic development and early life was associated with greater pro-inflammatory
responses to LPS [138]. Lutein derivatives generated from UV-irradiation have additionally been shown
to have anti-inflammatory effects via inhibition of serum TNFα and IL-6 in LPS-treated mice [139].
Lutein has additionally been shown to suppress Th2 lymphocyte-mediated airway inflammation in
a murine model of asthma [140]. However, in a study conducted in healthy adults by Graydon et
al. [141], lutein (10 mg/day) and zeaxanthin (5 mg/day) supplementation for 8 weeks did not affect
serum ICAM-1, VCAM-1 or CRP levels [141]. These results may be indicative of a lower bioavailability
of lutein and zeaxanthin from supplements, or perhaps a lack of an anti-inflammatory effect in healthy
individuals who do not exhibit physiological stress and tissue dysfunction [8,76].
3.4. Egg Proteins
As detailed above, eggs contain a variety of bioactive proteins in the white fraction, including
ovalbumin, ovotransferrin, ovomucin, lysozyme, and avidin [54]. These proteins possess antibacterial
and immunoprotective properties, yet are also capable of inducing unfavorable pro-inflammatory
responses in individuals allergic to egg proteins [99–101]. Egg white-derived lysozyme naturally
exerts antimicrobial activity against Gram-positive and Gram-negative bacteria through hydrolysis
of structural peptidoglycans in the bacterial cell walls, in addition to giving rise to antibacterial
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peptides from within its complete protein structure through enzymatic hydrolysis [142,143]. In a
porcine model of dextran sodium sulfate (DSS)-induced colitis, hen egg lysozyme supplementation
reduced intestinal gene expression of pro-inflammatory cytokines (TNFα, IL-6, IFNγ, IL-8, IL-17)
while increasing expression of anti-inflammatory IL-4 and transforming growth factor β (TGFβ).
Further, lysozyme attenuated weight loss, colonic crypt distortion, muscle wall thickening, and gastric
wall permeability observed in control DSS-treated animals [97]. Ovotransferrin, an iron-binding
glycoprotein with antibacterial activity, has additionally been shown reduce inflammatory colitis
pathology in a DSS-induced mouse model of colitis [95,144]. Oral administration of egg ovotransferrin
reduced inflammatory cytokines, while additionally mitigating clinical markers of colitis, including
weight loss and histological scores of the colon [95]. Egg yolk-derived phosvitin additionally
has significant bactericidal activity against E. coli, which was shown to be attributable to its high
metal-chelating properties, in addition to its high surface activity under thermal stress [145]. Ovokinin,
a biologically active peptide derivative of ovalbumin, has been shown to lower blood pressure in
spontaneously hypertensive rats when provided via oral administration [146]. This phenomenon was
dependent upon the presence of egg yolk phospholipids during administration, provided as either the
whole egg yolk, the yolk phospholipid fraction, or isolated egg phosphatidylcholine [146].
In addition to the bioactive proteins above, utilization of immunoglobulin Y (IgY) in medicine
has additionally shown promising results in promoting passive immunity against a variety of
pathogens in the treatment of conditions such as colitis, influenza, and infection of Clostridium
botulinum, Staphylococcus aureus, Candida albicans, and Helicobacter pylori [96,147]. In cystic fibrosis
patients, daily use of a mouthwash containing IgY antibody purified from eggs of hens immunized
against Pseudomonas aeruginosa significantly decreased Pseudomonas aeruginosa colonization [148].
Together, these findings highlight a unique immunomodulatory and anti-inflammatory role of
egg-derived proteins.
4. Effects of Egg Intake on Inflammation in Human Populations
As outlined above, eggs contain a variety of bioactive components that possess pro- and/or
anti-inflammatory properties. Each of these components likely contribute to the overall response
observed in human subjects following egg consumption; however, evidence suggests that the effects
of egg intake on inflammatory markers differs across populations, based on body weight and health
status [30–33,35,36]. The following section explores these findings, with a summary of the relationship
between egg intake and inflammation presented in Table 2.
Table 1. Effects of egg intake on inflammation in different human populations.
Population, n Intervention Conditions Effect on Inflammation Ref.
Healthy Adults
n = 66 4 eggs/day for 4 weeks; AHANCEP step 1 diet ↑ serum amyloid A, CRP [30]
n = 40 2-egg meal ↑ postprandial TMAO [31]
Young men, n = 24 1-, 2-, or 4-egg meal ↑ ex vivo J774 macrophage cellfree cholesterol [149]
Young men and women, n
= 50 2 eggs/day for 4 weeks ↓ AST and ALT [150]
Overweight
Men, n = 28
3 eggs/day for 12 weeks, ad
libitum carbohydrate-restricted
diet
↓ CRP ↑ adiponectin [32]
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Table 2. Cont.
Population, n Intervention Conditions Effect on Inflammation Ref.
Insulin resistant
Lean, n = 76 4 eggs/day for 4 weeks; AHANCEP step 1 diet ↔serum amyloid A, CRP [30]
Obese, n = 59 4 eggs/day for 4 weeks; AHANCEP step 1 diet ↔serum amyloid A, CRP [30]
Metabolic syndrome
Men and women, n = 37




Men and women, n = 37
3 eggs/day for 12 weeks,
moderate
carbohydrate-restricted diet
↓TNFα, serum amyloid A [35]
Men and women, n = 5








Men and women, n = 29 1 egg/day for 5 weeks ↓TNFα and AST ↔ CRP [38]
Men and women, n = 65 2 eggs/day for 12 weeks ↔CRP and homocysteine [151]
Abbreviations: ↑: increase; ↓: decrease; ↔: no change; AHA: American Heart Association; ALT: alanine
aminotransferase; AST: aspartate aminotransferase; CRP: C-reactive protein; IL-1β: interleukin 1 β; NCEP: National
Cholesterol Education Program; PBMC; peripheral blood mononuclear cells; T2DM: type 2 diabetes mellitus; TMAO:
trimethylamine-N-oxide; TNFα: tumor necrosis factor α.
4.1. Healthy Populations
A number of intervention trials conducted in healthy adults have demonstrated a
pro-inflammatory response to egg intake. Tannock et al. [30] investigated the effects of egg consumption
in lean insulin sensitive, lean insulin resistant, and obese insulin resistant subjects on an American Heart
Association (AHA)—National Cholesterol Education Program (NCEP) step 1 diet. Interestingly, after
consuming 4 eggs per day for 4 weeks, CRP and serum amyloid A—both acute phase inflammatory
proteins—were significantly increased in the lean insulin sensitive subjects, whereas no changes
were observed in either lean or obese insulin resistant groups—despite their having higher baseline
levels of inflammation [30]. This was associated with increased cholesterol absorption in the lean
insulin sensitive subjects, whereas both lean and obese insulin resistant subjects exhibited greater
cholesterol synthesis [58]. In a crossover study conducted in 13 subjects with LDL-C over 130 mg/dL
(>3.36 mmol/L), addition of daily egg yolk to a diet of 30% fat (predominantly polyunsaturated and
saturated fatty acids) for 32 days resulted in increased susceptibility of LDL to in vitro oxidation [152].
Increased susceptibility to plasma and LDL oxidation was additionally observed by Levy et al. [153] in
subjects consuming 2 eggs per day for 3 weeks. These subjects additionally exhibited minor increases
in plasma glucose [153], contributing to the controversial body of research regarding the effects of egg
intake on T2DM risk [26,27]. Similarly, healthy subjects who consumed a 2-egg meal exhibited increased
plasma levels of pro-inflammatory TMAO postprandially; however, these increases were dependent
upon the presence of normal intestinal microbiota, as administration of an oral broad-spectrum
antibiotic suppressed the egg-induced increase in TMAO [31]. In a study by Ginsberg et al. [149], the
serum from healthy men following consumption of a meal containing 0, 1, 2, or 4 eggs was incubated
with J774 murine macrophage cells for 18 h. Following incubation, cellular free cholesterol content
of J774 cells was highest when incubated with serum post-egg consumption when compared to the
0-egg meal [149]. Although markers of inflammation were not assessed, elevated levels of leukocyte
cholesterol is known to increase the pro-inflammatory potential of the cell [120,121]. Conversely, in
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a study in college-aged men and women participating a crossover study, liver enzymes aspartate
aminotransferase (AST) and alanine aminotransferase (ALT) were lower following consumption of a
2-egg per day for 4 weeks vs. an oatmeal breakfast, whereas no changes were observed in CRP [150].
4.2. Overweight
It has been well established that excessive weight gain and obesity is associated with a chronic
state of low-grade systemic inflammation and metabolic tissue dysfunction. This physiological milieu
is thought to stem from dysfunctional adipose, which becomes stressed as it attempts to expand in
order to accommodate an excess influx of nutrients [8]. In contrast to what is observed in most healthy
populations, egg consumption in overweight populations shows beneficial anti-inflammatory effects.
In a study by Ratliff et al. [32], overweight men consuming 3 eggs per day for 12 weeks while following
an ad libitum carbohydrate-restricted diet showed reductions in plasma CRP, that were not observed in
overweight men consuming a carbohydrate restriction diet with yolk-free egg substitute. However,
men consuming the egg substitute showed significant decreases in pro-inflammatory MCP-1 [32].
Interestingly, men on both whole egg and egg substitute groups increased plasma levels of the
anti-inflammatory adipokine adiponectin over 12 weeks, with greater increases observed in the whole
egg group (+21% vs. +7%) [32]. Consumption of eggs for breakfast has additionally been shown
to increased satiety in overweight/obese women [154] and healthy men [155] when compared to a
bagel breakfast, while also promoting weight loss and reductions in daily caloric intake [155,156].
Increased satiety from egg consumption has also been observed in young adults [157]. Together, these
findings suggest that egg consumption may improve inflammation in overweight/obese individuals
undergoing weight loss—either through direct action of bioactive components or indirect action of
promoting satiety, weight loss, and restoration of adipose tissue function.
4.3. Metabolic Syndrome
Metabolic syndrome is characterized by a clustering of cardiometabolic risk factors that increase
an individual’s risk of developing CVD and T2DM by 2- and 5-fold, respectively [20]. Individuals with
metabolic syndrome commonly present with insulin resistance, endothelial dysfunction, adverse
lipoprotein profiles, and a chronic state of low-grade inflammation [158]. However, similar to
what has been observed in obesity, egg consumption has been shown to mitigate inflammation
in metabolic syndrome. In men and women classified with metabolic syndrome following a moderate
carbohydrate-restricted diet, consumption of either 3 eggs per day or the equivalent amount of
yolk-free egg substitute for 12 weeks lowered oxLDL [34]. Interestingly, reductions in plasma TNFα
and serum amyloid A were only observed in the group consuming whole eggs that included the yolk,
whereas no changes in CRP, adiponectin, IL-6, or IL-10 were observed in either whole egg or egg
substitute groups [35].
The effects of egg consumption during carbohydrate restriction in metabolic syndrome was further
assessed in regard to peripheral blood mononuclear cell inflammation [33,36]. Despite increases in
peripheral blood mononuclear cell (PBMC) toll-like receptor 4 (TLR4) mRNA expression, whole egg
intake did not alter lipopolysaccharide-induced TNFα or IL-1β secretion by PBMCs. Surprisingly,
lipopolysaccharide-induced TNFα or IL-1β secretion in PBMC was increased over the 12 week
period in subjects consuming the yolk-free egg substitute. Interestingly, there was a trend toward a
decrease in PBMC cholesterol content in the whole egg group, as changes in PBMC cholesterol content
over the 12-week intervention positively correlated with lipid raft content [33,36]. These changes
corresponded to increased PBMC mRNA expression of ABCA1, which is known to exert direct and
indirect anti-inflammatory activity [120,121]. Egg consumption in metabolic syndrome has additionally
been shown to increase HDL-phosphatidylethanolamine content and the ex vivo cholesterol-accepting
capacity of serum from lipid-loaded macrophages [46]. While the anti-inflammatory properties of
egg-induced, phosphatidylethanolamine-enriched HDL were not assessed, phosphatidylethanolamine
may confer antithrombotic properties [159,160]. Thus, taken together with the reductions in serum
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amyloid A, which is predominantly associated with HDL in circulation, it is possible that some of
these observations may be attributable to more anti-inflammatory and functional HDL [35,46,161].
4.4. T2DM
Of all populations, the recommendation of egg intake in T2DM is one of the most controversial,
given the results of some epidemiological studies that found a positive association between egg intake
and T2DM risk [26,27]. However, similar to what has been observed in obese and metabolic syndrome
populations, egg intake in T2DM appears to reduce markers of inflammation. In a randomized,
crossover study conducted in patients with well-controlled T2DM, intake of 1 whole egg per day
breakfast for 5 weeks significantly reduced AST and TNFα when compared to an oatmeal-based
breakfast [38]. Further, there were no differences in fasting glucose, glycosylated hemoglobin (HbA1c),
CRP, or plasma lipids between the egg and oatmeal breakfast periods, suggesting that consumption of
one egg per day may mitigate the inflammation characteristic of T2DM without negatively affecting
traditional markers of glucose tolerance and CVD risk [38]. Similarly, in a study by Pearce et al. [151],
T2DM patients fed a hypoenergetic high-protein, high-cholesterol diet (achieved by consuming
2 eggs/day) for 12 weeks exhibited no adverse changes in T2DM and CVD biomarkers. Conversely,
egg consumption resulted in greater increases in serum HDL-cholesterol and plasma lutein when
compared to T2DM patients consuming a low cholesterol hypoenergetic, high-protein diet that lacked
eggs. However, no changes in serum CRP or plasma homocysteine were observed in either group [151].
Thus, it appears eggs may confer anti-inflammatory benefits in patients with well-controlled T2DM.
4.5. Acute Infection
The findings on egg intake and inflammation outlined above not only have implications for chronic
metabolic diseases, but also for immune function in cases of acute infection, where inflammation is
essential to clearing pathogenic factors. While research on egg intake in immunity is limited, one
study by Pérez-Guzmán et al. [162] investigated the effects of a cholesterol-rich diet on the treatment
of, and recovery from, pulmonary tuberculosis. Adult patients with newly diagnosed pulmonary
tuberculosis were assigned to consume a cholesterol-rich diet (800 mg cholesterol/day, provided
by egg yolk, butter, beef liver, and dairy products) or a control diet (250 mg cholesterol/day) for
8 weeks while remaining hospitalized and receiving anti-tubercular drug treatments. Interestingly,
subjects following the cholesterol-rich diet exhibited faster reductions in sputum production and
clearance of mycobacteria from sputum cultures [162]. Given these findings, and those highlighted
above, the effects of egg intake in parameters of immunity across different populations warrants
further investigation.
4.6. Implications from Human Studies
As presented above, the majority of research suggests that egg intake promotes a
pro-inflammatory response in healthy adults [30,31], whereas the consumption of eggs in conditions
of overweight [32], insulin resistance [30], metabolic syndrome [35,36], and T2DM [38,151] have
either an anti-inflammatory or neutral effect. It is possible that this variation is attributable to
differences in intestinal absorption of dietary cholesterol, which is known to be increased in healthy,
non-insulin resistant individuals [30,56–58]; however, it is possible that other factors impact the
dietary response to eggs, such as the composition of the microbiome or genetic variation [31,114].
It is additionally important to recognize potential confounding variables across studies, such as
differences in the number of eggs consumed per day, concurrent dietary treatments/interventions, or
medication regimens.
5. Conclusions
Bioactive egg components, including phospholipids, cholesterol, lutein, zeaxanthin, and proteins,
possess a variety of pro- and/or anti-inflammatory properties, which may have important implications
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for the pathophysiology of numerous chronic diseases and immune responses to acute injury. The
unique formulation of the egg food matrix significantly impacts the bioaccessibility and absorption of
these components, allowing each bioactive component to likely contribute to the overall effects of egg
intake on inflammatory processes. Thus, as opposed to solely basing dietary recommendations for
egg intake on cholesterol content, it is likely more beneficial to consider the relationship between egg
intake and inflammation in different populations. Moreover, given the essentiality of pro-inflammatory
responses in normal immune defense against pathogens, further research into the role of egg intake on
immunity is warranted. Together, the findings presented in this review have important implications for
population-specific dietary recommendations that add complexity to current guidelines and standards
of clinical practice.
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Abstract: Intake of antioxidants through diet is known to be important in reducing oxidative damage
in cells and improving human health. Although eggs are known for their exceptional, nutritional
quality, they are not generally considered as antioxidant foods. This review aims to establish the
importance of eggs as an antioxidant food by summarizing the current knowledge on egg-derived
antioxidants. Eggs have various natural occurring compounds including the proteins ovalbumin,
ovotransferrin and lysozyme in egg white, as well as phosvitin, carotenoids and free aromatic amino
acids in egg yolk. Some lipophilic antioxidants such as vitamin E, carotenoids, selenium, iodine
and others can be transferred from feed into egg yolk to produce antioxidant-enriched eggs. The
bioactivity of egg antioxidants can be affected by food processing, storage and gastrointestinal
digestion. Generally thermal processing methods can promote loss of antioxidant properties in
eggs due to oxidation and degradation, whereas gastrointestinal digestion enhances the antioxidant
properties, due to the formation of new antioxidants (free amino acids and peptides). In summary, in
addition to its well-known nutritional contribution to our diet, this review emphasizes the role of
eggs as an important antioxidant food.
Keywords: hen eggs; naturally-occurring antioxidants; antioxidant-enriched eggs; processing;
gastrointestinal digestion
1. Antioxidants in Human
An antioxidant can be defined as “any substance that delays, prevents or removes oxidative
damage to a target molecule” [1] or “any substance that directly scavenges reactive oxygen species
(ROS) or indirectly acts to up-regulate antioxidant defenses or inhibit ROS production” [2]. The
human body produces many enzymatic and nonenzymatic endogenous antioxidants in order to
provide the primary defense against superoxide and hydrogen peroxides. The major antioxidant
enzymes are superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione
reductase (GRx) and peroxiredoxins [3]. Nonenzymatic endogenous antioxidants include coenzyme
Q10, vitamin A, glutathione, uric acid, lipoic acid, bilirubin, L-carnitine, etc. [3,4]. There are many
different mechanisms by which antioxidants exert protective effects against oxidative damage. They
can scavenge free radicals and other reactive species by stopping initiation or propagation of free
radicals chain reactions in the system, scavenging singlet oxygen, sequestering transition metal
ions to prevent generation of free radicals, reducing localized oxygen concentration, and inhibiting
pro-oxidative enzymes such as lipoxygenases [3,5,6]. Antioxidants can work synergistically with
each other against different types of free radicals and reactive species. The most efficient enzymatic
antioxidants are glutathione peroxidase (GSH-Px), catalase, and SOD [7]. GSH-Px and SOD (in two
forms: CuZnSOD and MnSOD) are found in mitochondria and cytosol, whereas catalases are located
in peroxisomes [8]. SOD converts superoxide into H2O2 and oxygen, while GSH-Px and catalase
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react with H2O2 to produce water and oxygen [8]. Although the gene expression and activity of these
enzymes in the cell are well regulated to maintain redox homeostasis, internal and external factors
such as aging, inflammation, smoking and toxins can influence the balance [7].
Glutathione (GSH) is a water soluble tripeptide (L-γ-glutamyl-L-cysteinylglycine) that can react
with ROS using its thiol group and oxidized to form glutathione disulfide (GSSG) which can then
convert back to GSH by combined action of NADPH (reduced nicotinamide-adenine di-nucleotide
phosphate) cofactor and GRx [3,4]. GSH is also involved in regeneration of ascorbate [3]. Coenzyme
Q10, present in all cells and membranes, is the only endogenously synthesized liposoluble antioxidant.
It is an effective antioxidant which prevents lipid peroxidation during the initiation step and is
involved in regenerating vitamin E [9]. Uric acid is a metabolic product of purine nucleotide, and can
be absorbed back into the body during kidney filtration into the plasma [3]. A potent singlet oxygen
and hydroxyl radical scavenger, uric acid prevents lysis of red blood cells by peroxidation [10].
2. Dietary Antioxidants
Intake of antioxidants through diet is thought to be important in reducing oxidative damage [11–14].
These antioxidants play a critical role in protecting cellular components from potentially damaging
ROS and thereby maintaining homeostasis and optimal cellular functions. Synthetic antioxidants such
as butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), tert-butylhydroquinone (TBHQ)
and propyl gallate (PG) have been used in both food and pharmacological applications [15]. However,
because of the possible toxic and carcinogenic effects associated with BHT and BHA, their use is legally
restricted [16,17]. As a result, there is a growing interest in using natural antioxidants for food and
therapeutic applications which prompt the scientific community to explore new sources of natural
and dietary antioxidants [3,15,18,19]. The most known groups of natural antioxidants are vitamin C,
vitamin E, carotenoids and flavonoids and more recently, peptides with antioxidant properties derived
from various plant and animal sources [15,19].
Most of the plant derived antioxidant compounds are phytochemicals including phenolics,
flavonoids and carotenoids whereas the prominent animal-derived antioxidants are amino-derived
compounds such as amino acids, peptides and proteins [20].
Vitamin E, a well-known chain breaking antioxidant, prevents propagation of lipid peroxidation
reactions by donating its phenolic hydrogen to the lipid peroxyl radical [15]. Vitamin E will become a
radical itself (tocopheroxyl radical), but is more stable due to delocalization of the solitary electron
over the aromatic ring structure [15,21]. Lipid soluble vitamin E is considered the most important
antioxidant in preventing lipid peroxidation. Carotenoids are another class of lipid soluble compounds
with antioxidant properties. The main mechanisms are singlet oxygen quenching, reacting with
free radicals and delocalizing the unpaired electrons with the aid of unsaturation and resonant
stabilization [22,23]. Singlet oxygen scavenging ability of lutein and zeaxanthin is suggested as the
main protective mechanism of eye macular against blue light-induced oxidative damage [24,25].
Carotenoids can also prevent lipid peroxidation and play a protective role in carcinogenesis [26].
Although beneficial at moderate concentration, high doses of supplementation of β-carotenoids in
high concentration can act as a pro-oxidant [22,27].
Vitamin C or ascorbic acid, a water soluble vitamin, has been shown to be effective against
the superoxide radical anion, H2O2, the hydroxyl radical and singlet oxygen [15,28]. It also acts
synergistically with vitamin E by reacting with tocopheroxyl radical to regenerate its antioxidant
ability [29]. Flavonoids represent a class of phytochemicals which are known to have antioxidant
properties depending on structural features such as the number and position of the hydroxyl groups
and number of phenolic rings, etc. [27,30]. They have been reported to scavenge peroxyl radicals,
inhibit lipid peroxidation, and chelate metal ions [27,31].
Fruits, vegetables, oil seeds, nuts, cereals, spices, herbs, and grains are important sources of
antioxidants such as phenolics, flavonoids and carotenoids. A great deal of research has been conducted
on their antioxidant properties in vivo, in vitro as well as on extraction and purification methods,
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applications in food products, bioavailability, and anti-nutritional aspects [32–36]. Among many plant
sources, berries and fruits are known for their high phenolic content including phenolic acids, and
anthocyanins and their high antioxidant capacity [37]. Most vegetables including tomatoes, red pepper,
Brassica vegetables, onion, garlic and red beet are found to have high antioxidant capacity mainly
attributed to their flavonoid, carotenoid, vitamin C contents [38–41]. Although cereal grains are not
considered rich sources of antioxidants compared to fruits and vegetables, grains and grain products
are staple food components in the human diet and therefore their contribution is still significant [42–44].
The major phenolic compounds are phenolic acids such as ferulic acid, the dominating phenolic acid
in wheat, caffeic acid, p-coumaric acid, p-hydroxybenzoic acid, vanillic acid and protocatechuic
acid, etc. [44]. In addition, they contain other compounds which may exert antioxidant effects, for
example, vitamin E, folates, minerals (iron, zinc) and trace elements (selenium, copper and manganese),
carotenoids, etc. It has been suggested that antioxidant capacity of cereals is usually underestimated
because of the bound phenolic compounds which do not contribute during in vitro assays, but can be
released in the gut to exert the antioxidant activity [45,46].
Compared to antioxidants from plant sources, the available research on animal-derived
antioxidants is limited. Proteins and peptides have been known to inhibit lipid oxidation through
inactivation of ROS, scavenging free radicals, chelation of prooxidative transition metals, reduction of
hydroperoxides, and alteration of the physical properties of food systems [47]. The most abundant
antioxidant dipeptides in skeletal muscles are histidine-containing dipeptides, such as carnosine
and anserine [48]. The peptide concentration varies from about 500 mg per kg of chicken thigh to
2700 mg per kg of pork shoulder depending on the type of muscle [47]. Their antioxidant properties
are believed to arise through radical scavenging and metal chelation abilities [48]. The presence of
thiol groups and aromatic side chains (tryptophan, tyrosine and phenyl alanine) and imidazole ring in
histidine [49,50] are recognized as important structural features for their antioxidant properties. Casein
derived peptides from milk proteins have been reported to inhibit enzymatic as well as non-enzymatic
oxidation of lipids [51,52]. Generation of antioxidative peptides from milk proteins has been studied
in detail [53]. Antioxidant peptides from egg proteins have also been reported [54,55]. Apart from
proteins, other antioxidant compounds in animal tissues such as vitamin E and ascorbic acid are
well-known for their antioxidant properties [56]. Some aquatic animals including salmon and shrimp
contain high amounts of carotenoids with strong antioxidant properties. Astaxanthin, a carotenoid
found in high concentrations in fish and shrimp, showed strong singlet oxygen and radical scavenging
ability, which was 100 times greater than α-tocopherol activity [57]. The activity was mainly attributable
to the presence of hydroxyl and keto endings on each ionone ring in the structure of astaxanthin [58].
3. Egg as an Antioxidant Food Commodity
3.1. Chemical and Nutritional Composition of Eggs
Egg is composed of three parts: egg shell with membranes, egg white albumen, and yolk,
accounting for approximately 9.5%, 63% and 27.5% of the whole shell egg [59]. The edible portion of
the egg consists of water (74%), proteins (12%), lipids (12%), carbohydrate (<1%) as well as vitamins
and minerals [60]. The chemical and nutrient composition of egg is well documented [60–63]. The
protein fraction is distributed in both egg white (ovalbumin, ovotransferrin, ovomucoid, ovomucin,
etc.) and yolk (high density lipoproteins, low density lipoproteins and livetins). Eggs proteins are high
quality proteins and are used as a golden standard for measuring the quality of other food proteins [61].
Almost all egg lipids are located in yolk and approximately 65% of yolk lipids are triglycerides, while
phospholipids, cholesterol and carotenoids make 30%, 4%, <1%, respectively [64]. The fatty acid
composition of egg yolk can be manipulated through feed formulation to produce eggs enriched with
polyunsaturated fatty acids with benefits beyond basic nutrition [65]. Based on the standardized
poultry feed, about 30%–35% from the total fatty acids are saturated fatty acids (SFA), 40%–45% are
monounsaturated fatty acids (MUFA), and 20%–25% are polyunsaturated fatty acids (PUFA) [66]. Egg
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yolk lipids have been used as a source of long-chain polyunsaturated fatty acids, Docosahexaenoic
acid (DHA) and phospholipids to incorporate into infant formula [67,68]. Eggs are also considered a
good source of micronutrients such as vitamins and minerals. Eggs contain ~16%, 29%, 9% and 9% of
the recommended daily intake (RDI) of phosphorus, selenium, iron, and zinc, and 10% of the RDI of
vitamin A, D, E, K, B2, B12, biotin and pantothenic acid [61]. It has been shown that some minerals
like selenium, and iodine can be enriched through fortification of feed [69,70]. In the same way as
minerals, vitamin contents of egg can be manipulated through hen’s feed formulation [71].
In addition to the nutritional value, egg components have various biological activities which may
render important health benefits [72]. Egg is a complete biological system designed to nourish and
protect the growing embryo from various pathogen invasions. As a result, egg shell with membranes
and egg white proteins possess physical and biological defense mechanisms such as viscosity, pH,
antimicrobial properties, etc. For a list of egg compounds with various bioactivities please refer
to [62,73].
3.2. Antioxidant Compounds in Eggs
Numerous compounds in both egg white and yolk exhibit antioxidant properties (Table 1). Many
egg proteins such as ovalbumin, ovotransferrin, phosvitin, egg lipids such as phospholipids, as well as
certain micronutrients such as vitamin E, vitamin A, selenium, and carotenoids, are reported to have
antioxidant properties. In addition, eggs can be further enriched with antioxidants (i.e., carotenoids,
vitamin E, selenium and iodine) through manipulation of poultry feed [58–61].
Table 1. Antioxidants in Egg.
Name of Compound Amount in Egg Mechanisms of Action
Egg white (% of egg white proteins)
Ovalbumin 54
Free thiol (SH) groups in ovalbumin regulate
the redox status and bind metal ions, thereby
exert antioxidant properties [74]; Increased
antioxidant activity when conjugated with
saccharides [74,75]
Ovotransferrin 12 Possess SOD-like superoxide scavengingactivity due to its metal chelating ability [76]
Ovomucin 3.5 Inhibit H2O2-induced oxidative stress inhuman embryonic kidney [77]
Lysozyme 3.4 Suppress reactive oxygen species (ROS) andoxidative stress genes [78]
Cystatin 0.05
Modulate the synthesis and release of NO•
production and thereby play a role in cellular
antioxidant pathways [79,80]
Egg yolk (% of yolk dry matter)
Phosvitin 4
Antioxidant activity based on metal chelating
ability; chelates iron and protects against
Fe-induced oxidative damage [81,82]
Phospholipids 10
Hydrolyl amines in the side chains of
phospholipids play a role in radical scavenging
and exert antioxidant properties [83]
Carotenoids <1
Unsaturated backbone and aromatic rings of
carotenoids aid in neutralizing singlet oxygen
and free radicals and protect against oxidative
damage [22,25,26]
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Table 1. Cont.
Name of Compound Amount in Egg Mechanisms of Action
Vitamin E <1
Vitamin E can donate its phenolic hydrogen to
scavenge free radicals [15]; protect membrane
fatty acids and plasma Low density
lipoproteins (LDL), High density lipoproteins
(HDL) against lipid oxidation [84]
Aromatic amino acids <1 Aromatic nature of tryptophan and tyrosinecontribute to the total antioxidant capacity [85]
3.2.1. Antioxidants Naturally Occurring in Eggs
Ovalbumin
Ovalbumin is a glycoprotein made of 385 amino acids and constitutes approximately 54% (w/w)
of the total egg white protein [60,86]. It contains six cysteine residues with a single disulfide bond
and is the only egg white protein with free SH (thiol) groups [60]. The presence of thiol groups
enable its ability to play a role in redox regulation and binding metal ions therefore exert antioxidant
properties [87–89]. In 1971, Goto and Shibasaki observed the protective effects of ovalbumin against
lipid oxidation in a linolenic model system [90]. When covalently attached with polysaccharides, the
radical scavenging activity of ovalbumin was significantly increased [74]. It was speculated that free
SH groups are responsible for the antioxidant activity of ovalbumin, which were effectively exposed
upon the conjugation with polysaccharides [74]. Further studies on glycated ovalbumin showed that
the activity is dependent on the type of sugars used and also the configuration of hydroxyl groups in
the sugar molecule [75,91].
Ovotransferrin
Ovotransferrin (also known as conalbumin), representing 12%–13% of the total egg white protein,
is a member of the transferrin family, a group of ion-binding proteins with an in vivo preference for
iron [60,92]. Ovotransferrin consists of two lobes, each capable of binding one atom of Fe3+ and
carbonate anion [60]. Among the two, the N-lobe is found to be more important for its antioxidant
properties [76].
Ovotransferrin was reported to possess SOD-like activity against superoxide anion promoted by
metal binding. The scavenging activity was dose-dependent and considerably higher than known
for antioxidants such as ascorbate or serum albumin [76]. Additionally, the iron-binding ability of
ovotransferrin has an indirect role in preventing iron-induced lipid peroxidation [60].
Lysozyme
Lysozyme is an enzyme present in almost all organisms. One egg contains approximately 0.3–0.4 g
of lysozyme [93]. Lysozyme is a defensin, a member of the family of native, highly conserved
host-defense proteins [78]. It contains an 18-amino acid domain that binds agents such as advanced
glycation end products (AGE), which contribute to the production of ROS and increased oxidative
stress (ROS). Liu et al., showed that lysozyme protects transgenic mice against acute and chronic
oxidative injury [78]. They also showed that hepatocytes incubated with lysozyme suppress cellular
ROS levels and oxidative response genes. In another study, the survival rate following acute or chronic
oxidative injury in lysozyme deficient transgenic mice was found to be significantly lower compared
to the control, indicating its protective role as an antioxidant [94].
Cystatin
Egg white cystatin is the first identified member of the cystatin family [95]. It is a small protein of
approximately 13 kDa molecular weight which makes up 0.05% of the total egg white proteins and
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contains two disulfide bonds [60]. Cystatin is an inhibitor of cysteine proteinases, thereby exerting
antibacterial properties [96,97]. It is also reported that chicken cystatin exerts immunomodulatory
activities by modulating the synthesis and release of NO• production in interferon γ-activated murine
macrophages [78–80,98,99]. Optimum levels of NO• is essential for regulation of certain cellular
antioxidant pathways [100]. Moreover, cystatin B, the group which chicken cystatin belongs to, has
recently found to involve in protecting cerebellar granule neurons from oxidative stress by playing
a role in oxidative stress-responsive signaling pathway [79]. Taken together, the role of cystatin in
modulating the NO• synthesis and protecting brain neurons from oxidative damage, provide us with
evidence of its potential activity as an antioxidant.
Ovoinhibitor
Ovoinhibitor, which makes approximately 1.5% of egg white proteins, inhibits serine proteinases
such as trypsin and chymotrypsin and also bacterial and fungal proteinases [93]. It was shown that
chymotrypsin proteinase inhibitors including ovoinhibtor are capable of inhibiting the formation of
ROS in activated human polymorphonuclear leukocytes during the inflammatory response [100]. They
demonstrated that about 29% of formation of H2O2 was inhibited by ovoinhibitor at a concentration of
20 μM [100].
Phosvitin
Phosvitin is the most phosphorylated protein containing nearly 80% of yolk protein phosphorous
and represents ~11% of yolk proteins [101]. More than half of its amino acid composition is serine,
which exists as phosphoserine. It has a strong metal-binding ability and approximately 95% of yolk
iron is bound to phosvitin. This high metal-binding capacity makes phosvitin a potential antioxidant,
particularly against iron induced oxidative damage [82]. Iron is essential for life; under normal
physiological conditions, the level is controlled by iron binding proteins ferritin and transferrin.
However, if the balance is disturbed causing iron overload in cells, the effects could be lethal as
humans have a very limited capacity to excrete excess iron. The excess iron in the form of Fe2+ can
participate in Fenton reaction to produce toxic OH• by reacting with H2O2.
Moreover, the circulating free iron can oxidize heart-muscle membranes, causing arrhythmia and
heart failure. The iron-chelating ability of phosvitin indicates its possible role in protecting iron-induced
oxidative damage. Phosvitin accelerates Fe2+ autoxidation, thereby reducing the availability of Fe2+
and inhibiting Fe2+-catalyzed OH• generation through Fenton reaction [102]. Additionally, phosvitin
is also proven to be effective against UV-induced lipid peroxidation in the presence of excess iron [103].
Phospholipids
Egg yolk phospholipids consist of 84% phosphatidylcholine (PC), 12% phosphatidylethanolamine
(PE), 2% sphingomyelin and 2% lysophosphatidylcholine and other minor compounds [64]. King,
Boyd, and Sheldon (1992) reported that egg yolk phospholipids exhibit antioxidant activity in a
refined salmon oil model system, and also demonstrated that the presence of nitrogen improved the
antioxidant activity of phospholipids [104]. The antioxidant activity was positively associated with the
degree of fatty acid unsaturation [81]. Hydroxy amines in the side chains of choline and ethanolamines
showed strong inhibition of lipid peroxidation, indicating the importance of side-chain amino acids
with hydroxyl groups in the antioxidant activity [105].
Carotenoids
Carotenoids are lipid soluble compounds responsible for the orange-yellow color of the egg
yolk. The health promoting properties of carotenoids are well documented [106,107]. More than
600 carotenoids have been identified to date and it is suggested than around 50 of them might occur in
our diet and 14 in human blood [107,108]. Human body do not synthesize carotenoids and must be
obtained through the diet. Therefore, it is important to consider the type and bioavailability of dietary
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carotenoids. Bioavailability of egg carotenoids is superior to those from green leafy vegetables [109,110]
due to the solubilization of yolk lipids, which makes eggs a unique and important carrier of
bioactive carotenoids. The profile of egg carotenoids is largely depend on hen’s feed composition,
therefore it can vary among different types of eggs [111,112]. Certain carotenoids are allowed to
use as poultry feed additives to improve color of the egg yolk, however, the amount and types of
carotenoid can be varied as per the country’s feed regulation [113]. In general, lutein, zeaxanthin,
canthaxanthin, β-apo-8’-carotenal, capsanthin, β-apo-8’-carotenoic acid ethyl ester, β-cryptoxanthin,
and citranaxanthin can be present in egg yolk [114].
Human plasma contains several carotenoids including β-carotene, α-carotene, β-cryptoxanthin,
lutein and zeaxanthin and their isomers [115]. Lutein, zeaxanthin and meso-zeaxanthin are the main
components of the eye macular pigment [116]. Lutein and zeaxanthin are well known for their role
in protecting the eye from age-related macular degeneration (AMD) [117]. The singlet oxygen and
radical scavenging activity of lutein and zeaxanthin is considered one of the two major mechanisms
for their beneficial effects against light-induced oxidative damage in eye macular, in particular, against
AMD [117–119]. The other major mechanism is their ability to absorb blue light, particularly before it
damages the photoreceptor cells, which is also considered a passive antioxidant action [117]. A recent
study demonstrated that pre-incubation of human lens epithelial cells (HLEC) with lutein, zeaxanthin
and α-tocopherol, dramatically reduced the levels of H2O2-induced protein carbonyl, MDA, and DNA
damage [120]. Further, lutein, zeaxanthin and α-tocopherol supplementation increased GSH levels
and GSH: GSSG ratio, particularly in response to oxidative stress [120]. Dietary supplementation with
lutein reduced plasma lipid hydroperoxides and the size of aortic lesions in mice [121] and reduced the
plasma levels of oxidized-LDL in guinea pigs [122], indicating a protective role in ROS induced early
atherosclerosis. The ability of lutein and zeaxanthin to scavenge hydroxyl and superoxide radicals
is attributed to the presence of double bonds which makes a bond with the free radical to produce a
highly resonance-stabilized C-centered radical [123]. Lutein, zeaxanthin and β-cryptoxanthin have
also been shown to scavenge peroxynitrite which may play a role in LDL protection against oxidative
damage [124].
Vitamins and Minerals
On average egg contains around 1.1 mg of vitamin E [61] which is equivalent to 8.5% of RDA.
Vitamin E, especially α-tocopherol as the most active form, is a well-known lipophilic chain-breaking
antioxidant known to protect long-chain polyunsaturated fatty acids in the membranes of cells
and thus maintain their bioactivity [125,126]. In plasma, vitamin E exists with LDL and HDL,
providing protection against oxidation [84,127]. Supplementing with vitamin E increased resistance
to LDL-oxidation and is associated with a lower risk of coronary diseases in both men [128] and
women [129]. Eggs can be enriched with vitamin E to provide up to 150% RDA without formation of
off flavour [130], not only providing the aforementioned benefits, but also protecting against oxidation
of long chain fatty acids in yolk [130].
Certain minerals present in egg yolk including selenium and iodine also contribute to the
antioxidant properties. Selenium is an essential mineral present in antioxidant selenoproteins such as
GPx, thioredoxin reductases (TrxR) and selenoprotein P (Sepp1) [131]. Iodine has a potential role as an
antioxidant in human systems including the eye, thyroid and the breast [132]. Iodine deficiency can
increase the stimulation of thyroid gland by TSH resulting in excessive H2O2 [132].
Egg-Derived Antioxidative Peptides
Antioxidant activity was reported from egg white and egg yolk proteins. Recently,
many studies have reported antioxidant properties of egg white proteins hydrolyzed using
different enzymes and some have even purified the potential antioxidant peptides [133–136].
For example, Liu et al., used alcalase to produce and purified three novel peptides with
antioxidant properties, DHTKE (Asp-His-Thr-Lys-Glu), FFGFN (Phe-Phe-Glu-Phe-His) and MPDAHL
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(Met-Pro-Asp-Ala-His-Leu) [137]. Similarly, our recent studies showed that “protease P” hydrolysed
egg white produce twopotent antioxidant peptides, AEERYP (Ala-Glu-Glu-Arg-Tyr-Pro) and
DEDTQAMP (Asp-Glu-Asp-Thr-Gln-Ala-Met-Pro) [138]. Trypsin hydrolysate prepared from egg white
protein precipitate, obtained as a by-product in cystatin and lysozyme isolation, showed a considerably
better radical scavenging activity than those prepared from chymotrypsin and elastase [139,140].
Adult male spontaneously hypertensive rats fed with peptic digested egg white for 17 weeks showed
increased radical-scavenging capacity of the plasma and lowered MDA concentration in the aorta,
and exerted a beneficial effect on the lipid profile, lowering triglycerides and total cholesterol without
changing HDL levels [141]. Two peptides derived from lecithin-free egg yolk exhibit protection
against lipid peroxidation in intoxicated normal human liver cells [142]. Both peptides contained a
leucine residue at their N-terminal positions which were thought to contribute to their antioxidant
properties [142]. Another study showed that egg yolk protein hydrolysate exhibited superoxide and
hydroxyl radical scavenging activity, effectively inhibiting thiobarbituric acid reactive substances
(TBARS) formation from ground beef and tuna homogenates, indicating its potential as a natural
antioxidant [143].
The peptide, Tyr-Ala-Glu-Glu-Arg-Tyr-Pro-Ile-Leu, derived from pepsin hydrolyzed ovalbumin,
which was previously reported to possess angiotensin converting enzyme (ACE)-inhibitory activity,
also exhibited a strong radical scavenging activity and delayed the LDL-oxidation induced by Cu2+ [54].
Peptic digests of ovalbumin inhibited the action of OH• and O2•− and also prevented the oxidation of
linoleic acid in linoleic acid autoxidation system [144]. In-vivo studies showed that supplementation
with these peptic digests of ovalbumin significantly decreased the production of oxidants and oxidative
damage in serum and liver of aged mice [144].
Enzymatic hydrolysis of ovotransferrin was shown to lead to enhanced overall antioxidant
activity. Two tetrapeptides (Trp-Asn-Ile-Pro and Gly-Trp-Asn-Ile) were characterized from thermolytic
hydrolysate of ovotransferrin [145]. Trp-Asn-Ile was suggested as the responsible peptide motif for the
high activity of the above tetrapeptides [146]. A tripeptide Ile-Arg-Trp, derived from ovotransferrin
showed strong radical scavenging activity which was attributed to tryptophan and the peptide bond
between Trp and Arg [146]. It is known that Trp can exert radical scavenging properties mainly due
to the presence of the indole ring [147,148]. A recent study demonstrated that grafting a catechin
moiety significantly increased the antioxidant activity of ovotransferrin implicating its potential as
neutraceutical and functional food [149]. Peptides derived from lysozyme are reported to possess
antioxidant properties [150–152].
Egg white ovomucin, a sulfated glycoprotein accounting for 3.5%–4% of egg white proteins, is
responsible for the jelly-like structure of egg white [60,153]. Recently, ovomucin derived pentapeptide
Trp-Asn-Trp-Ala-Asp was reported to reduce H2O2-induced oxidative stress in human embryonic
kidney (HEK-293) cells by inhibiting intracellular ROS accumulation and blocking the ROS activated
mitochondria-mediated cell apoptosis pathway [154]. Others also reported on antioxidant properties
of peptides derived from ovomucin [75,134].
Phosvitin phosphopeptides (PPP) obtained from tryptic digestion of egg yolk phosvitin showed
protective effects against H2O2-induced oxidative stress in human intestinal epithelial cells [155,156].
The antioxidative activity of PPP was similar to that of glutathione and positively related to the
phosphorous content. PPPs are also assumed to be involved with up-regulating glutathione and
associated antioxidative enzymes such as glutathione reductase, glutathione S-transferase, and catalase
and thus reducing the oxidative stress [157]. Furthermore, the antioxidative activity of PPPs on
H2O2-induced oxidative stress retained after gastrointestinal digestion [81].
3.2.2. Antioxidant Enriched Eggs
Owing to its high lipid content, many lipid-soluble antioxidant compounds such as
lutein/zeaxanthin, vitamin E, selenium, iodine lycopene can be incorporated into egg yolk [158]. The
most studied are omega-3 fatty acids, which are incorporated into eggs by feeding fish oil, flax seed,
101
Nutrients 2015, 7, 8274–8293
algae, or other ingredients to laying hens [159]. High contents of omega-3 fatty acids might increase
susceptibility to fatty acid oxidation therefore simultaneously enrichment of eggs with antioxidants
such as vitamin E and carotenoids was suggested to decrease fatty acid oxidation and provide a good
source of dietary antioxidant [158].
Carotenoids are naturally occurring in egg yolk in varied amounts depending on hen’s feed. Feed
fortification with natural sources such as marigold (Tagetes erecta) or alfalfa (Medicago sativa) extracts
are sources of lutein, while other sources such as corn (Zea mays) and red pepper (Capsicum annuum)
provide zeaxanthin and capsanthin respectively [113,160]. Canthaxanthin, β-apo-8′-carotenal and
β-apo-8′-carotenoic acid ethyl ester are chemically synthesized and incorporated into the feed [114].
Lutein and zeaxanthin are two major egg carotenoids that can be found in human serum, skin
and eye macular and involved in the protective roles against oxidative stress [161,162]. Lutein
content of enriched eggs can be increased up to 15-fold compared to the control group, for example
enriched egg contains around 1.9 mg of lutein [130]. Lutein enriched eggs show a higher lutein
bioavailability compared to lutein, lutein ester supplements, and spinach [110]. Lycopene is a
hydrocarbon carotenoid reported to have strong antioxidant properties effective in reducing the risk of
prostate carcinoma [163,164]. Although lycopene is not usually found in eggs, lycopene enrichment
can be achieved via feed fortification with tomato powder and lycopene could reduce yolk lipid
peroxidation [165].
Vitamin E is the major lipophilic antioxidant compound in our body that may provide the primary
protection against free radical induced lipid peroxidation [125]. The daily requirement is approximately
15 mg α-tocopherol equivalents per day [166]. Since vitamin E is needed to protect membrane lipids
from being peroxidized, this amount can be increased with higher intake of polyunsaturated fatty
acids [167,168]. Egg can be enriched to provide around 20 mg of vitamin E per egg, which is more than
the daily requirement, and also provide protection against unsaturated fatty acid peroxidation [158].
Folate, a water soluble B-group vitamin is shown to reduce the incidence of neural tube defects in
newborns [169]. Egg yolk can be enriched with highly bioavailable folate through fortification of feed
with folic acid to provide up to 12.5% of the recommended daily intake of folate [170,171]. Almost all
the folate in egg exists in the form of 5-methyltetrahydrofolate (5-MTHF), and showed high stability
during cooking [172]. Folates are reported to have antioxidant properties and among different forms,
5-MTHF was reported to have the most prominent antioxidant activity, which was attributed to the
electron donating effect of the 5-amino group [173]. In vivo and ex vivo studies with human vessels
showed that 5-MTHF improves NO-mediated endothelial function, decreases superoxide production,
scavenge peroxynitrite and also reversed endothelial nitric oxide synthase (eNOS) uncoupling, thereby
exerts antioxidant effects [174,175].
Both selenium and iodine, which are known to have antioxidant properties, can be effectively
transferred into the egg yolk. Eggs can be supplemented to provide up to 50% and 150% of the daily
requirements of selenium and iodine respectively [158,176]. Collectively, these antioxidant enriched
eggs provide multiple advantages by serving as a dietary source of several nutrients including omega 3,
vitamin E, vitamin D, selenium, iodine and also as an important source of antioxidants such as lutein.
3.3. Effect of Processing, Storage Conditions and Gastrointestinal Digestion on Egg Antioxidants
Foods are subjected to various processing and storage conditions before consumption, which
may influence the antioxidant capacity of food components. The effect of food processing and storage
conditions on the overall antioxidant activity of a particular food is a result of several different events
occurring consecutively or simultaneously. According to Nicoli et al., there are three possible effects of
food processing on the overall antioxidant capacity [177]:
1. The total antioxidant capacity is not affected: as a result of no changes in natural antioxidant
compounds or loss of naturally occurring antioxidants balanced by formation of compounds
with novel or improved antioxidant properties,
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2. The total antioxidant capacity is increased: as a result of improvement of antioxidant properties
of naturally occurring compounds or formation of new antioxidant,
3. The total antioxidant capacity is decreased: loss of naturally occurring antioxidants or formation
of new compounds with pro-oxidant activity.
Most thermal processing methods can create environments that can lead to oxidation, thermal
degradation, and leaching of vitamin C and phenolic compounds, which would reduce the antioxidant
activity [178]. With regard to carotenoids, processing can lead to the dissociation of compounds from
plant matrix resulting in increased carotenoid antioxidants, and improved digestive absorption [179–181].
Most of the fruits and vegetables contain phenolic compounds, carotenoids and vitamin C, which
are differently affected by processing conditions. Consequently, the total antioxidant capacity can be
increased [182–184] or decreased [184–187]. In animal-derived foods, the antioxidant capacity depends
mainly on amino compounds (proteins, peptides and amino acids) and vitamin E.
Heat modification of egg white proteins, ovalbumin, lysozyme and ovomucoid via Maillard
reaction resulted in protein-sugar conjugates, leading to increased radical scavenging properties [188].
Chen, Chi, and Xu showed that there are no significant differences in terms of DPPH
(1,1-diphenyl-2-picrylhydrazyl) radical-scavenging activity, reducing power, and lipid peroxidation
inhibitory activity of spray dried and freeze-dried egg white protein hydrolysates compared to the
undried sample [135]. Antioxidant properties of egg yolk phosvitin is due to its iron binding abilities;
heating phosvitin at 110 ◦C for 40 min did not change the iron binding ability of phosvitin [189].
Carotenoids and vitamin E in egg yolk are reported to be influenced by thermal processing.
In the presence of heat, light, oxygen, etc., carotenoids can undergo trans-cis isomerization, or
they can be degraded resulting in altered or loss of bioactivity [190]. Boiling of eggs resulted in
a 10%–20% carotenoid loss [112], whereas pasteurizarion did not change the carotenoid content [191].
Storage conditions such as temperature can also affect the antioxidant properties of eggs. Storage at
refrigeration temperature for two weeks reduced significantly the total carotenoid content in raw eggs
enriched with omega-3 and carophyll (canthaxanthin preparation), while at room temperature, the
losses were observed after 7 days of storage [192]. The vitamin E content of eggs was also significantly
reduced by thermal processing accompanied with increased lipid oxidation products [193,194].
Pretreatments with ultrasound, high-intensity pulsed electric field (PEF) or high pressure can
affect the antioxidant activity of egg proteins/peptides. Pretreatment with PEF significantly increased
the antioxidant activity of egg white protein hydrolysate which was attributed to the release of free
amino acids and small peptides with antioxidant properties [134]. Also, high pressure processing and
sonication or ultrasound pretreatments are shown to improve the degree of hydrolysis of egg white
proteins which result increased antioxidant properties [195,196].
Gastrointestinal digestion involves extreme pH conditions and various enzymes which might
cause degradation of antioxidant componds or generation of novel antioxidant compounds. Many
recent research activities have evaluated the changes in antioxidant capacity of different food products
after gastrointestinal digestion using diverse model systems. After gastrointestinal digestion, the
antioxidant activity of wheat [197], gooseberries [198], grapes [199], soymilk [200], saithe and
shrimp [201] and loach protein hydrolysate [202] increased several times, attributed mainly to increased
free amino acid content and short chain peptides generated during digestion. However, the antioxidant
activity of some foods such as apples [203] and Feijoada whole meal (a traditional Brazilian dish
containing vegetables) [204] was significantly reduced.
Many studies have reported the formation of antioxidant peptides after simulated gastrointestinal
digestion of egg components [81,134,150]. A recent study showed that different types of domestic
cooking methods such as boiling and frying decreased the antioxidant activity [134]. Nevertheless,
simulated gastrointestinal digestion of cooked egg with pepsin and pancreatin significantly increased
the antioxidant activity, which was attributed to the release of amino acids and antioxidant
peptides [134]. Our recent studies on effect of simulated gastrointestinal digestion of egg yolk
antioxidant using highly sophisticated intestinal model TIM-1 showed that, lutein and zeaxanthin, the
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main egg carotenoids, remain stable during the gastrointestinal digestion and also highly bioaccessible
possibly due to the association with yolk fat [205], it is likely that they retain their antioxidant activity.
Moreover, gastrointestinal digestion significantly increased the total antioxiant activity of cooked egg
yolk (about 5–8 fold), which is presumed to be a result of increased free amino acid content and release
of antioxidant peptides
4. Summary
Oxidative stress is hypothesized to be responsible for the onset and development of various
diseases and ageing. Dietary antioxidants are thought to impart potential benefits in reducing the
risk of some chronic diseases by maintaining redox homeostasis. There is extensive research on the
presence and characterization of antioxidants from fruits, vegetables, cereals and herbs; however, there
is only limited research with regard to antioxidants from animal products. Eggs are an important part
of our breakfast and an excellent source of high quality proteins, lipids, vitamins and minerals. Many
egg proteins such as ovalbumin, ovotransferrin, phosvitin, and egg lipids such as phospholipids, as
well as certain micronutrients such as vitamin E, vitamin A, selenium, and carotenoids, are reported to
have antioxidant properties. Furthermore, eggs can be enriched with antioxidants (i.e., carotenoids,
vitamin E, selenium and iodine) through manipulation of poultry feed. Domestic cooking tended to
reduce the antioxidant activity of egg, while gastrointestinal digestion of cooked eggs increased the
antioxidant due to the release of amino acid and peptides.
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Abstract: Despite their low cost and high nutrient density, the contribution of eggs to nutrient
intake and dietary quality among Mexican-American postpartum women has not been evaluated.
Nutrient intake and dietary quality, as assessed by the Healthy Eating Index 2010 (HEI-2010), were
measured in habitually sedentary overweight/obese (body mass index (BMI) = 29.7 ± 3.5 kg/m2)
Mexican-American postpartum women (28 ± 6 years) and compared between egg consumers (n = 82;
any egg intake reported in at least one of three 24-h dietary recalls) and non-consumers (n = 57). Egg
consumers had greater intake of energy (+808 kJ (193 kcal) or 14%; p = 0.033), protein (+9 g or 17%;
p = 0.031), total fat (+9 g or 19%; p = 0.039), monounsaturated fat (+4 g or 24%; p = 0.020), and several
micronutrients than non-consumers. Regarding HEI-2010 scores, egg consumers had a greater total
protein foods score than non-consumers (4.7 ± 0.7 vs. 4.3 ± 1.0; p = 0.004), and trends for greater
total fruit (2.4 ± 1.8 vs. 1.9 ± 1.7; p = 0.070) and the total composite HEI-2010 score (56.4 ± 12.6
vs. 52.3 ± 14.4; p = 0.082). Findings suggest that egg intake could contribute to greater nutrient
intake and improved dietary quality among postpartum Mexican-American women. Because of
greater energy intake among egg consumers, recommendations for overweight/obese individuals
should include avoiding excessive energy intake and incorporating eggs to a nutrient-dense, fiber-rich
dietary pattern.
Keywords: diet; eggs; healthy eating index; Hispanic women; nutrient intake
1. Introduction
Hispanics, the largest minority group in the United States (U.S.) [1], have a higher prevalence of
obesity and cardiometabolic disease risk factors relative to other ethnic groups, disproportionately
increasing their risk for chronic conditions such as cardiovascular disease and diabetes [2,3]. Among
women of reproductive age, excess weight gain during pregnancy and failure to lose weight
postpartum have been associated with long-term obesity and further risk for chronic diseases [4]. This
is of particular concern for postpartum Hispanic women due to higher pre-pregnancy obesity rates [5]
and the presence of many contributors to excessive weight retention after childbirth [6].
Several dietary factors are essential for the prevention and management of chronic diseases.
Studies have shown that a higher dietary quality is inversely related to chronic disease risk factors
such as waist circumference, low density lipoprotein (LDL)-cholesterol, insulin and C-reactive protein
(CRP) [7,8]. Despite the known benefits of consuming adequate diets, available surveillance data on
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dietary composition suggest that, as for other ethnic groups, the diet of Mexican-American adults
is in need for improvement, as indicated by reports of high intake of solid fats, added sugars, and
sugar-sweetened beverages, and low intake of vitamins D and E, calcium and potassium, whole grains,
dairy products, dark greens, and highly colored vegetables [9–13].
Due to their cholesterol content, the contribution of eggs to a healthful dietary pattern continues
to be controversial [14–17]. Whereas some studies have identified eggs as part of a “healthful”
or “prudent” dietary pattern with greater Healthy Eating Index (HEI) scores [18,19], others have
identified eggs as components of dietary patterns associated with greater risk for adverse outcomes
including overweight and obesity, metabolic syndrome, and insulin resistance [20,21]. However,
data from prospective cohort studies suggest that egg intake is not associated with increased risk of
coronary heart disease, stroke, and mortality, although it may be associated with increased risk of type
2 diabetes [22,23]. Eggs are an inexpensive food with high quality protein and a rich source of nutrients
including choline, folate, selenium, and vitamins A, B, D, E, and K, and, if fortified, ω-3 fatty acids [24].
The nutritional value of eggs can be an important contributor to the health of women of reproductive
age and to positive pregnancy outcomes particularly in disadvantaged populations with limited access
to more costly healthy foods [24,25]. Folate, choline and docosahexaenoic acid (DHA), all of which can
be supplied by eggs, are important nutrients during reproductive age for their role in the prevention
of adverse pregnancy outcomes related to fetal central nervous system development [25–27].
The World Agricultural Supply and Demand Estimates Report [28] shows that the U.S. had an
annual per capita consumption of 263 eggs in 2014, while Mexico is reported to have the highest
consumption in the Americas with 335 eggs per person/year. Data from the 2001–2002 National Health
and Nutritional Examination Survey (NHANES) suggested that eggs accounted for 7% of the servings
from meat and beans group among the general U.S. population [29]. Estimates using NHANES III
data suggested that 18.7% of U.S. adults were egg consumers (i.e., individuals who reported intake
of at least one egg-group product in a 24-h recall) [30]. Compared to non-consumers, egg consumers
were less likely to have inadequate intakes of vitamins B12, A, E, and C. Furthermore, relative to other
ethnic groups, a greater proportion of Mexican Americans (31.8%) were egg consumers [30].
Despite the known nutritional content of eggs and their potential benefit towards the health of
reproductive-age women, information regarding their contribution to a healthful diet among Hispanic
women of reproductive age is limited to a report with a diverse sample of pregnant women, most
of them of Caribbean descent [31]. Thus, the objective of the present study was to compare nutrient
intake and dietary quality, as assessed by the Healthy Eating Index 2010 (HEI-2010) [32], an algorithm
that measures conformance to the 2010 Dietary Guidelines for Americans [33], between egg-consumers
and non-consumers among Mexican-American postpartum women.
2. Study Design
2.1. Participants
Participants were 139 habitually sedentary overweight or obese (BMI between 25 and 35 kg/m2)
Mexican-American postpartum women (18–40 years old, at least six weeks but less than six months
after childbirth) enrolled into Madres para la Salud (Mothers for Health; Madres), a social support
community-based intervention promoting physical activity [34]. Exclusion criteria included currently
engaged in regular, strenuous physical activity; currently pregnant or planning on becoming pregnant
within the next 12 months; using antidepressants or anti-inflammatory medications; and having a
BMI less than 25 or greater than 35 kg/m2. Only baseline data were used for the current analysis. The
study was approved by Arizona State University’s Institutional Review Board, and all participants
provided written consent to participate. The study was registered at ClinicalTrials.gov (Identifier:
NCT01908959).
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2.2. Measures
Trained bilingual research staff collected and processed all baseline sociodemographic,
anthropometric and diet data prior to the randomization allocation. Standard procedures were
used to measure in triplicate height, weight, and waist circumference.
Three unannounced 24-h recalls using a five-step, multiple-pass method were collected to assess
baseline dietary intake data [35]. The dietary recalls were randomly collected during all seven days of
the week, including two week days and one weekend day. The Nutrition Data System for Research
(NDSR) software version 2009, developed by the Nutrition Coordinating Center (NCC), University
of Minnesota, Minneapolis, MN, was used to analyze dietary data. Dietary variables of interest
were estimates of total energy intake, amount and percentage of energy provided by macronutrients,
and selected micronutrients. Egg intake was reported as servings per day, with one serving being
equivalent to one large egg. Participants were classified as egg consumers if they reported any egg
intake (including egg products) in at least one of the three 24-h dietary recalls (mean egg intake
>0 servings/day).
Diet quality was assessed by calculating the HEI-2010, as described elsewhere [32]. Briefly, the
HEI-2010 includes 12 components divided into adequacy components that should be included in the
diet (total fruit, whole fruit, total vegetables, greens and beans, whole grains, dairy, total protein foods,
seafood and plant proteins, and fatty acids) and moderation components that should be limited (refined
grains, sodium, and empty calories). Individual components are scored from 0 to 5, 10, or 20 points; the
total HEI-2010 score is calculated as the sum of all individual components, for a total of 100 possible
points [36]. Maximum scores correspond to conformance to the dietary guidelines, reflecting higher
consumption of adequacy components and lower consumption of moderation components. The
scoring standards are assessed as food group and nutrients consumed per intake of 4184 kJ (1000 kcal),
percentage of total energy intake, or a ratio, providing information on a density basis rather than
absolute amounts [32]. The recommended approach to calculating HEI scores using NDSR was
followed [37].
2.3. Statistical Analysis
All statistical analyses were conducted with software IBM SPSS Statistics for Windows, version
21.0 (IBM Corp., Armonk, NY, USA). Descriptive characteristics of participants and dietary data are
presented in text and tables as mean ± standard deviation (SD). Nutrient intake for carbohydrates,
protein, fat, and saturated fat was expressed as percentages of total energy. We used independent
groups t-tests to compare egg consumers and non-consumers on each of the nutrient intake measures,
each HEI-2010 component, and the HEI-2010 total score.
3. Results
3.1. Participant Characteristics
Participants were 139 women (28 ± 6 years old) self-identified as Mexican or Mexican-American
(Table 1). Per study design, all participants were overweight or obese (mean BMI = 29.7 ± 3.5 kg/m2)
with mean waist and hip circumferences of 86 ± 9 cm and 106 ± 8 cm, respectively, and mean body fat
of 38.6% ± 4.6%. Based on dietary intake data from three dietary recalls, 57 women (41% of participants)
were classified as egg non-consumers, whereas 82 women (59% of participants) were classified as egg
consumers. There were no significant differences in age, BMI, waist or hip circumferences, or body fat
percent between egg consumers and non-consumers.
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Table 1. Characteristics of study participants a.





(n = 82) p Value
Age (year) 28.3 ± 5.6 28.8 ± 5.4 27.9 ± 5.7 0.331
Body mass index (kg/m2) 29.7 ± 3.5 29.3 ± 3.3 29.9 ± 3.7 0.321
Waist circumference (cm) 86.0 ± 9.0 86.1 ± 9.6 85.9 ± 8.7 0.895
Hip circumference (cm) 105.5 ± 7.6 105.4 ± 7.5 105.5 ± 7.8 0.934
Body fat (%) 38.6 ± 4.6 38.6 ± 4.7 38.5 ± 4.6 0.963
a Data shown as mean ± SD.
3.2. Nutrient Intake
Intake of total energy, macronutrient, and select micronutrient intake data for egg consumers and
non-consumers are displayed in Table 2. Relative to non-consumers, egg consumers had 14% greater
energy intake (p = 0.033), associated with consuming 17% more protein (p = 0.031) and 19% more fat
(p = 0.039). There were no significant differences between egg non-consumers and consumers in the
absolute amount of saturated and polyunsaturated fat, including ω-3 fatty acids, but monounsaturated
fat intake was 24% greater for egg consumers than non-consumers (p = 0.020). There were no significant
differences between egg non-consumers and consumers in the proportion of energy provided by
macronutrients (data not shown), with the exception of monounsaturated fat (10.5% ± 2.4% of energy
for non-consumers vs. 11.6% ± 3.1% of energy for consumers; p = 0.026). As expected, egg consumers
had greater intake of dietary cholesterol (109%; p < 0.0001) than non-consumers. Whereas there were
no significant differences between groups in total or added sugars intake, egg consumers had greater
intake of total fiber (22%; p = 0.035) and soluble fiber (29%; p = 0.017) relative to non-consumers.
Regarding micronutrient intake (Table 2), there were no significant differences between groups
in dietary vitamin A, vitamin C, vitamin E, vitamin K, thiamin, niacin, vitamin B6, folate, calcium,
or iron. However, egg consumers had greater intakes of vitamin D (31%; p = 0.033), riboflavin (29%;
p = 0.006), vitamin B12 (32%; p = 0.031), choline (59%; p < 0.0001), sodium (23%; p = 0.008), potassium
(21%; p = 0.011), and phosphorus (19%; p = 0.012) than non-consumers. There were no significant
differences in dietary lutein + zeaxanthin between groups.
Table 2. Comparison of total energy, macronutrient, and select micronutrient intake between egg
consumers and egg non-consumers among postpartum Mexican American adult women a.








Energy (kJ) 6137 ± 2208 5660 ± 1934 6468 ± 2334 0.033
Energy (kcal) 1466 ± 528 1353 ± 462 1546 ± 561 0.033
Total Carbohydrate (g) 160 195 ± 69 184 ± 61 203 ± 74 0.113
Total Protein (g) 0.66/kg 59 ± 24 53 ± 22 62 ± 25 0.031
Total Fat (g) 52 ± 25 47 ± 24 56 ± 26 0.039
Saturated Fat (g) 18 ± 9 16 ± 8 19 ± 9 0.131
Monounsaturated Fat (g) 19 ± 10 17 ± 9 21 ± 10 0.020
Polyunsaturated Fat (g) 11 ± 6 10 ± 7 12 ± 6 0.138
ω-3 Fatty Acids (g) 1.09 ± 0.77 0.99 ± 0.83 1.15 ± 0.71 0.205
Cholesterol (mg) 228 ± 148 139 ± 124 291 ± 131 0.0001
Total sugars (g) 93.7 ± 41.3 88.4 ± 37.2 97.3 ± 43.8 0.213
Added sugars (g) 62.9 ± 35.3 61.6 ± 33.4 63.8 ± 36.7 0.715
Total dietary fiber (g) 25 13.5 ± 7.0 12.0 ± 5.0 14.6 ± 8.0 0.035
Soluble fiber (g) 4.1 ± 2.6 3.5 ± 1.5 4.5 ± 3.1 0.017
Vitamin A (μg) c 500 625 ± 396 563 ± 401 668 ± 389 0.126
Vitamin C (mg) 60 62.3 ± 53.8 54.0 ± 44.2 68.2 ± 59.2 0.128
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Vitamin D (μg) 10 4.95 ± 3.53 4.19 ± 3.39 5.48 ± 3.55 0.033
Vitamin E (mg) 12 4.92 ± 3.02 4.48 ± 3.21 5.22 ± 2.87 0.159
Vitamin K (μg) 90 42.5 ± 42.6 38.6 ± 34.8 45.2 ± 47.2 0.375
Thiamin (mg) 0.9 1.22 ± 0.57 1.16 ± 0.54 1.26 ± 0.58 0.268
Riboflavin (mg) 0.9 1.67 ± 0.86 1.43 ± 0.76 1.83 ± 0.90 0.006
Niacin (mg) 11 16.7 ± 7.9 15.9 ± 7.9 17.3 ± 8.0 0.328
Vitamin B6 (mg) 1.1 1.60 ± 1.09 1.44 ± 1.00 1.70 ± 1.14 0.165
Total folate (μg) 320 332 ± 210 295 ± 197 357 ± 217 0.090
Vitamin B12 (μg) 2.0 4.74 ± 3.48 3.98 ± 3.00 5.27 ± 3.70 0.031
Choline (mg) 425 237 ± 110 176 ± 79 279 ± 110 0.0001
Sodium (mg) 1500 2569 ± 1132 2266 ± 945 2780 ± 1206 0.008
Potassium (mg) 4700 1788 ± 781 1587 ± 629 1927 ± 848 0.011
Calcium (mg) 800 779 ± 358 735 ± 301 826 ± 390 0.142
Phosphorus (mg) 580 1018 ± 415 913 ± 349 1091 ± 443 0.012
Iron (mg) 8.1 12.6 ± 7.0 11.4 ± 6.4 13.4 ± 7.3 0.091
Lutein + Zeaxanthin (μg) 680 ± 979 547 ± 648 773 ± 1150 0.181
a Data shown as mean ± SD; b DRI = Dietary Reference Intake for women 31–50 years old; displayed as Adequate
Intake for fiber, choline, vitamin K, sodium and potassium, and as Estimated Average Requirement for all other
nutrients, when applicable; c Retinol Equivalents.
3.3. Healthy Eating Index 2010
Estimated mean HEI-2010 individual component and total scores for egg non-consumers and
consumers are presented in Table 3. There were no significant differences in adequacy component
scores between groups, with the exception of the total protein foods score, which was greater in egg
consumers than in non-consumers (p = 0.004). There was a non-significant trend for egg consumers
to have a greater total fruit score relative to non-consumers (p = 0.070). There were no significant
differences between groups in moderation component scores, although relative to non-consumers,
there were trends for egg consumers to have a lower score (greater intake) for sodium (score of 4.5 ± 3.5
vs. 3.5 ± 3.0 out of 10; p = 0.074) and a greater score (lower intake) for empty calories (score of 8.8 ± 5.7
vs. 10.6 ± 5.3 out of 20; p = 0.059). The total composite HEI-2010 score did not differ significantly
between groups, although was slightly greater for egg consumers (52 ± 14 vs. 56 ± 13 out of 100 points
for egg non-consumers and consumers, respectively; p = 0.082).
Table 3. Estimated mean total Healthy Eating Index (HEI)-2010 and component scores among between
egg consumers and egg non-consumers among postpartum Mexican American adult women, expressed
as absolute score and percentage of the maximum score a.





(n = 82) p Value
Adequacy Components
Total Fruit (0–5) 2.2 ± 1.7 1.9 ± 1.7 2.4 ± 1.8 0.070
Whole Fruit (0–5) 2.4 ± 1.9 2.1 ± 1.9 2.6 ± 1.9 0.168
Total Vegetables (0–5) 2.5 ± 1.2 2.6 ± 1.3 2.5 ± 1.1 0.710
Greens and Beans (0–5) 1.6 ± 1.6 1.8 ± 1.9 1.4 ± 1.4 0.227
Whole Grains (0–10) 7.6 ± 3.2 7.6 ± 3.4 7.6 ± 3.1 0.885
Dairy (0–10) 5.9 ± 3.3 5.8 ± 3.3 6.0 ± 3.3 0.729
Total Protein Foods (0–5) 4.5 ± 0.9 4.3 ± 1.0 4.7 ± 0.7 0.004
Seafood and Plant Proteins (0–5) 2.8 ± 2.1 2.2 ± 2.1 2.7 ± 2.1 0.173
Fatty Acids (0–0) 4.3 ± 2.9 3.9 ± 2.8 4.6 ± 3.0 0.116
a Data shown as mean ± SD.
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(n = 82) p Value
Moderation Components
Refined Grains (0–10) 7.5 ± 3.1 7.0 ± 3.2 7.8 ± 3.1 0.127
Sodium (0–10) 3.9 ± 3.3 4.5 ± 3.5 3.5 ± 3.0 0.074
Empty Calories (0–20) 9.8 ± 5.5 8.8 ± 5.7 10.6 ± 5.3 0.059
Total Score (0–100) 54.7 ± 13.5 52.3 ± 14.4 56.4 ± 12.6 0.082
a Data shown as mean ± SD.
4. Discussion
This study assessed the contribution of eggs to dietary quality among an understudied group
of the population, Mexican-American postpartum women, by comparing nutrient intake and
HEI-2010 scores between egg-consumers and non-consumers. This report is of importance because
there is limited information regarding contributors to nutrient intake and dietary quality among
Mexican-American women of reproductive age. Study findings indicated that egg consumers had
greater intakes of energy, protein, fat, monounsaturated fat, cholesterol, total and soluble fiber, vitamin
D, riboflavin, vitamin B12, choline, sodium, potassium, and phosphorus, and a modestly higher
HEI-2010 score than non-consumers. Similarly, in the only study of its kind conducted in a diverse
sample of pregnant Hispanic women, egg consumers had higher intakes of several nutrients including
protein, fat, vitamins K and E, cholesterol, total polyunsaturated fatty acids, and DHA [31]. Comparable
information among postpartum women is lacking.
In the current study, a greater proportion of participants (59% or n = 82) reported consuming
eggs than what has been reported for U.S. adults (19%) or Mexican-American adults (32%) using
NHANES III data [30]. A majority of study participants (78%) were immigrants of Mexican origin
who had been in the U.S. for 12 ± 7 years [34,38,39]. Several reports indicate that multiple factors that
are part of the immigration experience, such as acculturation, generational status, and time in the
U.S., are associated with lifestyle modifications often associated with less healthful dietary patterns
in part due to immigrants’ lack of familiarity with available foods in their new environment [40–43].
However, eggs are a low-cost common protein source in the Mexican diet, as evidenced by the high
per capita consumption of eggs in Mexico compared to other countries [28], which may have made
eggs a nutritious and familiar dietary choice among the generally low-socioeconomic status study
participants [34,38,39]. Nevertheless, the possibility cannot be ruled out that the methodology used in
the current study (three 24-h recalls) may have better allowed to capture individual instances of egg
intake than using only one 24-h recall for NHANES.
In the current study, energy intake was greater for egg consumers than non-consumers.
Considering that participants were overweight or obese, this increased energy intake could be of
concern because it could potentially translate into long-term weight gain, even when mean total energy
intake was lower than what has been reported among U.S. adult women (7543 ± 59 kJ/day (1803
± 14 kcal/day) according to NHANES 2009-2010 data [44]). The greater energy intake among egg
consumers could have been in part attributed to greater fat intake. Differences in fatty acid intake
were due to greater monounsaturated fatty acids in the diet of egg consumers vs. non-consumers,
which explains the greater, albeit non-significant, HEI-2010 fatty acid ratio score ((polyunsaturated
fatty acids + monounsaturated fatty acids)/saturated fatty acids) for egg consumers. Although these
differences cannot be solely attributed to the fatty acid contribution from eggs, it is noteworthy that
roughly 50% of fatty acids in eggs are monounsaturated [45]. Regarding polyunsaturated fatty acids,
fortified eggs can be an important dietary contributor to ω-3 fatty acids. A study including Mexican
pregnant women reported that 20% of total DHA intake was supplied by eggs [27]. In a diverse sample
of pregnant Hispanic women, a greater proportion of egg consumers than non-consumers had DHA
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consumption in the highest tertile of intake [31]. In the current study, differences in ω-3 fatty acid
intake between egg non-consumers and consumers were not statistically significant. Although as
expected in the current study egg consumers had greater dietary cholesterol than non-consumers,
intake levels did not exceed current recommendations for cholesterol intake (300 mg/day) [46].
Adequate protein intake is crucial for women of reproductive age to maintain maternal and fetal
tissue accretion during pregnancy and milk production during lactation [47–49]. In fact, a recent
report [50] suggested that protein needs for pregnancy may be even higher than current dietary
reference intake recommendations of 1.1 g/kg of body weight/day [46]. In the current study, both
absolute protein intake and the HEI-2010 score for total protein foods were greater for egg consumers
than non-consumers, although as previously reported the total protein HEI-2010 score was indicative of
appropriate consumption of protein-containing foods for all participants [38]. Intake of animal protein
was also greater for egg consumers than for non-consumers, although non-significantly different
(data not shown). However, the high-quality nature of egg protein [24] may provide an additional
nutritional advantage to women who incorporate eggs as part of their diet in the postpartum period.
In the present study, egg-consumers had a greater intake of vitamin D compared to non-consumers.
According to NHANES 2003–2006 data, eggs were ranked the third main source of vitamin D (after
milk and fish/seafood), contributing with about 5% of vitamin D intake among adults in the United
States [51]. This is important considering that it is estimated that between 40% and 80% of U.S. adults,
depending on gender and age range, have inadequate vitamin D intake [52]. Furthermore, results from
a meta-analysis study showed that low maternal vitamin D levels during pregnancy are associated
with risk of preeclampsia, gestational diabetes, preterm birth and small-for-gestational age [53].
All participants in the current study had HEI-2010 scores suggesting intake of diets with low
quality or in need for improvement (55 ± 14 relative to a maximum score of 100). A report using
NHANES data suggested that at the population level HEI-2010 total score was 53 [54]. Furthermore,
participants were not meeting intake recommendations for several nutrients, including fiber, Ca,
vitamin E, vitamin C and folate. Egg consumers had a greater HEI-2010 score for total protein foods,
and trends towards greater scores for total fruit and empty calories, and lower score for sodium. These
differences resulted in a modestly greater total HEI-2010 score for egg consumers.
The main risk associated with egg consumption in the U.S. is salmonellosis, mainly due to
consumption of raw or undercooked eggs [55]. The risk is particularly important during pregnancy
since salmonellosis may be transmitted to the fetus, increasing the risk of preterm delivery and
intrauterine death [55,56]. In a study about food safety, most pregnant women were aware about
recommendations to avoid raw eggs; however, they still reported consumption of eggs with runny yolk
(35%) and cookie dough containing raw eggs (40%), indicating the need to improve instructions given
to this target group [57]. Nevertheless, the potential benefits associated with their high nutritional
quality outweigh risks as long as eggs are properly cooked before consumption.
Prior reports from the current study have documented that participants included a large
proportion of women living under disadvantaged socio-economic conditions in neighborhoods with
limited food access [34,38,39]. In general, Hispanic households have been documented to have greater
food insecurity rates than the general population [58]. Thus, an additional benefit of egg intake for
the target population in the current study as well as other Hispanic subgroups is associated with
their low cost. In general, the cost of foods is directly associated with protein but inversely associated
with carbohydrate content [59]. In contrast, relative to other animal sources of protein, eggs are an
inexpensive nutrient-dense, high-protein, low-carbohydrate food [24,59]. According to the Nutrient
Rich Foods Index, developed as an effort to aid consumers select nutritious food choices under financial
constraints, eggs are a low cost source of protein, vitamin A, vitamin B12, riboflavin, calcium and zinc,
providing excellent nutritional value for the money [60].
An important limitation of the current report is that dietary assessment was conducted using
three 24-h dietary recalls, a method subject to intake underreporting, particularly among women and
Hispanic individuals [61,62], as indicated by the relatively low energy intake observed in the current
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study. Although this limitation was addressed by calculating the HEI-2010 scores on an energy-density
basis when assessing dietary quality [32], differences observed in individual nutrient intakes between
egg consumers and non-consumers, particularly macronutrients, are likely a result of absolute energy
intake and not solely due to egg consumption. Moreover, data from 24-h dietary recalls may not be the
best indicator of habitual food consumption, including eggs.
5. Conclusions
The current report suggests that Mexican-American women who consumed eggs had greater
nutrient intake and higher dietary quality than non-consumers. Whereas these data do not indicate
that egg intake directly improves dietary quality, it could potentially be an indicator of a healthier
dietary pattern. Despite the greater energy intake observed among egg consumers, the low cost and
high nutritional quality of eggs make them an ideal protein source that is likely to provide greater
benefit than risk to the target population, especially if dietary recommendations focus on consuming
eggs as part of a dietary pattern that also includes nutrient-dense and fiber-rich foods and maintaining
a healthy body weight.
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Abstract: The 1968 American Heart Association announced a dietary recommendation that all
individuals consume less than 300 mg of dietary cholesterol per day and no more than three whole
eggs per week. This recommendation has not only significantly impacted the dietary patterns of
the population, but also resulted in the public limiting a highly nutritious and affordable source of
high quality nutrients, including choline which was limited in the diets of most individuals. The
egg industry addressed the egg issue with research documenting the minimal effect of egg intake on
plasma lipoprotein levels, as well as research verifying the importance of egg nutrients in a variety
of issues related to health promotion. In 2015 dietary cholesterol and egg restrictions have been
dropped by most health promotion agencies worldwide and recommended to be dropped from the
2015 Dietary Guidelines for Americans.
Keywords: eggs; dietary cholesterol; plasma cholesterol; lipoproteins; choline; xanthophylls
1. Introduction
Of the vast variety of foods that humans consume, only one has ever been specifically singled
out for restriction in an effort to reduce cardiovascular disease (CVD) risk in the population—the
egg. The most widely known dietary recommendation in the world is the 1968 admonition from
the American Heart Association (AHA) to consume no more than three egg yolks per week [1]. For
consumers this provided a recommendation they could easily incorporate into their lifestyles (in 1968
who knew what 10% of calories from saturated fat or 300 mg cholesterol actually meant); for health
professionals it was easy to explain dietary equivalency (high dietary cholesterol equals high blood
cholesterol equals high CVD risk) without getting into detailed explanations of fat, calories, etc.; and
for the media it was an ideal icon for the hazards of our modern dietary patterns which lead to high
CVD incidence. The only negative effect was on the egg industry which saw a substantial drop in per
capita egg consumption over the subsequent years. The question many scientists raised was whether
or not this recommendation would actually have any impact on CVD rates. But like the mistaken
views in nutritional sciences, it was thought that it couldn’t hurt. In the long run it turned out that not
only was the recommendation based on misunderstood data and effectively useless, it actually did
damage to the general public in terms of their nutritional needs.
2. The Egg Industry Responds
The egg industry was faced with a difficult situation in 1968: fight back and be accused of putting
profits ahead of public health or simply give in to the dietary cholesterol phobia being promoted by
the AHA and later on by the US government. The other challenge, should the industry decide to
finance research in an attempt to prove the egg innocent of the charges, was the fact that in science
the accusation that the findings of any study from “industry funded research” are often a quick
nullification of the credibility of the results and the investigators involved. But the attacks from health
promotion organizations and the media on how harmful meat, dairy and eggs were because of their
fat and cholesterol content necessitated that the animal food commodity groups respond, and overall
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their responses were based on the use of science. The decline in egg consumption in the US after the
AHA recommendations were publicized, and further still after the 26 March 1984 Time magazine
cover (which referred to a drug study), prompted the US egg industry to establish the Egg Nutrition
Center (ENC) to promote research and initiate health education efforts to address issues raised by
the AHA in 1968, the Select Committee on Nutrition in 1977 (predecessor of the Dietary Guidelines
Advisory Committee), and eventually the National Cholesterol Education Program (NCEP) of the
Heart, Lung and Blood Institute of the National Institutes of Health (NIH). In addition, a number
of non-government organizations (NGOs) had gotten on the bad egg, bad cholesterol bandwagon
as an effective way to raise funds and there was a virtual avalanche of new food products touting
“low-cholesterol” and “cholesterol-free” (cholesterol-free peanut butter?) in print, radio and TV
advertising. And for most people the concept of “low cholesterol” was a confusion between dietary
cholesterol and blood cholesterol. The evils of cholesterol, and eggs, were constantly presented to
the consumer.
The egg industry’s goal in forming ENC was to formulate a scientific basis for addressing the
dietary cholesterol issue. ENC formed a scientific advisory panel in 1984 composed of clinical and
university research scientists to help formulate a long range research plan, as well as to serve as
consultants to the industry and spokespersons on behalf of the industry. Contrary to the “consensus”
argument, not all nutritional scientists were convinced that the low-fat, low-cholesterol diet was the
best answer to our CVD problems. I served on that original scientific advisory panel because I had
carried out studies on the effects of egg intake on blood cholesterol levels and endogenous cholesterol
metabolism [2] and had serious doubts regarding the contribution of dietary cholesterol to blood
cholesterol levels and CVD risk [3].
The scientific bases for the original dietary cholesterol restriction was based on three lines of
evidence: animal studies showing cholesterol in the diet increased plasma cholesterol levels and
development of atherosclerosis; epidemiological evidence that high dietary cholesterol was associated
with high CVD incidence; and clinical studies showing that high cholesterol intake resulted in increased
serum cholesterol levels. While the evidence of harm seems strong, each line of evidence was open
to debate. Animal studies often used herbivores which were hypersensitive to dietary cholesterol as
compared to omnivores (rabbit versus dog). Studies in suitable animal models often required use of
pharmacological levels of cholesterol in the diet in order to elicit a response. Epidemiological data in
the 1960s and 1970s relied on simple correlation analyses to show associations and did not account
for collinearity of nutrients (saturated fat and cholesterol found in animal products). Eventually
multivariate analysis of dietary lipids and CVD incidence documented that dietary cholesterol was not
an independent risk factor [4–6]. Clinical feeding studies had two limits: use of pharmacological levels
of dietary cholesterol (for example, six eggs per day for six weeks) and in the early studies reliance
on measurement of total plasma cholesterol as the marker of risk [6]. Use of physiological dietary
cholesterol levels and analysis of lipoprotein cholesterol distribution, including LDL size, provide a
very different perspective on risk assessment [6].
Over the years the egg industry funded a variety of animal and clinical studies investigating
the effects of egg intake on plasma total and lipoprotein cholesterol levels and metabolism under
various conditions. These studies indicated that eggs had little effect on CVD risk [6]. Retrospective
analysis of existing clinical data also indicated that eggs and dietary cholesterol, when consumed
at physiological, not pharmacological levels, did not significantly affect CVD risk profiles [6–8].
Retrospective review of epidemiological studies which involved analysis of egg intake showed that
egg intake was not associated with CVD incidence [6]. The more modern epidemiological studies
using multivariate analysis reported that dietary cholesterol was non-significant as an independent
factor in CVD incidence [4–6]. Based on these facts, the egg industry considered that it was justified in
its efforts to challenge the egg restriction recommendation. Of course, one could predict a backlash to
such a challenge.
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3. Speaking with One Voice
By 1995 there was a concerted effort to unify all the US national dietary recommendations (so as
not to confuse the public) such that the AHA guidelines, the NCEP guidelines, the Dietary Guidelines
for Americans, and the Nutrition Facts Panel from the Food and Drug Administration (FDA) all set the
dietary cholesterol recommendation at less than 300 mg/day (For detailed reviews of the history of the
rationale and implementation of dietary lipid guidelines and their subsequent demise, see Taubes [7]
and Teicholz [8].) One question rarely raised by these various agencies or by the scientific community
was why 300 mg/day, why not 250 or 400 mg/day or whatever. Determining how the 300 mg/day
number was chosen back in 1968 remains a mystery without a satisfactory answer other than it was
half of what the estimated cholesterol intake was at the time. Irrespective of the scientific rationale for
the number, it became established dogma in the nutrition community. Since one large egg contained
213 mg of cholesterol, per capita egg consumption continued to be low. ENC continued to argue
against egg recommendations and presented the science documenting no significant effect of eggs on
CVD risk. The counter argument was that the evidence showed that egg intake did increase plasma
cholesterol levels [9,10], although at a level which was miniscule and offset by comparable increases in
both LDL and HDL cholesterol levels with no change in the LDL:HDL ratio (i.e., no change in relative
risk) [11,12]. (1995 was also the year that I accepted the position of Executive Director of ENC).
4. A New Approach
In 1995 the egg industry initiated a two pronged approach to dealing with the dietary cholesterol
issue: detailed studies of the effects of egg intake on CVD risk factors and studies of the contribution
of eggs to a healthy diet across the lifespan. It was clear to the egg industry that simply funding
more egg feeding studies was not going to significantly impact the perception of eggs as potentially
harmful. Attempts to fund research analyzing data from large epidemiological studies were met with
great resistance due to the curse of “industry funded research” negation and the hesitation of some
researchers to be seen as not going along with the “consensus” that dietary cholesterol was harmful.
And it was clear that no matter how many feeding studies were presented that the various agencies
involved were not going to simply change the recommendations because they were wrong. In view of
these factors the egg industry decided that it needed to give the policy makers a reason to change; i.e.,
implement the “do no harm” imperative.
ENC initiated research projects on a wide variety of themes to document why eggs should be
included in the diet. The eventual outcomes of these studies were a surprise to both the egg industry
and health agencies. Many of these findings are reported in the associated papers in this issue of
the journal.
1. Nutritional Value of Eggs: It is widely recognized that eggs are a highly nutritious food based
on their high quality protein and compliment of vitamins and minerals [13]. Eggs are one of the
most widely available economical sources of animal protein. In addition, many of the nutrients
in eggs can be increased by altering the hen’s diet (Se, vitamin E, vitamin D, omega-3 fatty acids,
xanthophylls and folate to name just a few). Due to the recommendation to eat no more than three
whole eggs per week, and in some parts of Central and South America no more than two eggs
per week, those in the lower socioeconomic classes have been scared away from an affordable
source of high quality nutrition. It made little sense to restrict a highly nutritious food from
the diets of those with sub-optimal nutrient intake whose main health issue was not the over
consumption prevalent in the US. This became more obvious when considering the nutritional
needs of growing children, pregnant women, and the elderly.
2. Egg Protein and Satiety: Egg protein, especially egg yolk protein, has a significantly greater
satiety effect than other protein sources [14,15]. Studies have shown reduced caloric intake after
an egg breakfast compared to a bagel breakfast [16], greater weight loss over 8 weeks with an
egg as compared to a bagel breakfast as part of a hypocaloric diet [17], and larger changes in
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satiety hormones with an egg breakfast [18]. The five decade long shift from eggs for breakfast
to carbohydrate rich cereals might not have been the best approach to weight maintenance and
probably contributed to our national obesity problem.
3. Egg Protein and Sarcopenia: There are a number of factors which can impact the dietary
availability of high quality animal protein for seniors: availability, affordability, preparation
limits, and ease of chewing and digesting. Affordable sources of high-quality animal protein
in the diet, especially eggs that are widely available and easy to cook, chew and digest, are of
significant importance for growth and development in children as well as for reducing the rate of
sarcopenia and maintaining lean muscle tissue mass in the elderly [19]. After 40 plus years of
hearing about the dangers of egg cholesterol, many seniors studiously avoid eggs, probably to
their detriment [20].
4. Egg Xanthophylls: Lutein and Zeaxanthin: Eggs provide highly bioavailable forms of the
xanthophylls lutein and zeaxanthin which are related to lower risks for age-related macular
degeneration and cataracts [21–24] as well as some types of cancer [22,25] and carotid artery
atherosclerosis [26]. Studies showed that egg lutein had high bioavailability [21] and that adding
eggs to the diet could result in significant increases in macular pigment optical density [23,24].
What continues to make this line of investigation so intriguing is that the levels of lutein and
zeaxanthin in an egg can easily be increased up to ten-fold by adding marigold extract to the
hens’ feed. In fact, today lutein enriched eggs are available in many parts of the world.
5. Egg Choline: Eggs are an excellent source of choline [27], an essential nutrient which has been
shown to be inadequate in the diets of 9 out of 10 adults in the U.S. Choline plays an important
role in fetal and neonatal brain development [28] and inadequate choline intake during pregnancy
increases the risk for neural tube defects such as spina bifida [29]. Choline intake is also associated
with decreased plasma levels of homocysteine and inflammatory factors, which are related to
increased cardiovascular disease risk [30]. Recent studies have also shown that high intake of
choline is associated with reduced breast cancer incidence and mortality [31,32]. Unfortunately,
studies also show that a majority of the population, including a majority of pregnant and lactating
women, do not have adequate choline intakes and that adding an egg a day to the diet could
alleviate this inadequacy [33]. The importance of choline in fetal and neonatal brain development
has been shown in numerous studies and inadequate choline intakes during these critical periods
can have very negative effects [34–36].
6. The egg industry also supported a series of studies looking at the chronic and acute effects of egg
intake on endothelial function in a variety of patients and found no evidence of adverse effects
with daily egg ingestion on any cardiac risk factors in normolipidemic and hyperlipidemic adults
or in adults with CVD [37–39].
5. An Outdated Hypothesis Slowly Put to Rest
In 1999 Hu et al. [40] published one of the first large, long term population studies on egg intake
and CVD incidence. The results from over 117,000 men and women documented no differences in
CVD risk between those consuming one egg a week versus one egg a day. Other large epidemiological
studies have reported similar findings reporting that egg intake is not associated with CVD risk [41,42].
Meta-analyses have come to the same conclusion [43–45].
In 2002 the AHA dropped its specific egg restriction of 3–4 per week while keeping the less
than 300 mg/day of dietary cholesterol guideline. While the US continued to recommend limits on
dietary cholesterol, a large number of countries removed dietary cholesterol restrictions from their
national dietary guidelines (Australia, Great Britain, Ireland to name a few). It took another twelve
years for AHA to pronounce that “There is insufficient evidence to determine whether lowering
dietary cholesterol reduces LDL-C.” [46]. In an equally surprising turn of events, the 2015 Dietary
Guidelines Advisory Committee (DGAC) stated in its report that “Previously, the Dietary Guidelines
for Americans recommended that cholesterol intake be limited to no more than 300 mg/day. The 2015
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DGAC will not bring forward this recommendation because available evidence shows no appreciable
relationship between consumption of dietary cholesterol and serum cholesterol, consistent with the
conclusions of the AHA/ACC report.” [47]. A recommendation known worldwide that lasted for
47 years has simply been discarded and we can all go back to including eggs in our diets. The United
States, which had first promoted the “no more than 300 mg/day cholesterol” recommendation, was
now one of the last countries to do away with it. It is interesting to note that it required a much
greater amount of research to prove that egg intake was unrelated to CVD risk than it did to initially
condemn it as a significant contributor to CVD incidence. This nutritional saga shows that dietary
recommendations need to be based more on science than belief and that industry funded research can
be a valid approach to address specific issues and when applying proper scientific methods, can be of
benefit to both the industry and the public.
6. Conclusions
For almost 50 years eggs and dietary cholesterol have been thought to contribute to high plasma
cholesterol levels and increased CVD risk. Based on this belief dietary recommendations in the US
and most countries have included dietary cholesterol and egg restrictions. Half a century of research
have shown that egg and/or dietary cholesterol intake is not associated with increased CVD risk. In
addition, research studies have shown that egg intake addresses a number of nutrient inadequacies
and can make important contributions to overall health across the life span. Dietary cholesterol and
egg restrictions have now been removed from most national dietary recommendations.
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Abstract: Vitellogenin (Vtg), the major egg yolk precursor protein, is traditionally thought to provide
protein- and lipid-rich nutrients for developing embryos and larvae. However, the roles of Vtg as well
as its derived yolk proteins lipovitellin (Lv) and phosvitin (Pv) extend beyond nutritional functions.
Accumulating data have demonstrated that Vtg, Lv and Pv participate in host innate immune defense
with multifaceted functions. They can all act as multivalent pattern recognition receptors capable
of identifying invading microbes. Vtg and Pv can also act as immune effectors capable of killing
bacteria and virus. Moreover, Vtg and Lv are shown to possess phagocytosis-promoting activity as
opsonins. In addition to these immune-relevant functions, Vtg and Pv are found to have antioxidant
activity, which is able to protect the host from oxidant stress. These non-nutritional functions clearly
deepen our understanding of the physiological roles of the molecules, and at the same time, provide
a sound basis for potential application of the molecules in human health.
Keywords: vitellogenin; lipovitellin; phosvitin; immunity; antioxidant activity
1. Introduction
Most fishes are oviparous, with their eggs being fertilized externally [1]. Eggs or haploid
reproductive cells, which develop into viable embryos after fertilization, are the final product of oocyte
growth and differentiation [2]. Generally, several steps are involved in oocyte development: formation
of primordial germ-cells (PGCs), and transformation of PGCs into oogonia and then to oocytes.
Subsequently, massive maternal information and molecules needed for early embryo development
are deposited in growing oocytes during vitellogenesis, including RNAs, proteins, lipids, vitamins,
and hormones [2,3]. One of the most important proteins deposited in oocytes is vitellogenin (Vtg),
a member of the large lipid transfer protein (LLTP) superfamily [3–5]. Vtg is a high molecular mass
glycolipophosphoprotein, usually circulating in the blood (vertebrates)/hemolymph (invertebrates) as
a homodimer [4,6–8]. There are usually several isoforms of Vtg in a given species, which are encoded
by a multigene family [9,10]. For instance, three vtg genes have been identified in chicken Gallus
gallus [11,12], four in Africa frog Xenopus laevis [13,14], and six in nematode Caenorhabditis elegans [15].
Multiple vtg genes are also common in teleosts. It has been documented that there are seven vtg genes
in zebrafish Danio rerio [16,17], two vtg genes in carp Cyprinus carpio [18], four vtg genes in medaka
Oryzias latipes [10], three vtg genes in striped bass Morone saxatilis [19], and three vtg genes in white
perch Morone americana [20]. All vitellogenins (Vtgs) encoded by multiple genes display a similar
structure in vertebrates, such as fish, and invertebrates, particularly insects [21,22]. In most cases, Vtg
contains three conserved domains, the LPD_N (also known as vitellogenin_N or LLT domain), which
is identified at the N-terminus, the domain of unknown function (DUF) 1943, and the von Willebrand
factor type D domain (vWD), which is located at the C-terminus and distributed over a wide range
of proteins [21]. Occasionally, a domain of unknown function called DUF1944 is found to be present
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in between DUF1943 and vWD in some Vtg proteins from vertebrates such as chicken and fish [22].
Beginning at the N-terminus, a complete fish Vtg consists of a signal peptide, a lipovitellin heavy chain
(LvH), a phosphorylated serine-rich phosvitin (Pv), a lipovitellin light chain (LvL), and a β-component
(β-C) plus a C-terminal coding region (CT) comprising the vWD (Figure 1) [4,19,20,23]. Notably, some
teleostean Vtgs lack Pv and much of the carboxyl-terminus (β-component and C-terminal peptide),
consisting of only LvH and LvL [23]. Pv are also absent in most invertebrate Vtg [8,16].
Figure 1. Schematic summary of structure of a complete teleost vitellogenin (Vtg). A short signal
peptide (SP) is shown at the N-terminus, flowing by a lipovitellin heave chain (LvH), a phosphorylated
serine-rich phosvitin (Pv), a lipovitellin light chain (LvL), and a β-component (β-C) plus a C-terminal
coding region (CT).
Vtgs, the precursors of egg yolk proteins, are present in the females of nearly all oviparous
species including fish, amphibians, reptiles, birds, most invertebrates and the platypus. Vtgs are
usually synthesized in an extra-ovarian tissue (in the liver of vertebrates, the hepatopancreas of
crustaceans and the fat body of insects) and transported by the circulation system to the ovary, where
it is internalized into growing oocytes via receptor-mediated endocytosis during vitellogenesis with
diverse proportional composition [2,7,19,24–31]. Interestingly, the rates of different Vtgs internalized
by growing oocytes are not always equal to the rates of circulating Vtgs in the blood, which may
be due to the regulation of the system of multiple ovarian receptors engaged in endocytosis of
different Vtgs [32–35]. Once internalized into the oocytes, Vtgs are proteolytically cleaved by the
aspartic protease cathepsin D to generate yolk proteins, such as Lv subunits, Pv and β-C [36–43]. Lv
subunits and Pv are stored in yolk globules or platelets, while β-C remains in cytoplasm as a soluble
fraction [44–46]. Lv, the largest yolk protein derived from the proteolytic processing of Vtgs, is an
apoprotein delivering mainly phospholipids into developing oocytes [36,47]. Pv, the smallest yolk
protein, largely consists of phosphorylated serine residues thought to stabilize nascent Vtg structure
during lipid loading and to enhance solubility of Vtg in the blood [4,47]. β-C and CT, the small
cleavage products of vWD that contains a highly conserved motif of repeated cysteine residues, are
postulated to stabilize the Vtg dimer for cellular recognition and receptor binding, and to protect
Vtg or its product yolk proteins from premature or inappropriate proteolysis [4,19,20]. All these yolk
proteins are later used as the nutrients by developing embryos to nourish their cells [48,49].
Vtgs were once regarded as a female-specific protein [50,51]; however, synthesis, albeit in smaller
quantities, has been shown to occur in male and even sexually immature animals [52–54], suggesting
that Vtgs presumably fulfill a more general role independent of gender. Recently, both Vtgs and yolk
proteins have been shown to be connected with the immune defense and antioxidant activity in fish,
challenging the traditional view that Vtgs and yolk proteins were simple source of nutrients for the
developing embryos. Below we will discuss the immune-relevant and antioxidant activities of Vtgs
and yolk proteins in fish.
2. Immune-Relevant Activities of Vtgs and Yolk Proteins
2.1. Immune Roles of Vtgs
Accumulating data demonstrated several non-nutritional roles for Vtg. For instance, Vtgs
were shown to be associated with the social organization, temporal division of labor and foraging
specialization, regulation of hormonal dynamics and change in gustatory responsiveness in the
honeybee Apis mellifera, an advanced eusocial insect (Figure 2) [55–58]. Recent studies show that
Vtgs also play immune-relevant roles (Figure 2). The first solid evidence showing that Vtg preforms
an immune-relevant role was the observation by Zhang et al., that Vtg purified from the ovaries of
the protochordate amphioxus (Branchiostoma japonicum) exhibited hemagglutinating activity against
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chick, toad and grass carp erythrocytes as well as antibacterial activity against the Gram-negative
bacterium E. coli [59]. Soon after that, Vtg purified from the rosy barb Puntius conchonius was found to
be capable of inhibiting the growth of the Gram-negative bacteria E. coli, E. aerogenes and Pseudomonas
putida as well as the Gram-positive bacteria Staphylococcus aureus, Bacillus subtilis and Streptococcus
pyogenes [60], and Vtg from the carp capable of suppressing the growth of E. coli and S. aureus in a dose
dependent-manner [61]. Interestingly, Vtgs from protostomes also appear to have antibacterial activity.
Vtg from the scallop (Patinopecten yessoensis) was recently shown to have antibacterial activity against
Gram-positive and Gram-negative bacteria [62]. In addition, Vtg in the nematode C. elegans seems also
involved in its antibacterial defense. A reduced survival was observed in the vtg-knockdown C. elegans
after pathogen infection [63]. Another evidence for a role of invertebrate Vtg associated with resistance
against bacteria was provided by the enhancement of resistance of nematode against the pathogen
Photorhabdus luminescens, when the production of Vtg was stimulated by estrogen 17β-estradiol and
phytoestrogen daidzein. However, reduction of Vtg caused by soy isoflavone genistein diminished
the host resistance to P. luminescens [64]. Taken together, it appears that the antibacterial activity is a
universal property of Vtgs from both vertebrates and invertebrates.
Figure 2. Multiple roles of vitellogenin (Vtg). Vtg is traditionally thought to provide protein- and
lipid-rich nutrients for developing embryos and larvae. However, accumulating data demonstrate
that its roles extend beyond the nutritional function. In the advanced eusocial insect honeybee, Vtgs
were shown to be associated with the social organization, temporal division of labor and foraging
specialization, regulation of hormonal dynamics and change in gustatory responsiveness. Recent
studies show that Vtgs also play immune-relevant roles. Vtg is able to recognize the invading microbes
as a multivalent pattern recognition receptor, kill bacteria or neutralize virus as an effector molecule as
well as enhance phagocytosis as an opsonin. Besides, Vtg also exhibits activities to hemagglutinate
erythrocytes and aggregate pathogens. In addition to immune roles, Vtg plays another novel role as
an antioxidant.
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Shi et al. showed that intraperitoneal injection of E. coli was able to enhance the level of serum Vtg
in male P. conchonius [60]. This has recently been confirmed by Lu et al., who showed that expression of
vtg genes in the skin of zebrafish was induced following the challenge with Gram-negative bacterium
Citrobacter freundii [65,66]. Moreover, an increased expression of vtg was also detectable in the
insect Bactericera cockerelli after infected by “Candidatus Liberibacter solanacearum” via transcriptome
analyses [67]. These data together suggest that Vtg may play an active role in the anti-infection of the
host in vivo. Actually, Tong et al. showed that Vtg produced in male zebrafish as a consequence of
induction by lipopolysaccharide (LPS) and lipoteichoic acid (LTA) is an acute phase reactant, with
antibacterial activity against E. coli and S. aureus [68].
Vtg appears to play a multifaceted immune-relevant functions. Li et al. demonstrated that
Vtg of the marine fish Hexagrammos otakii was able to bind to Gram-negative bacterium E. coli and
Gram-positive bacterium S. aureus as well as fungus Pichia pastoris [69]. The binding to E. coli and
S. aureus was also detected for carp and zebrafish Vtgs [61,68]. The binding of Vtgs to bacteria
provides them ability to aggregate pathogens as well as to recognize the invading microbes [61].
Further examination via ELISA assay showed that Vtgs exhibited specific affinities to the components
conserved within a class of microbes, called pathogen-associated molecular patterns (PAMPs),
including LPS of Gram-negative bacteria, LTA of Gram-positive bacteria, peptidoglycan (PGN) of
Gram-negative and positive bacteria, and glucan of fungi [61,69]. These observations indicate that
Vtg first functions as a multivalent pattern recognition receptor capable of identifying invading
Gram-negative and Gram-positive bacteria as well as fungi, and is involved in host immune defense
as a detector. In a recent study attempting to search PGN recognition proteins in giant tiger shrimp
(Penaeus monodon), an 83 kDa protein was isolated by in vitro PGN pull-down binding assay and
identified as a Vtg-like protein via mass spectrometry as well as Western blots with monoclonal
antibodies specific of Vtgs reported from P. monodon [70], implicating that invertebrate Vtg may
also play a pattern recognition receptor role. Scanning electron microscopy as well as bacterial cell
and protoplast lysis assays showed that H. otakii Vtg was able to kill pathogenic bacteria by lysing
the whole cells (with cell walls) instead of protoplast (without cell walls) via interaction with LPS
and LTA [71]. These show that Vtg functions as an effector molecule, capable of directly killing
bacteria. Interestingly, Vtg was also shown to be able to enhance the phagocytosis of microbes by
macrophages. Li et al. first reported that H. otakii Vtg could facilitate engulfing of the microbes E. coli,
S. aureus and P. pastoris by head-kidney-derived macrophages in vitro [69]. Later, Vtg of carp was
shown to possess similar phagocytosis-promoting activity [61]. In an in-situ study of impacts of
urban wastewater on freshwater mussel Elliptio complanata, it was observed that the production of
Vtg-like proteins was strongly associated with phagocytosis [72], suggesting a relation between Vtg
and phagocytosis in invertebrates. Besides, H. otakii Vtg was found to be capable of binding to the cell
surface of macrophages but not that of red blood cells [61,69]. Collectively, these observations indicate
that Vtg is an opsonin functioning as a bridging molecule between host macrophages and invading
pathogens, thereby leading to enhanced phagocytosis. Notably, Liu et al., established that the H. otakii
Vtg was able to opsonize the fungus P. pastoris for phagocytosis by macrophages isolated from sea bass
Lateolabrax japonicas, implying that the opsonization of Vtg was not species-specific [73]. Further study
revealed that Vtg-opsonized phagocytosis showed properties typical of type I phagocytosis, including
pseudopod extension, tyrosine kinase dependence, and up-regulation of pro-inflammatory cytokine
genes tnf-α and il-1β [73]. Therefore, Vtg is a pattern recognition receptor capable of identifying
pathogens, a bactericidal molecule capable of damaging bacterial cell walls, and an opsonin capable of
enhancing phagocytosis of pathogens by macrophages. The multifaceted immune-relevant activities
of Vtg are in part endowed with its different domains. It was reported by Sun et al. that both DUF1943
and DUF1944 as well as vWD contribute to the function of Vtg as a pattern recognition receptor, and
DUF1943 and DUF1944 (but not vWD) also contribute to the function of Vtg as an opsonin [21].
Recently, Garcia et al. showed that Atlantic salmon Vtg possessed neutralizing ability for infectious
pancreatic necrosis virus [74], suggesting that Vtg is also involved in host antiviral immunity. This
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seems further supported by the observation that the mosquito (Anopheles gambiae) Vtg was able to
interfere with anti-plasmodium response [75]. These denote that in addition to antibacterial activity, Vtg
also has antiviral activity, which demands detailed study in the future.
2.2. Immune Roles of Yolk Proteins
Lv and Pv are the principal yolk proteins generated by the proteolytic cleavage of Vtg. As Vtg is
an immune-competent molecule, it is thus reasonable to hypothesize that Lv and Pv also have similar
immune activities. This hypothesis was first tested by Zhang and Zhang [76]. They demonstrated
that the native Lv purified from ovulated eggs of the rosy barb P. conchonius was able to interact
with LPS, LTA and PGN, as well as E. coli and S. aureus, but not with self-molecules such as the
egg extracts prepared, indicating that Lv is a molecule capable of recognizing non-self components.
Moreover, the bacterial binding activity of Lv enabled it to enhance the phagocytosis of bacteria by
macrophages, suggesting that Lv is also an opsonin functional in developing embryos/larvae [76].
Similarly, Pv was also shown to play a critical role in the immunity of zebrafish embryos via acting as
a pattern recognition receptor and an antimicrobial effector molecule [77]. In line with this, hen egg
yolk Pv was also shown to be able to inhibit the growth of the Gram-negative bacterium E. coli and
the Gram-positive bacterium S. aureus under thermal stress [78,79]. Of note, the affinity of Pv to LPS
enabled the protein a capacity to neutralize endotoxin, promoting the survival rate of endotoxemia
mice [79]. It was recently shown that a truncated Pv (Pt5) consisting of the C-terminal 55 residues
of zebrafish Pv also displayed similar immune activities with Pv, including antimicrobial activity
against E. coli, Aeromonas hydrophila and S. aureus, and specific affinity to LPS, LTA, and PGN [77].
Intraperitoneal injection of this Pv-derived peptide was able to increase the survival rate of zebrafish
challenged with pathogenic A. hydrophila and to markedly decrease the number of the pathogen in
multiple tissues, suggesting that Pt5 could inhibit multiplication/dissemination of pathogen in host
as an antimicrobial agent. In addition to direct antimicrobial activity, Pt5 was also shown to be able
to regulate the host immune responses via suppressing the expression of pro-inflammatory cytokine
genes (il-1β, il-6, tnf-α and ifn-γ) and simultaneously enhancing the expression of anti-inflammatory
cytokine genes (il-10 and il-4), suggesting a dual role of Pt5 as both immune effector and modulator [80].
Recently, a mutant peptide of Pt5 (designated as Pt5e), generated by site-directed mutagenesis, was
shown to have stronger bactericidal activity and LPS-neutralizing activity [81]. Besides, Sun et al.
demonstrated that recombinant zebrafish Pv was capable of inhibiting the formation of the cytopathic
effect in lymphocystis disease virus (LCDV)-infected cells and reducing the virus quantities in the
infected cells as well as in the infected zebrafish, suggesting that Pv possesses an antiviral activity and
participates in immune defense of host against the infection by viruses like LCDV [82]. Taken together,
these data show that like Vtg, Lv and Pv are both immune-competent molecules involved in immune
response of the host against invading pathogenic microbes.
3. Antioxidant Activities of Vtgs and Yolk Proteins
In addition to immune roles, another novel role of Vtg is antioxidant activity (Figure 2). It
was first shown by Ando and Yanagida that Vtg from the eel Anguilla japonica was able to resist
the copper-induced oxidation, and could protect the very low density lipoprotein (VLDL) against
copper-induced oxidation [83]. This was the first observation reporting that Vtg has antioxidant
activity, and serves to suppress the free-radical reactions in fish oocytes. Similar antioxidant activity
was also suggested for the nematode (C. elegans) Vtg [84]. In the honeybee, Vtg was demonstrated
to be able to reduce oxidative stress by scavenging free radicals, thereby increasing the lifespan in
the facultatively sterile worker castes and reproductive queen castes [85,86]. The honeybee Vtg was
also demonstrated in a recent study to be capable of recognizing cell damage through its binding to
membrane and shielding living cells from damage by reactive oxygen species (ROS) [87]. It is clear
that Vtg protects cells from ROS damage in both invertebrates and vertebrates.
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It is well known that hen egg yolk Pv, as Vtg-derived major protein, show strong antioxidant
activity owing to its high serine and phosphorus content, which makes this protein one of the strongest
iron-chelating agents [88–90]. Very recently, we showed that zebrafish recombinant phosvitin (rPv)
was an antioxidant agent capable of inhibiting the oxidation of the linoleic acid, and scavenging
the 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical. We also showed that zebrafish rPv is a cellular
antioxidant capable of protecting radical-mediated oxidation of cellular biomolecules. Importantly,
zebrafish rPv is non-cytotoxic to murine macrophages RAW264.7 [91]. These results show that Pv in
fish is also a strong antioxidant agent. If Lv, another major Vtg-derived protein, has any antioxidant
activity remains open, which is worthwhile exploring.
4. Potential Applications in Human Health
Antibiotics are globally utilized to control microbial infections in clinical practice up to date,
however cases of resistance to the majority of antibiotic classes have been reported, which has become
a serious threat to human health in many parts of the world [92,93]. It is thus essential to develop new
antibiotic agents to combat these resistant pathogens. Antimicrobial proteins/peptides (AMPs) are
potential candidates to solve this problem. As a protein/peptide with antimicrobial activity widely
present in plants, animals and microbes, AMP commonly is a cationic and amphipathic molecule with a
net positive charge and a high percentage of hydrophobic residues [94]. These structure characteristics
provide AMP the ability to interact with the anionic cell wall and phospholipid membranes of
microorganisms, which makes it more difficult for pathogens to evolve resistance [95]. Vtg and its
derived protein Pv from oviparous species, especially teleost fishes, both display antibacterial activities
with a broad antibacterial spectrum [59–62,68,71,77–79], and hence can be used as pro-drug to develop
novel antibiotic agents. For example, based on the residual sequence of Pt5, the C-terminal peptide of
zebrafish Pv, a total of six mutant peptides were generated by a single or double mutagenesis; among
them, a mutant called Pt5e showed stronger antibacterial activities against E. coli and S. aureus [81],
and was able to kill five strains of multiple drug resistance bacteria isolated from clinical cases via
disturbing their cell membrane integrity (Data not shown).
Sepsis is a serious disease characterized by a systemic inflammatory response syndrome caused
by infection. Severe sepsis is complicated by tissue damage and organ dysfunction, which can lead
to sequential multi-organ failure followed by death [96]. The primary trigger of sepsis is thought
to be LPS, or endotoxin, a major component of the cell wall of Gram-negative bacteria, which is
released when bacteria grow or are abolished by antibiotics or host immunity. LPS, as a conserved
molecular signature of Gram-negative bacteria, can specifically interact with Vtg, Lv, Pv and their
derived peptides [21,61,62,69,71,76,77,79,81], making it possible to utilize these proteins/peptides to
develop LPS-neutralizing agents for sepsis treatment. In line with this, both Pv and Pt5e exhibiting
LPS-neutralizing ability had been shown to be able to promote the survival rate of endotoxemia mice.
Moreover, both Pv and Pt5e displayed neither cytotoxicity to murine RAW264.7 macrophages nor
hemolytic activity towards human red blood cells [79,81], suggesting that they can be a safe potential
candidate for therapeutics of sepsis.
Antioxidant agents have attracted a great deal of attention in recent years because of their roles
in prevention of chronic diseases and utilization as preservatives in food and cosmetics [97–99]. Vtg
and its derived Pv both have antioxidant activities against ROS. As these proteins are components of
our food source, they are thus natural antioxidant agents. These suggest that they can be can be an
important antioxidant with a potential in preservation of food and cosmetics as well as in mediation of
chronic disease states.
5. Conclusions
Vtg, the precursor of major egg yolk proteins, is traditionally thought to provide protein- and
lipid-rich nutrients for developing embryos and larvae. However, accumulating data indicate that Vtg
as well as its derived yolk proteins Lv and Pv also play non-nutritional functions: they are not only
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involved in immune defense but also antioxidant reaction. These non-nutritional functions clearly
better and deepen our understanding of the physiological roles of the molecules, and at the same time,
provide a sound basis for potential application of the molecules in human health.
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Abstract: Ovotransferrin or conalbumin belong to the transferrin protein family and is endowed with
both iron-transfer and protective activities. In addition to its well-known antibacterial properties,
ovotransferrin displays other protective roles similar to those already ascertained for the homologous
mammalian lactoferrin. These additional functions, in many cases not directly related to iron binding,
are also displayed by the peptides derived from partial hydrolysis of ovotransferrin, suggesting a
direct relationship between egg consumption and human health.
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1. Introduction
Ovotransferrin (Otrf) or conalbumin belongs to the family of transferrin iron-binding
glycoproteins. In mammals, two different soluble iron-binding glycoproteins are present: (i) serum
transferrin, involved in iron transport and delivery to cells and (ii) lactoferrin, involved in the so-called
natural immunity. Differently, Otrf is the only soluble glycoprotein of the transferrin protein family
present in avian. Otrf is present both in avian plasma and egg white and possesses both iron-transfer
and protective properties [1]. Otrf represents about 12%–13% of total egg white proteins and contributes
to promoting the growth and development of the chicken embryo mainly preventing the growth of
micro-organisms together with other proteins such as lysozyme [2], cystatin [3,4], ovomacroglobulin [5]
and avidin [6]. Galliformes (chicken, Gallus gallus and turkey, Meleagris gallopavo) appear to possess
albumens with greater antimicrobial activity than those of the anseriformes (duck, Anas platyrhynchos),
possibly due to higher concentrations of ovotransferrin and of the broad active c-type lysozyme [7].
However, recent evidence indicates that Otrf is endowed not only with the antibacterial activity related
to iron withholding, but also with other roles related to the protection of the growing embryo, including:
regulation of iron absorption; immune response; and anti-bacterial, anti-viral and anti-inflammatory
properties. Some of these properties are shared by both the human protein homologues and peptides
deriving from its partial enzymatic hydrolysis [8], being in this latter case also increased.
The state of the art hereby described suggests that Otrf and its peptides can be used as functional
food ingredients and as important components for nutraceuticals, being characterized both by
protective functions and by substantial nutritional benefits; for these reasons, the utilization of
Otrf and its peptides in functional foods can present several additional advantages over other
natural compounds.
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2. Ovotransferrin Synthesis and Structure
Otrf is a monomeric glycoprotein containing 686 amino acids, with a molecular weight of 77.9 kDa
and an isoelectric point of 6.0 [9,10].
The avian transferrin gene is transcripted in the liver and the oviduct. In the liver, the transferrin
is secreted in the serum, where it is involved in iron transport and storage, while the oviduct transferrin
(ovotransferrin) is secreted at high levels in the egg white. In particular, progesterone and oestrogen
regulate the expression of Otrf in the oviduct: oestrogen can interact with chromatin through a nuclear
receptor protein stimulating transcription and synthesis of the protein precursor [11]. Instead, the
transcription of serum Otrf may depend on iron concentration [12]. Although the serum transferrin
and Otrf have the same amino acidic sequence, they differ in the glycosylation sites. The glycan of
Otrf is constituted by four residues of mannose and four residues of N-acetylglucosamine whereas
serum transferrin is composed of two residues of mannose, two residues of galactose, three residues of
N-acetylglucosamine, and one or two residues of sialic acid at its C-terminus [13–15].
Like the mammalian transferrins, the single chain of Otrf consists of two globular lobes (N-
and C-lobes), interconnected by a α-helix of nine amino acidic residues (residues 333–341) that can
be released by tryptic digestion. Each lobe contains an iron binding site and is divided in two
domains, (domains N1 and N2 in the N-lobe and domains C1 and C2 in the C-lobe, respectively;
Figure 1A) [16–18].
As shown in Figure 1, the domains are linked by anti-paralleled β-strands. The N- and C-lobes
show about 38% sequence homology; indeed, it is has been hypothesized that all members of transferrin
family resulted from gene fusion and duplication [19]. Fifteen disulfide bridges stabilize the structure.
Six of them are conserved in both lobes, while three are present only in the C-lobe, conferring to the
lobes a different metal affinity.
Figure 1. (A) Ribbon representation and the solvent-accessible surface (in transparency) of holo-Otrf
(PDB ID:1OVT) [16]. N1, N2 and C1, C2 indicate the subdomains of each lobe. (B) The N-lobe iron
binding site of hen’s ovotransferrin (PDB ID:1OVT). The amino acids involved in iron binding are
shown in sticks. H-bonds are displayed by purple broken lines. Both in (A) and (B), the iron is indicated
as a yellow sphere. (C) Schematic ribbon representation of the OTAP-92 peptide. The three disulfide
linkages are represented in yellow, while the hydrophobic residues are highlighted in blue. The peptide
is shown with the same conformation displayed in the intact protein. Molecular graphic images were
produced using the UCSF chimera package [20].
Each lobe has the capability to reversibly bind one Fe3+ ion along with one CO32− anion. Although
each lobe displays a high sequence homology, they show different iron-binding properties. In particular,
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the (approximate) iron binding affinity is 1.5 × 1018 M−1 for the C-lobe and 1.5 × 1014 M−1 for
the N-lobe. As mentioned before, this difference is due to the presence, in the C-lobe, of an extra
interdomain disulfide bond, Cys478-Cys671, which confers less flexibility and possibly less affinity
towards Fe3+ ion [21].
From a stereochemical point of view, the iron binding pocket is conserved among all members
of transferrins [16–18,22–24]. As shown in Figure 1B, in the N-lobe there are two phenolate oxygens
of two tyrosine residues (Tyr92 and Tyr191), a carboxylate oxygen of the aspartic acid (Asp60), and
the imidazole nitrogen of the histidine (His250), together with two oxygens of the synergistically
bound CO32− anion. In C-lobe, the corresponding amino acids are Asp 395, Tyr524, Tyr431 and His592,
respectively. In this latter, Arg460 keeps in place the carbonate moiety while in the N-lobe Arg121
plays the same role. Upon iron binding, each lobe of Otrf undergoes large conformational change;
the observed movement is necessary to bury the metal inside the polypeptide chain given that, in its
absence, the iron-coordinating amino acidic residues are solvent exposed.
3. Antibacterial Activity of Ovotransferrin and Its Peptides
Among the several protective functions of Otrf, the most important one is likely to be the
antibacterial activity, which is directly related to the Otrf’s ability to bind iron (Fe3+), making it
unavailable for bacterial growth [25,26]. This bacteriostatic activity is reversed by adding iron ions
to the medium and it is blocked by iron saturation [27]; moreover, it can be enhanced by (i) adding
carbonate ion [28] which is one of the iron ligands in the Otrf metal binding site [29]; (ii) increasing the
pH from 6 to 8 [27]; (iii) and immobilizing Otrf by covalent linkage to Sepharose 4B [30]. An increase
of the bacteriostatic activity towards E. coli O157:H7 as iron chelator was demonstrated using a
combination of ovotransferrin, NaHCO3, and EDTA [31]. The antibacterial activity was demonstrated
also in an in vivo study using newborn guinea pigs orally infected with E. coli 0111 B4 [32]. On the
contrary, citrate exerts an antagonistic effect in those bacteria that possess a receptor for iron-citrate
complex [32]. The most sensitive species to the iron deprivation effect of Otrf are Pseudomonas spp.,
Escherichia coli, Streptococcus mutans, while the most resistant ones are Proteus spp., and Klebsiella
spp. [32], according to the ability of these latter bacteria to produce molecules (i.e., siderophores) able
to compete with Otrf for iron binding. However, it is worth noting that some bacterial species that
are also human pathogens, e.g., Neisseria meningitidis, Neisseria gonorrhoeae and Moraxella catarrhalis,
have developed a mechanism for acquiring iron directly from transferrin-like proteins through surface
receptors capable of specifically binding ovotransferrin [33].
Other studies suggested that part of the antibacterial activity of Otrf is not simply due to the
removal of iron from the medium, but also involves more complex mechanisms related to a direct
binding of Otrf to the bacterial surface. As a matter of fact, it has been initially demonstrated
that the antibacterial activity of Otrf decreased when the protein is separated by dialysis from the
bacteria, a condition in which it can exert only the iron-chelating property [34]. Accordingly, it was
shown that Otrf is able to permeate the E. coli outer membrane and access the inner membrane,
causing both ion leakage inside bacteria and the uncoupling of the respiration-dependent energy
production [35]. The antibacterial effect of Otrf towards Salmonella enterica (serovar Choleraesuis) has
been also demonstrated to be dependent on culture conditions that either favor or hinder binding Otrf
to the bacterial surface [36]. These data suggest that this Otrf function, not related to iron binding,
could be due to a cationic bactericidal domain which, as other transferrins, is located in the N-lobe [35].
The isolation of the bactericidal domain of Otrf, was carried out by Zhou and Smith in 1990 by
a partial acid proteolysis. OTAP-92 is a peptide of 9.9 kDa, consisting of 92 aminoacidic residues
(Leu109-Asp200) showing strong sequence similarity with defensins [37]. This peptide is characterized
by three disulfide bridges (Cys115-Cys197, Cys160-174, and Cys171-Cys182) and several positively
charged residues (Figure 1, panel C).
It has been suggested that the antibacterial action of OTAP-92 may be due to its relatively
high alkalinity and to the cysteine array. Both these features are shared by native antibacterial
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peptides [38,39] and by insect defensins whose mechanism of action involves the blocking of the
voltage-dependent K+ channels [38–42].
As concerning the possible biotechnological applications of the Otrf antibacterial activity, Ko and
coworkers [31] showed that a combination of Otrf, NaHCO3, EDTA and/or Lysozyme have a potential
growth inhibition effect against E. coli O157:H7 or L. monocytogenes, demonstrating also a potential
application of Otrf as a natural preservative for food (i.e., pork chops and commercial hams) [31,43,44].
4. Antiviral Activity of Ovotransferrin and Its Peptides
The antiviral activity of Otrf was firstly demonstrated towards the avian herpesvirus Marek’s
disease virus (MDV), and no correlation between antiviral efficacy and iron saturation was found [45].
It has been postulated that the ovotransferrin antiviral activity towards MDV is associated with two
Otrf fragments: DQKDEYELL (hOtrf219-27) and KDLLFK (hOtrf269-301 and hOtrf633-638) capable of
blocking Marek’s disease virus infection in chicken embryo fibroblasts (CEF), even though the infection
blocking efficiency of the isolated peptides is lower than that of the intact protein [46]. Interestingly,
from an evolutionary point of view, these two Otrf peptides share sequence homology with two protein
fragments, derived from human and bovine lactoferrin, known to be effective against Herpes simplex
Virus (HSV-1) [47].
5. Antioxidant Activity of Ovotransferrin and Its Peptides
Ovotransferrin is a superoxide dismutase-mimicking protein exhibiting a superoxide radical
(O2•−)-scavenging activity. Furthermore, self-cleaved Otrf exhibited O2•− scavenging capacity greater
than intact protein [48,49]. Accordingly, it has been shown that, after digestion by thermolysin and
pepsin, the resulting Otrf hydrolysates possessed significantly higher oxygen radical absorption
capacity (1.69 μmol Trolox equivalent mg−1) than natural ovotransferrin [50].
Kim and coworkers [51] demonstrated that the antioxidant effects of hen’s ovotransferrin and
of its hydrolyzed peptides is approximately 3.2–13.5 times higher than superoxide anion scavenging
activity than Otrf, with the maximum activity displayed by octapeptides. Similar results were obtained
for oxygen radical absorbance capacity assay and against the oxidative stress-induced DNA damage in
human leukocytes [51]. In addition, Otrf-derived peptides showed synergistic antioxidant effects with
Vitamin C, epigallocatechin gallate (EGCG), and caffeic acid [52]. Otrf hydrolyzate (obtained using
enzymes such as protamex, alkalase, trypsin, and α-chymotrypsin) showed protective effects against
oxidative stress including DNA damage in human leukocytes [53].
The conjugation of ovotransferrin with catechin (a polyphenol antioxidant found in tea, wine,
fruits, with high affinity to bind protein) improved the oxygen radical absorbance capacity of the
protein. The ovotransferrin-catechin conjugates were prepared using a hydrogen peroxide–ascorbic
acid pair as radical initiator system and alkaline method [54]. Moreover, it has been also
shown that catechin, after the conjugation reaction and after UPLC (Ultra-Performance Liquid
Chromatography), MALDI-TOF (Matrix Assisted Laser Desorption Ionization Time-of-Flight) and
Liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis, was bound to lysine
(residues 327) of the Otrf peptide DLLFKDSAIMLK (residues 316–327) and to glutamic acid (residues
186) of the Otrf peptide FFSASCVPGATIE (residues 174–186) present in ovotransferrin N-lobe [54].
Autocleaved Otrf was shown to (i) hinder effectively the discoloration of ß-carotene (used as
radical target in a bleaching test); (ii) prevent the oxidation of linoleic acid during five days of storage at
4 ◦C; and (iii) show strong Cu2+- and Ca2+-binding capacities, suggesting that it could be a good source
of natural antioxidants. Once again, its metal-chelating activity could be at least partly responsible for
the observed antioxidant mechanisms [55].
In conclusion, the use of Otrf-derived conjugates as a novel proteinaceous antioxidants as
ingredient in the nutraceutical and functional food is desirable.
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6. Anti-Inflammatory Activities of Ovotransferrin and Its Peptides
During inflammation in avians, Otrf, as well as the positive acute phase protein (APP),
is up-regulated both in vivo and in vitro [56–63]; its levels in blood remain elevated as long as
the inflammation persists [64,65]. Indeed, the use of blood Otrf concentration as an infection
and inflammation marker in chickens has been hypothesized [66]. Otrf may act directly as an
immunomodulator [63], even though its role in inflammation preventing microbial growth [67] and
acting as an antioxidant against Fenton reaction products [36] cannot be ruled out.
More recently, two tripeptides, IRW and IQW, both derived from Otrf hydrolysis, were found
to attenuate TNF-α-induced inflammatory responses and oxidative stress in vascular endothelial
cells [68]. Furthermore, other peptides derived from ovomucoid showed an immunomodulating
activity against T-cells and macrophage-stimulating activities in vitro [69], indicating that they also can
be good candidates for pharmaceutical use in humans [70].
7. Other Protective Activities of Ovotransferrin and Its Peptides
In the last years, it has been reported that Otrf underwent thiol-linked auto-cleavage after
reduction, and produced partially hydrolyzed products with very strong anticancer effects against
colon (HCT-116) and breast cancer (MCF-7) by inducting apoptosis [71].
An antihypertensive subsidiary function of the Otrf was detected in the hen Otrf’s peptide
KVREGT, showing an IC50 value of 9.1 μM towards angiotensin I-converting enzyme [72]. Moreover,
the same peptide displayed both a strong ACE-inhibitory and a vasodilatory activities [73].
Ovotransferrin has also shown both in vitro and in vivo development promoting activity, which
has been associated to its iron binding/transport capabilities. Ovotransferrin is transiently expressed
and secreted in large amounts during the in vitro differentiation of hypertrophic chondrocytes
into osteoblast-like cells. Cells expressing ovotransferrin also co-express ovotransferrin receptors,
suggesting a self-regulatory mechanism in the control of chondrocyte differentiation to osteoblast-like
cells [74–79].
Otrf shares with human and bovine lactoferrin a proteolytic activity catalyzing the hydrolysis of
several synthetic substrates [80]. Serine protease inhibitors PMSF (phenylmethylsulfonyl fluoride),
LPS (lipopolysaccharide) and Pefabloc impair this proteolytic activity suggesting that it is similar to
that of serine proteases [81,82]. This function is conserved in several mammalian lactoferrins but not in
serum transferrins, and thus it is plausible that it belongs to the protective functions of Otrf, although
the physiological target has not been identified, yet.
Lastly, Ibrahim et al. [83] demonstrated the efficiency of Otrf to serve as a drug carrier to improve
the solubility of three water-insoluble antibiotics and to facilitate their specific delivery into microbial
or infected cells. For a complete overview of the Otrf properties, see Table 1.














• Membrane damage [7,25,32]
147


















































































• Iron delivery [77,78]
MYOTROPHIC • Iron delivery [74]
NEUROTROPHYC • Iron delivery [79]























































Nutrients 2015, 7, 9105–9115
8. Conclusions
Many of the Otrf’s protective properties, described in this review and outlined in Table 1,
contribute, in addition to the well-known iron transfer activity, to the proper development of the
chicken embryo. Moreover, the demonstration that several defensive properties of Otrf are also
possessed by its proteolytic fragments and that these properties may be of importance for human
wellness strongly support the use of egg white (preferably raw or cooked at low temperature to
preserve ovotransferrin properties) and its derivatives as dietary additives in normal and pathological
human conditions.
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In 1968, the American Heart Association recommended the consumption of no more than
300 mg/day of dietary cholesterol and emphasized that no more than 3 eggs should be eaten per
week, resulting in substantial reductions in egg consumption, not just by diseased populations but
also by healthy individuals, and more importantly by poor communities in undeveloped counties who
were advised against consuming a highly nutritious food. These recommendations did not take into
account that eggs not only contain important nutrients for overall health but also components which
exert protection against chronic disease. The newly-released 2015 dietary guidelines finally took into
consideration the epidemiological information and the data from clinical interventions and eliminated
an upper limit for dietary cholesterol. This special issue addresses the history of the recommendations
for eggs [1], the components of eggs providing beneficial effects against disease [2–6], the relationship
between egg intake and healthy eating index [7]; the protective effects of eggs against inflammation [8]
and oxidative stress [9]. Finally, the controversies surrounding egg intake and risk for diabetes are
presented in a review of epidemiological data [10] and in a clinical study [11].
The history of the recommendations of dietary cholesterol and the politics behind those
recommendations as well as the perception of the public and the creation of the Egg Nutrition
Center in the US are thoroughly discussed alongside the lines of evidence on which the original
recommendations were based [1]. The number of studies supporting the lack of evidence of an
association between dietary cholesterol and risk of heart diseases and the evidence-based research
associated with the elimination of dietary cholesterol from the current dietary guidelines are presented
in chronological order [1].
Eggs have been recognized as functional foods due to the presence of bioactive components,
which may play a role in the prevention of chronic and infectious diseases [2]. The presence of
antimicrobial, antioxidant, anti-cancer and hypotensive properties are discussed in this review [2].
Phospholipids are among the bioactive components of eggs [3]. Sphingomyelin and phosphatidyl
choline have been postulated to regulate cholesterol absorption and inflammation and, interestingly,
the incorporation of egg phospholipids into high density lipoprotein (HDL) appears to be a major factor
in the cholesterol-accepting capacity of this lipoprotein [3]. Ovotransferrin, a protein present in egg, is
well known for its antibacterial properties [4]. There is evidence that ovotransferrin and its peptides
possess antiviral activity, as well as antioxidant and anti-inflammatory properties [4]. In addition, egg
yolk proteins including vitellogenin, lipovitellin and phosvitin have also been shown to participate in
the immune defense system, capable of killing bacteria and viruses as well as promoting phagocytosis
activity [5]. A study conducted in rats demonstrated that egg white protein was very useful for the
recovery of iron-deficiency anemia [6]. These roles of egg proteins in protecting against bacterial
infection further document the association between egg consumption and health [4–6].
The role of eggs on the healthy eating index (HEI) was evaluated in 139 obese post-partum
Mexican American women [7]. This article details the role of eggs as a component of the diet
in some of these women and how egg-eaters achieved higher HEI scores, mainly by the higher
consumption of high quality protein [7]. The anti-inflammatory properties of eggs have been
demonstrated in numerous studies [8]. Among the egg components with anti-inflammatory properties
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are: phospholipids, the carotenoids, lutein and zeaxanthin and egg proteins. The mechanisms of action
of these anti-inflammatory components is discussed in detail [8]. The components of eggs that have
been shown to participate in the immune defense and act as anti-inflammatory agents, have also been
shown to be anti-oxidants [9]. The role of eggs as an anti-oxidant food commodity due to the presence
of specific egg proteins, carotenoids and phospholipids is thoroughly discussed in this review [9].
There is controversy regarding egg consumption and patients diagnosed with diabetes [10].
While it is clear that heart disease does not increase by egg intake, some of the epidemiological data
appear to find a relationship between egg intake and diabetes [10]; thus, the authors emphasize the
need for more clinical interventions in patients with diabetes. A clinical study compared the effects of
two distinctive breakfasts in diabetic patients in a crossover design: one egg per day or 1 cup of oatmeal
per day for 5 weeks each [11]. The authors report that there were no differences in the parameters
related to cholesterol or glucose metabolism between dietary interventions. However, following
egg consumption, there was a reduction of liver enzymes and inflammatory markers in these
patients. [11]. Thus, this study demonstrates that, for this specific population, egg intake did not
increase cardiovascular disease risk but was rather protective against inflammation. It is clear that
more clinical interventions are needed so that more conclusive statements can be generated regarding
egg intake and risk for people with diabetes.
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